
==== Front
Front PharmacolFront PharmacolFront. Pharmacol.Frontiers in Pharmacology1663-9812Frontiers Media S.A. 10.3389/fphar.2018.00940PharmacologyReviewIntracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery Konings Gonda 12†Brentjens Linda 12†Delvoux Bert 12Linnanen Tero 3Cornel Karlijn 12Koskimies Pasi 3Bongers Marlies 12Kruitwagen Roy 12Xanthoulea Sofia 12Romano Andrea 12*1GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands2Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, Netherlands3Forendo Pharma Ltd., Turku, FinlandEdited by: Walter Jäger, Universität Wien, Austria

Reviewed by: Ashwini Chand, Olivia Newton-John Cancer Research Institute, Australia; Philippa Saunders, University of Edinburgh, United Kingdom

*Correspondence: Andrea Romano a.romano@maastrichtuniversity.nlThis article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

†These authors have contributed equally to this work

19 9 2018 2018 9 94028 3 2018 02 8 2018 Copyright © 2018 Konings, Brentjens, Delvoux, Linnanen, Cornel, Koskimies, Bongers, Kruitwagen, Xanthoulea and Romano.2018Konings, Brentjens, Delvoux, Linnanen, Cornel, Koskimies, Bongers, Kruitwagen, Xanthoulea and RomanoThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Our understanding of the intracrine (or local) regulation of estrogen and other steroid synthesis and degradation expanded in the last decades, also thanks to recent technological advances in chromatography mass-spectrometry. Estrogen responsive tissues and organs are not passive receivers of the pool of steroids present in the blood but they can actively modify the intra-tissue steroid concentrations. This allows fine-tuning the exposure of responsive tissues and organs to estrogens and other steroids in order to best respond to the physiological needs of each specific organ. Deviations in such intracrine control can lead to unbalanced steroid hormone exposure and disturbances. Through a systematic bibliographic search on the expression of the intracrine enzymes in various tissues, this review gives an up-to-date view of the intracrine estrogen metabolisms, and to a lesser extent that of progestogens and androgens, in the lower female genital tract, including the physiological control of endometrial functions, receptivity, menopausal status and related pathological conditions. An overview of the intracrine regulation in extra gynecological tissues such as the lungs, gastrointestinal tract, brain, colon and bone is given. Current therapeutic approaches aimed at interfering with these metabolisms and future perspectives are discussed.

intracrinologyendometriumestrogenslungsgastrointestinal tractcentral nervous systemboneKWF Kankerbestrijding10.13039/501100004622UM-13-5782
==== Body
Introduction
The term “intracrinology,” coined in 1988 by prof Labrie, refers to the ability of peripheral tissues to use blood precursors and generate steroids (Labrie, 1991). Several studies have been published but several controversies still exist and relate to the following technical and biological aspects: (a) some intracrine enzymes in peripheral tissues have low expression (300–50,000-times lower than in endocrine glands Stoffel-Wagner, 2001; Murakami et al., 2006, close to the detection limit of standard methods like western blotting and immunohistochemistry -IHC); (b) the technology to robustly quantify steroids (liquid-/gas-chromatography tandem mass-spectrometry -LC-MS or GC-MS), became available during the last 5–10 years only (Rosner et al., 2013); (c) intracrine pathways are highly complex.

This review summarizes our knowledge of intracrinology in peripheral tissues like the endometrium, lungs, gastrointestinal tract (GIT), bone and central nervous system (CNS), with special attention to the metabolism of estrogens. Drug development and potential therapeutic approaches are discussed. In this review, the enzymes involved in steroid deactivation/clearance (Rižner, 2013, 2016; with the exclusion of steroid sulphotransferases) and those involved in the transport of conjugated steroids through the plasma membrane (Rižner et al., 2017) are not described. Studies on serum/tissue steroid levels are reported and discussed only if based on gold standard GC/LC-MS.

From ovarian estrogen synthesis to intracrinology
Local steroid metabolism is possible because those enzymes responsible for steroid synthesis in classical glands (ovaries, adrenals, testes) are expressed in peripheral tissues, where additional and alternative routes for metabolizing steroids are present and make intracrine networks intricate and flexible (Figures 1, 2, Tables 1, 2). In particular, several compounds generated through these pathways, although not being estrogens, can have estrogenic action, because able to bind and activate the estrogen receptors. The biologic activity of the various compounds is given in Table 1, and in Figure 2, by the color codes.

Figure 1 Steroid structure. (A) structure of the C21 steroid progesterone (P, used as an example), with carbon numbering and steroid ring numbering. In the storied graphics in Figures 1B and 2, the H groups and the relative bonds will be omitted (with the exclusion of the H in 5α-reduced steroids - androstanes and pregnanes). Methyl groups will be indicated by the bonds only without the CH3 group. (B) structures of C21 pregnene (Δ4 and Δ5, i.e., double bond between C4 and C5 or between C5 and C6, respectively), pregnane (5α-reduced steroid), C19 androstene (Δ4, Δ5) and androstane and C18 (A-ring)-aromatic estrogens. Chemical structures were designed with the aid of Sketcher V2.4 (Ihlenfeldt et al., 2009), available online at PubChem (www.ncbi.nlm.nih.gov; pubchem.ncbi.nlm.nih.gov) (Kim et al., 2016).

Figure 2 Intracrine networks. Major intracrine networks metabolizing steroids. In this figure, each reaction reports the catalyzing enzymes whose role in that specific reaction is established based on robust evidences (in vitro, ex vivo, in vivo). Additional enzymes whose involvement in the same reactions is less robustly demonstrated or based only on in silico or cell-free assay are reported in Table 2. The role of 17βHSD3 is disregarded in this figure because restricted to tissues that are not assessed in the present review (testes, prostate, Table 2).

Color codes:



OV ovarian specific referring to 3β-HSD2 (see text); — dotted arrows indicate reactions that are not fully demonstrated to occur or for which the responsible enzyme is not identified yet; (enzyme name) enzymes indicated by brackets are supposed to catalyze the indicated reaction based on the theoretical assumptions, no experimental proof is yet available; & these compounds (THP, 3αDHP and allopregnandiol) exist as various hydroxyl α/β isomers (3, 5, 17) with no activity, classic action or neuroactivity (see Table 2); * the role of DHRS11 in steroid metabolism is reported only recently by one publication (Endo et al., 2016).

Table 1 Major steroidal compounds.

1. Abbreviation (used here)		Blood concentration ** (nM)	Biologic activity***	Entries*	
2. Common name					
3. Chemical name					
1. none	PREGNANES	n.d.		CAS:516-59-6	
2. none			HMDB:60408	
3.5α-pregnan-20-ol-3-one1			CB:0504265	
			ChEBI:81469	
1. none	3a. M S: 28–4910	3a. GABAA+		
2. allopregnandiol (4 isomers)	3a. F: 0.2–0.710; S: 13–2010		
3 a. 5α-pregnane-3α,20α-diol ∧			a.CAS:566-58-5	
 b. 5α-pregnane-3β,20β-diol			b.CAS:516-53-0	
 c. 5α-pregnane-3β,20β-diol			c.CAS:516-53-0	
 d. 5α-pregnane-3β,20α-diol			d.CAS:516-53-0	
1.5αDHP	F: 0.2–1.1(5, 10)	PR+ GABAA+	CAS:566-65-4	
2. allopregnanedione			HMDB:0003759	
3.5α-pregnane-3,20-dione			ChEBI:28952	
1. none	n.d.	CAS:570-59-2		
2. none			CB:4441841	
3.5α-pregnan-17α-ol-3,20-dione				
1. none	n.d.	CAS:6890-65-9		
2. none			CB:7269033	
3.5α-pregnan-3,17α-diol-20-one 2∧				
1. THP (isomer 1/4)	All: 0.2–106	GABAA+	CAS:516-54-1	
2. allopregnanolone3	M: 0.1–0.210; S: 3.6–1010	HMDB:0001449		
3.3α-hydoxy-5α-pregnan-20-one	F: 0.1–0.210; S: 4.0–6.710	PC:262961		
1. THP (isomer 2/4)	M S: 8.6–1810	GABAA+	CAS:128-20-1	
2. pregnanolone3	F: 0.06–0.110; S: 5.5–1010	HMDB:0062782		
3.3α-hydroxy-5β-pregnan-20-one			CHEBI:1712	
			PC:31402	
1. THP (isomer 3/4)	M S: 7.8–1010	GABAA−	CAS:516-55-2	
2. isopregnanolone3	F: 0.08–0.210; S: 3.7–7.110	(THP-S)	HMDB:0001455	
3.3β-hydoxy-5α-pregnan-20-one			PC:92787	
1. THP (isomer 4/4)	All: 0.3–36	CAS:128-21-2		
2. epipregnanolone3	M S: 0.4–0.610	GABAA−	HMDB:0001471	
3.3β-hydoxy-5β-pregnan-20-one	F: 0.02–0.0410; S: 1.5–2.510	(THP-S)	PC:228491	
1.3αDHP	PREGNENES	n.d.	GABAA+	CAS:25680-68-6	
2.3α-dihydroprogesterone			PC:121951	
3.4-pregnen-3α-ol-20-one				
1.3βDHP4	n.d.	PC:121951		
2.3β-dihydroprogesterone				
3.4-pregnen-3β-ol-20-one				
1. P	M: 0–0.46	PR+	HMDB:01830	
2. progesterone	Fpre: 0–806			
3.4-pregnene-3,20-dione	Fpost: 0–0.46			
1.17OHP	M: 0.61–7.06	PR+	CAS:68-96-2	
2.17α-hydroxyprogesterone	F: 0.21–2.36	HMDB:0000374		
3.17-hydroxypregn-4-en-3,20-dione			CHEBI:17252	
			PC:6238	
1.20αDHP	PREGNENES	Fpre: 0.8–11.76	PR+	CAS:145-14-2	
2.20α-dihydroprogesterone			HMDB:0003069	
3.20α-hydroxypreg-4-en-3-one			PC:8956	
1.17OHP5	M: 1.0–12 6	CAS:387-79-1		
2.17-hydroxypregnenolone	F: 0–6.06	HMDB:0000363		
3.5-Pregnen-3β,17α-diol-20-one			CHEBI:28750	
			PC:3032570	
1. P5	M: 1–156; S: 200–1,0006	GABAA− (P5-S)	CAS:145-13-1	
2. pregnenolone	Fpre: 1.0–156; S: 100–1,0006	HMDB:0000253		
3. pregn-5-en-3β-ol-20-one	Fpost: 1.0–156; S: 10–5006	CHEBI:16581		
			PC:8955	
1. none	ANDROSTANES		HMDB:0000899		
2. androstanedione	M: 0.37	CHEBI:22542		
3.5α-androstane-3,17-dione				
1. AN	All: 0.5–0.97	AR+ weak	HMDB:0000031	
2. androsterone	M: 0.4–4.06,10; S: 617–1,08010	GABAA+		
3.3α-hydroxy-5α-androstan-17-one	F: 0.3–0.610; S: 359–1,07010			
1.5βAN	M: 0.09–0.210; S: 32–7010	GABAA+	CAS:53-42-9	
2. etiocholanolone	F: 0.1–0.4 10; S: 34–8810	HMDB:00490		
3.3α-hydroxy-5β-androstan-17-one			CHEBI:28195	
			PC:5880	
1.3αDIOL	M: 0.4–0.59,10; S: 35–12110	ERβ+ weak	HMDB:0000495	
2. androstanediol	F: 0.03–0.06 10; S: 2.4–4.810	GABAA+		
3.5α-androstane-3α,17β-diol				
1.3βDIOL	All: 0.157			
2.3β-androstanediol	M S: 34–10310	ERβ+	HMDB:0000493	
3.5α-androstane-3β,17β-diol	F S: 8.7–1810			
1. EPI	M: 0.3–0.79,10; S: 211–53210	AR+ weak	CAS:481-29-8	
2. epiandrosterone	F: 0.3–0.710; S: 172–35010		HMDB:0000365	
3.3β-hydroxy-17-oxo-5α-androstane			CHEBI:541975	
			PC:441302	
1. DHT	M: 0/85–3.5 (50–100)6	AR+	HMDB:0002961	
2. dihydrotestosterone	Fpre: 0.08–1.36		CHEBI:16330	
3.17β-hydroxy-5α-androstan-3-one	Fpost: 0.03–1.656		PC:10635	
	ANDROSTENES		CAS:481-30-1		
1. EpiT8	M: 1.3–2.97	AR+ weak9	HMDB:0000628	
2. epitestosterone			CHEBI:42534	
3.17α-hydroxy-4-androsten-3-one			CB:10204	
			CAS 521-17-5	
1. A5	M: 2.6–3.79,10; S: 243–49410	AR+ weak	HMDB:0003818	
2. androstenediol	F: 0.8–1.110,11; S: 85–30210		CHEBI:2710	
3. androst-5-ene-3β,17β-diol			PC:10634	
1.17αA5	n.d.	AR+ weak	CAS:521-17-5	
2.17α- androstenediol		GAB AA−	HMDB:0003818	
3. androst-5-ene-3β,17α-diol			CHEBI:2710	
			PC:10634	
1. Δ4-A5	n.d.		CAS:1156-92-9	
2.4-androstenediol			HMDB:0005849	
3. androst-4-ene-3β,17β-diol			PC:12476620	
1. DHEA	M: 10–256; S: 2K-10K6	GABAA−	HMDB:0000077	
2. dehydroepiandrosterone	Fpre: 3.0–306; S: 1K-8K6	(DHEA and DHEA-S)		
3. (3β)-3-hydroxyandrost-5-en-17-one	Fpost: 2.0–206; S: 1K-6K6			
1. Abbreviation (used here)	Blood concentration
**
(nM)	Biologic activity***	Entries*	
2. Common name				
3. Chemical name				
1. A4	ANDROSTENES	All: 3.1–5.97	AR+	CAS:63-05-8	
2. androstenedione			HMDB:0000053	
3.4-Androstene-3,17-dione			CHEBI:16422	
1. T	M: 5–256		CAS:55-22-0	
2. testosterone	Fpre: 0.2–2.06	AR+	HMDB:0000234	
3.17β-hydroxyandrost-4-ene-3-one	Fpost: 0.2–1.06		CHEBI:17347	
1. E2	ESTROGENS	M: 0.02–0.046		CAS:50-28-2	
2.17β-estradiol	Fpre: 0.005–1.06	ER+	HMDB:0000151	
3. (17β)-estra-1,3,5(10)-triene-3,17-diol	Fpost: 0.005–0.086		CHEBI:16469	
1. E1	M: 0.033–0.16; S: 2.0–4.06		CAS:53-16-7	
2. estrone	Fpre: 0.015–0.5; S: 2.0–5.06	ER+	HMDB:0000145	
3.3-hydroxy-1,3,5(10)-estratrien-17-one	Fpost: 0.01–0.12; S: 5–20(X10−3) 6		CHEBI:17263	
List of the steroids discussed in the present review with the major features. Nomenclature of these compounds is variable and aliases are given as Supplemental Materials.

* CAS: Chemical Abstracts Service, a division of the American Chemical Society (www.cas.org. Accessed on date: February 2018); HMDB: Human Metabolome Data Base (www.hmdb.ca. Accessed on date: February 2018) (Wishart et al., 2013); CB: Chemical Book (www.chemicalbook.com. Accessed on date: February 2018); ChEBI (www.ebi.ac.uk/chebi. Accessed on date: February 2018) (Morgat et al., 2015); PC: PubChem (www.ncbi.nlm.nih.gov; pubchem.ncbi.nlm.nih.gov. Accessed on date: February 2018) (Kim et al., 2016).

** M: male subjects; F: female subjects; Fpre: female premenopausal subjects; Fpost: female postmenopausal subjects; -S: sulphated compounds.

*** PR, ER, AR: compound activates the indicated steroid receptor; GABAA allosteric positive (+) or negative (–) modulator.

∧ This isomer is shown in Figure 2.

n.d.: not determined.

1 20β-/5β-isomers exist (CB8678436, Chemical Book - www.chemicalbook.com. Accessed on date: February 2018); 2Isomer 5α-pregnan-3β,17α-diol-20-one exists (CB:0291774, Chemical Book - www.chemicalbook.com. Accessed on date: February 2018); 3In general, 5α-reduced and 3α-hydroxysteroids are positive allosteric modulator of GABAA, whereas 3α- and 3β-sulphated hydroxysteroids and 5β-reduced steroids are negative allosteric modulator of GABAA. The 3β-hydroxy isomers of THP are inactive (Belelli and Lambert, 2005; Gibbs et al., 2006; 4This compound is GABAA receptor inactive; 5Pearson Murphy et al., 2001; 6Mueller et al., 2015), 7Data extracted from the Human Metabolome Data Base-HMDB (www.hmdb.ca. Accessed on date: February 2018) (Wishart et al., 2013); 8This compound is strong inhibitor of SRD5As. 9Kancheva et al. (2007) and 10Bicikova et al. (2013).

Table 2 Major enzymes involved in steroidogenesis.

	Chromosome	Protein (aa)**		
1. Abbr.	Gene size*	Dalton	1. Name 2. Family	
2. Gene ID	mRNA size*	Localization (L)***	3. Catalysis 4. Substrates****	
3. Gene name(s)	Exons (no)		5. Distribution   6. Cofactor	
1. StAR	Chr: 8p11.23		1. steroidogenic acute regulatory protein	
2. 6770	gene: 8.6	aa: 285	2. cytochrome P450	
3. STAR, STARD1	mRNA: 1.6	Dalton: 31,914	3. facilitate transport of cholesterol to mitochondria	
	Exons: 8	L: mitochon	4. cholesterol	
			5. restricted (adrenal, testis, ovary, placenta)	
1. CYP11A1			1. cytochrome P450 side-chain cleavage enzyme	
2. 1583	Chr: 15q24.1		2. cytochrome P450, type I	
3. CYP11A1;
CYP11A;
CYPXIA1;
P450SCC	Gene: 30.0	aa: 521	3. cleavage of cholesterol side-chain	
	mRNA: 2.0	Dalton: 60,102	4. cholesterol→P5	
	Exons: 9	L: mitochon	5. restricted (adrenal, testis, ovary, placenta)	
			6. NADP/NADPH	
1. CYP17A1	Chr: 10q24.32		1. steroid 17α-hydroxylase/17,20-lyase	
2. 1586	Gene: 6.6	aa: 508	2. cytochrome P450, type II	
3. CYP17A1; CPT7; CYP17; S17AH; P450C17	mRNA: 1.9	Dalton: 57,371	3. 17α-hydroxylase and 17,20-lyase activities	
	Exons: 8	L: EndRet	4. P5→DHEA; P→A4$; 5αDHP→androstanedione; THP→ 5α-pregnan-3,17α-diol-20-one	
			5. restricted (adrenal, testis, ovary, placenta)	
			6. NADP/NADPH	
1. CYP19A1	Chr: 15q21.1		1. cytochrome P450 aromatase	
2. 1588	Gene: 130.6	aa: 503	2. cytochrome P450, type II	
3. CYP19A1; ARO; ARO1; CPV1; CYAR; CYP19; CYPXIX; P-450AROM	mRNA: 1.5–4.5	Dalton: 57,883	3. oxidative demethylation of C19 to C18 (aromatisation)	
	Exons: 10	L: EndRet	4. A → E1; T → E2	
			5. restricted (adrenal, testis, ovary, placenta)	
			6. NADP/NADPH	
1. 3βHSD1	Chr: 1p11–12		1. 3β-hydroxysteroid dehydrogenase/Δ5 → 4 isomerase type I	
2. 3283	Gene: 8.1	aa: 373	2. short chain dehydrogenase/reductase superfamily	
3. HSD3B1; HSD3B; HSDB3; SDB3A; (more∧∧)	mRNA: 1.7	Dalton: 42,252	3. oxidative conversion of Δ5 3β-hydroxyl to Δ4 keto-steroids	
	Exons: 4	L: membrane	4. P5→P; 17OHP5→17OHP4; DHEA→A4; A5→T; 17αA5→EpiT	
			5. selectively distributed (placenta, periphery)	
			6. NADP/NADPH or NAD/NADH	
1. 3βHSD2	Chr: 1p11–13		1. 3β-hydroxysteroid dehydrogenase/Δ5→4 isomerase type II	
2. 3284	Gene: 8.1	aa: 372	2. short chain dehydrogenase/reductase superfamily	
3. HSD3B2; HSDB; HSD3B; SDR11E2	mRNA: 1.7	Dalton: 42,052	3. oxidative conversion of Δ5-3β-hydroxyl to Δ4-ketosteroids	
	Exons: 4	L: mitochon	4. P5→P; 17OHP5→17OHP4; DHEA→A4	
			5. restricted (adrenal, testis, ovary)	
			6. NADP/NADPH or NAD/NADH	
1. 17βHSD1	Chr: 17q11–21		1. 17β-hydroxysteroid dehydrogenase type 1	
2. 3,292	Gene: 6.0	aa: 328	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B1	mRNA: 1–2.4	Dalton: 34,950	3. reduction of 17-keto to 17β-hydroxyl (estrogens)	
E2DH; HSD17; EDHB17; EDH17B2; SDR28C1; (more∧∧)	Exons: 6	L: cytoplasm	4. (established) E1→E2; (A4→T in rodents) (postulated) DHEA→A51; P→20αDHP2;	
			DHT→3βDIOL11; DHT→ androstanedione11	
			5. selectively distributed (ovary, placenta (low in endometrium, breast)14,15	
			6. NADP/NADPH	
1. 17βHSD2	Chr: 16q24.1–2		1. 17β-hydroxysteroid dehydrogenase type 2	
2. 3294	Gene: 63	aa: 387	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B2 HSD17; SDR9C2; EDH17B2	mRNA: 1.5	Dalton: 42,785	3. oxidation of 17β-hydroxyl to 17-keto (estrogens & androgens)	
	Exons: 5	L: EndRet	4. (established) E2→E1; T→A4; DHT→androstanedione1,10; 20αDHP→P16; 5α-pregnan-20-ol
-3-one→5αDHP16; A5→DHEA1; 3αDIOL→AN5
(postulated) 3αDIOL→AN(1, 10); DHT→androstanedione1; A5→DHEA1; allopregnandiol→ THP16	
			5. selectively distributed (liver, intestine, endometrium, placenta, pancreas, prostate, colon,
kidney. Negative in heart, brain, skeletal muscle, spleen, thymus, ovary, or testis)(14, 17)	
			6. NAD/NADH	
1. 17βHSD3&&	Chr: 9q22		1. 17β-hydroxysteroid dehydrogenase type 3	
2. 3293	Gene: 67	aa: 310	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B3
EDH17B3;	mRNA: 1.2	Dalton: 34,516	3. reduction of 17-keto to 17β-hydroxyl (androgens)	
	Exons: 11	L: EndRet	4. (established) A4→T
(postulated) AN→3αDIOL(1, 3, 10); androstanedione→DHT(1, 9, 10)	
			5. restricted (testis; low in brain, blood, skin, adipose tissue)14	
			6. NADP/NADPH	
1. 17βHSD4	Chr: 5q23.1	aa: 736	1. 17β-hydroxysteroid dehydrogenase type 4	
2. 3295	Gene: 184	Dalton: 79,686	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B4	mRNA: 2.9	L: Peroxisome mitochon	3. fatty acid β-oxidation (steroids in pigs)	
DBP; MFE-2; MPF-2; PRLTS1; SDR8C1	Exons: 28		4. (established) very long chain branched fatty acids, bile acids
(postulated) A5→DHEA1; E2→E114	
			5. ubiquitous (liver, heart, prostate, testis, lung, skeletal muscle, kidney, pancreas, thymus, ovary, intestine, placenta, brain, spleen, colon, lymphocytes)14	
			6. NAD/NADH	
1. 17βHSD6	Chr: 12q13	aa: 317	1. 17β-hydroxysteroid dehydrogenase type 6	
2. 8630	Gene: 24.5	Dalton: 35,966	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B6	mRNA: 1.6	L: EndRet
microsomes	3. 3α-3β-epimerase; 17β-hydroxyl oxidation (5α-reduced steroids); retinoids	
HSE; RODH; SDR9C6	Exons: 8		4. (established) 3αDIOL→DHT10; AN→androstanedione5; AN→EPI
(postulated) 3αDIOL→AN5; E2→E15	
			5. selectively distributed (liver, testis, lung, spleen, brain, ovary, kidney, adrenal, prostate)14	
			6. NAD/NADP	
1. 17βHSD7	Chr: 1q23		1. 17β-hydroxysteroid dehydrogenase type 7	
2. 51478	Gene: 22.1	aa: 341	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B7	mRNA: 1.5	Dalton: 38,206	3. 3-ketosteroid reductase of sterols	
PRAP; SDR37C1				
	Exons: 9	L: EndRet	4. (established) Sterols/cholesterol biosynthesis; DHT→3βDIOL1	
			5. widely distributed (ovary, uterus, placenta, liver, breast, testis, neuronal tissue, adrenal gland, small intestine, prostate, adipose tissue lung, and thymus)(14, 18)	
			6. NADP/NADPH	
1. 17βHSD8	Chr: 6p21.3		1. 17β-hydroxysteroid dehydrogenase type 8	
2. 7923	Gene: 2.2	aa: 261	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B8	mRNA: 1.0	Dalton: 26,974	3. fatty acid elongation; steroid 17βHSD action (rodents).	
KE6; FABG; HKE6; FABGL; RING2; H2-KE6; (more∧∧)	Exons: 9	L: mitochon	4. (established) fatty acids (postulated) E2→E1	
			5. widely distributed (prostate, placenta, kidney, brain, cerebellum, heart, lung, small intestine, ovary, testis, adrenal, stomach, liver, adrenals)14−19	
			6. NAD/NADP	
1. 17βHSD9	Chr: 12q23		1. 17β-hydroxysteroid dehydrogenase type 9	
2. 5959	Gene: 4.4	aa: 318	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B9	mRNA: 1.4	Dalton: 34,979	3. retinoid metabolism (steroid metabolism in rodents)	
RDH5; (more∧∧)	Exons: 4	L: EndRet	4. (established) retinoids (postulated) AN→3αDIOL1; androstanedione→DHT1	
1. 17βHSD10	Chr: Xp11.2		1. 17β-hydroxysteroid dehydrogenase type 10	
2. 3028	Gene: 3.1	aa: 261	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B10	mRNA: 0.9	Dalton: 26,923	3. fatty acids & steroid oxidation; tRNA maturation	
ABAD; CAMR; ERAB; HCD2; MHBD; HADH2; MRPP2; MRX17; MRX31; (more∧∧)	Exons: 6	L: mitochon	4. (established) Isoleucine, fatty acid, bile acid metabolism, THP→5αDHP(20, 34)
(postulated) 3αDIOL→AN1,9; DHT→androstanedione1,9; T→A41	
			5. nearly ubiquitous (liver, small intestine, colon, kidney, heart, brain, placenta, lung, ovary, testis, spleen, thymus, prostate, leukocyte)14	
			6. NAD/NADH	
1. 17βHSD11	Chr: 4q22.1		1. 17β-hydroxysteroid dehydrogenase type 11	
2. 51170	Gene: 54.9	aa: 300	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B11	mRNA: 1.9	Dalton: 32,936	3. Short-chain alcohol dehydrogenases	
DHRS8; PAN1B; RETSDR2; SDR16C2; (more∧∧)	Exons: 7	L: EndRet	4. (established) lipids, sec. alcohols/ketones (postulated) 3αDIOL→AN1,9	
			5. nearly ubiquitous (liver, intestine, kidney, adrenal gland, heart, lung, testis, ovary, placenta, sebaceous gland and pancreas)14,21	
			6. NAD/NADH	
1. 17βHSD12	Chr: 11p11.2		1. 17β-hydroxysteroid dehydrogenase type 12	
2. 51144	Gene: 170.1	aa: 312	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B12	mRNA: 2.6	Dalton: 34,324	3. fatty acid elongation, steroid 17βHSD reductive action (rodents)	
KAR; SDR12C1	Exons: 11	L: EndRet	4. (established) branched/long chain fatty acids (postulated) E1→E2	
			5. ubiquitous (heart, skeletal muscle, liver, kidney, adrenal gland, testis, placenta, brain, pancreas, GIT, trachea, lung, thyroid, prostate, aorta, bladder, spleen, skin, ovary, breast, uterus, vagina)(14, 22)	
			6. NADP/NADPH	
1. 17βHSD13	Chr: 4q22.1		1. 17β-hydroxysteroid dehydrogenase type 13	
2. 345275	Gene: 19.1	aa: 300	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B13	mRNA: 2.3	Dalton: 33,655	3. and 4. unknown	
SCDR9; NIIL497; (more∧∧)	Exons: 6	L: extracell/EndRet	5. restricted (liver; low in bone marrow, lung, ovary, testis,
kidney, skeletal muscle brain, bladder)14	
1. 17βHSD14	Chr: 19q13.33		1. 17β-hydroxysteroid dehydrogenase type 14	
2. 51171	Gene: 23.7	aa: 270	2. short chain dehydrogenase/reductase superfamily	
3. HSD17B14	mRNA: 1.3	Dalton: 28,317	3. fatty acid & prostaglandin metabolism; 17βHSD activity	
DHRS10; SDR47C1; retSDR3	Exons: 8	L: cytoplasm	4. (established) fatty acids
(postulated) 3αDIOL→AN1,9; E2→E14; T→A44; A5→DHEA5	
			5. widely distributed (brain, liver, placenta, breast)14	
			6. NAD/NADH	
1. 17βHSD15	Chr: 14q24.1		1. retinol dehydrogenase 11	
2. 51109	Gene: 19.0	aa: 318	2. short chain dehydrogenase/reductase superfamily	
3. RDH11; PSDR1; ARSDR1; (more∧∧)	mRNA: 1.8	Dalton: 35,386	3. dehydrogenase activity of retinoid and steroids	
	Exons: 9	L: cytoplasm	4. (established) retinoids (post.) AN→3αDIOL1,9; androstanedione→DHT1,9	
			5. widely distributed
6. NADP/NADPH	
1. DHRS1123	Chr: 17q12		1. dehydrogenase/reductase 11	
2. 79154	Gene: 9.0	aa: 260	2. short chain dehydrogenase/reductase superfamily	
3. DHRS11	mRNA: 1.6	Dalton: 28,308	3. steroid 17HSD & 3βHSD activities; bile acids metabolism	
ARPG836; SDR24C1; spDHRS11	Exons: 7	L: extracell	4. E1→E2; A4→T; DHEA→A5; androstanedione→DHT; AN→3αDIOL; P→3αDHP23
5. nearly ubiquitous (testis, small intestine, colon, kidney)23
6. NADP/NADPH	
1. AKR1C1	Chr: 10p14–15		1. aldo-ketoreductase family 1 member C1	
2. 1645	Gene: 20.0	aa: 323	2. aldo-ketoreductase family	
3. AKR1C1	mRNA: 12	Dalton: 36,788	3. 20αHSD (strong) and 17βHSD (weak) activities; moderate 3-keto reduction to 3β-hydroxyl (> 3α)	
C9, DDH, DDH1, DD1, H-37, HBAB, MBAB HAKRC; DD1/DD2; 2-ALPHA-HSD; 20-ALPHA-HSD	Exons: 9	L: cytoplasm	4. (established) P→20αDHP6; 5αDHP→5α-pregnan-20-ol-3-one6; THP→allopregnandiol6; DHT→3βDIOL7; androstanedione→DHT7; 5α-pregnan-20-ol-3-one→allopregnandiol16; 5αDHP→THP16
(post.) DHT→3αDIOL7; A4→T7; E1→E27; 3αDIOL→AN7; 20αDHP→ P7; DHT→3βDIOL24; 5α-pregnan-17α-ol-3,20-dione→5α-pregnan-3,17α-diol-20-one16	
			5. ubiquitous	
			6. NADP/NADPH or NAD/NADH	
1. AKR1C2	Chr: 10p14–15		1. aldo-ketoreductase family 1 member C2	
2. 1646	Gene: 30.6	aa: 323	2. aldo-ketoreductase family	
3. AKR1C2
DD; DD2; TDD; BABP; DD-2; DDH2; HBAB; HAKRD; MCDR2; SRXY8; DD/BABP; AKR1C-pseudo	mRNA: 1.3 
Exons: 9	Dalton: 36,735
L: cytoplasm	3. 20αHSD (weak) and 17βHSD activities; 3-keto reduction to 3α- hydroxyl; bile-acid binding protein activity	
			4. (established) DHT→3αDIOL7,12; 5αDHP→THP7; androstanedione→AN25; 5α-pregnan-20-ol-3-one→ allopregnandiol16; 5αDHP→THP16; 5α-pregnan-17α-ol-3,20-dione→5α-pregnan-3,17α-diol-20-one16
(postulated) A4→ T7; E1→E27; P→20αDHP7; 3αDIOL→ DHT7; T→A47	
			5. ubiquitous	
			6. NADP/NADPH or NAD/NADH	
1. AKR1C3	Chr: 10p14–15		1. aldo-ketoreductase family 1 member C3	
2. 8644	Gene: 13	aa: 323	2. aldo-ketoreductase family	
3. HSD17B5
AKR1C3
DD3; DDX; PGFS; HAKRB; HAKRe; HA1753; HSD17B5; hluPGFS	mRNA: 1.2
Exons: 9	Dalton: 36,853
L: cytoplasm	3. 20αHSD (weak) and 17βHSD activities (androgens); 3-keto reduction to 3α-/β-hydroxyl (weak); 11-ketoprostaglandin reductase3	
			4. (established) A4→T7; DHT→3αDIOL7; 3αDIOL→AN7; 5αDHP→ THP7; 5α-pregnan-20-ol-3-one→ allopregnandiol16; 5αDHP→THP16; DHEA→A57; 5α-pregnan-17α-ol-3,20-dione→5α-pregnan-3,17α-diol-20-one16; androstanedione→DHT24
(postulated) E1→E27;T→A47; 20αDHP→ P7	
			5. nearly ubiquitous (prostate, mammary gland, liver, kidney, lung, heart, uterus, testis, brain, skeletal muscle, adipose tissue, pancreas, hearth, skeletal muscle, thymus, ovary, small intestine and colon)14,26	
			6. NADP/NADPH or NAD/NADH	
1. AKR1C4	Chr: 10p15.1		1. aldo-ketoreductase family 1 member C4	
2. 1109	Gene: 25.2	aa: 323	2. aldo-ketoreductase family	
3. AKR1C4	mRNA: 1.2	Dalton: 37,067	3. 20αHSD (weak) and 17βHSD activities; 3-keto reduction to 3α-hydroxyl (>3β).	
C11; CDR; DD4; CHDR; DD-4; HAKRA;	Exons: 9	L: cytoplasm	4. (established) DHT→3αDIOL7,10; androstanedione→AN7,8; other$$$
(postulated) A4→ T7; E1,→E27; P→20αDHP7; 3αDIOL→DHT7	
			5. restricted (liver) 6. NADP/NADPH or NAD/NADH	
1. SRD5A1
2. 6715
3. SRD5A1
S5AR 1	Chr: 5p15.31
Gene: 41.0
mRNA: 2.3
Exons: 5(7)	aa: 259
Dalton: 29,459
L: EndRet	1. steroid 5α-reductase 1 2. steroid 5α reductase family
3. androgen and pregnene metabolism
4. T→DHT; A4→androstanedione; 17OHP4→5α-pregnan-17α-ol-3,20-dione; P→5αDHP; 20αDHP→5α-pregnan-20-ol-3-one 5. ubiquitous	
1. SRD5A2	Chr: 2p23.1		1. steroid 5α-reductase 2	
2. 6716	Gene: 178.3	aa: 254	2. steroid 5α reductase family	
3. SRD5A2	mRNA: 2.5	Dalton: 28,393	3. androgen and pregnene metabolism	
	Exons: 5	L: microsomes	4. T→DHT; A4→androstanedione	
			5. restricted (prostate and androgen sensitive tissues)	
1. SRD5A3	Chr: 4q12		1. steroid 5α-reductase 3	
2. 79644	Gene: ….	aa: 318	2. steroid 5α reductase AND polyprenol reductase subfamily	
3. SRD5A3	mRNA: 4.1	Da: 36,521	3. androgen and pregnene metabolism	
CDG1P; CDG1Q; KRIZI; SRD5A2L; SRD5A2L1	Exons: 6	L: EndRet	4. T→DHT; A4→androstanedione; 17OHP4→5α-pregnan-17α-ol-3,20-dione; P→5αDHP; 20αDHP→5α-pregnan-20-ol-3-one	
			5. ubiquitous	
1. STS	Chr: Xp22.31		1. steroid sulphatase	
2. 412	Gene: 208.3	aa: 583	2. sulphatase	
3. STS	mRNA: 6.4	Dalton: 65,492	3. hydrolyses several 3β-hydroxysteroid sulfates	
ES; ASC; XLI; ARSC; SSDD; ARSC1	Exons: 16	L: microsomes EndRet	4. sulpho conjugated cholesterol, E1, E2, DHEA, P5, 17OHP5S, A5, EPI	
			5. ubiquitous (lung, aorta, thyroid, uterus, liver and testis)27−30	
1. SULT1E1	Chr: 4q13.3		1. estrogen sulphotransferase	
2. 6783	Gene: 50.0	aa: 35126	2. sulphotransferase 1	
3. SULT1E1	mRNA: 1.8	Dalton: 35,126	3. sulpho-conjugation of steroids	
EST; STE; EST-1; ST1E1; (more∧∧)	Exons: 9	L: cytoplasm	4. E1, DHEA (low affinity for E2)	
			5. moderately distributed (liver, adrenal, small intestine; low in brain, lung, testis,
leukocytes, placenta, salivary gland, stomach, thymus, trachea, uterus, kidney)(30, 31)	
1. SULT2A1	Chr: 19q13.3		1. dehydroepiandrosterone sulphotransferase	
2. 6822	Gene: 15.9	aa: 285	2. sulphotransferase 1	
3. SULT2A1	mRNA: 2.0	Dalton: 33,780	3. sulpho-conjugation of steroids, bile acids	
HST; ST2; STD; hSTa; DHEAS; ST2A1;	Exons: 6	L: cytoplasm	4. DHEA, P5, AN, 17OHP532, A532, AN33, EPI, bile acids	
			5. restricted (liver, adrenal, small intestine (low in colon, hearth,
prostate, stomach, testis, thyroid)30	
1. SULT2B1	Chr: 19q13.33		1. alcohol sulphotransferase	
2. 6820	Gene: 48.5	aa: 365	2. sulphotransferase 1	
3. SULT2B1	mRNA: 1.3	Dalton: 41,308	3. sulpho-conjugation of steroids	
HSST2; ARCI14	Exons: 7	L: cytoplasm	4. cholesterol, DHEA	
			5. moderately distributed (placenta, prostate, lung (low in kidney, salivary gland, small intestine, trachea)30	
1. SULT1A1	Chr: 16p11.2		1. phenol sulphotransferase 1	
2. 6817	Gene: 18.4	aa: 295	2. sulphotransferase 1	
3. SULT1A1	mRNA: 1.3	Dalton: 34,165	3. sulpho-conjugation of steroids	
PST; STP; STP1; P-PST; ST1A1; ST1A3; TSPST1; HAST1/HAST2	Exons: 13	L: cytoplasm	4. E2	
			5. nearly ubiquitous (adrenal, bone marrow, brain, colon, hearth, kidney, liver, lung, pancreas, leukocytes, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thymus, thyroid, trachea, uterus)30	
List of all enzymes discussed in the present review with the major features. Gene and gene product nomenclature is complex and variable and alias are given as Supplemental Materials. Gene structure (chromosome location, gene length), transcript features (length, exons) and protein characteristics (amino-acid length, molecular weigh and cell localization) were obtained from GeneCards (www.genecards.org. Accessed on date: February 2018) (Stelzer et al., 2016).

* Length in kilo nucleotides.

** number of amino-acids.

*** Abbreviations: EndRet: endoplasmic reticulum; extracell: extracellular; mitochon: mitochondria.

**** For some enzymes, substrate specificity based on robust evidences are indicated as ‘established’, whereas other reactions whose catalyzes is supported by less robust experimental evidences (mostly using recombinant proteins in vitro/cell-free assays) are indicated as “postulated.”

$ This reaction of CYP17A1 does not occur in vivo in humans (Miller and Auchus, 2011).

$$$ AKR1C4 has an important detoxifying function in the liver and converts chlordecone into chlordecone alcohol.

&& 17βHSD3 is testis specific and the reactions catalyzed by this enzyme are not reported in Figure 2.

∧∧ For this gene, additional gene names exist, for details see NCBI database (https://www.ncbi.nlm.nih.gov/).

1 Luu-The and Labrie (2010), Labrie and Labrie (2013), and Labrie (2015); 2 Smuc and Rizner (2009), 3 Miller et al. (2012b), 4 Sivik (2012); 5 GeneCards (www.genecards.org. Accessed on date: February, 2018) Stelzer et al. (2016), 6 Smuc and Rizner (2009), 7 Penning et al. (2004), Steckelbroeck et al. (2010); 8 Jin et al. (2011), 9Manenda et al. (2016), 10Balk and Knudsen (2008), 11Gangloff et al. (2003), 12Bélanger et al. (2002), 13Perez Carrion et al. (1994), 14Möller et al. (1999), Moeller and Adamski (2009), 15Cornel et al. (2017), 16Sinreih et al. (2017b), 17Casey et al. (1994), 18Törn et al. (2003), 19Ohno et al. (2008), 20Yang et al. (2016), 21Chai et al. (2003), 22Sakurai et al. (2006), 23Endo et al. (2016). 24Rižner and Penning (2014), 25Manenda et al. (2016), 26Lin et al. (1997), 27Miki et al. (2002), 28Foster et al. (2008a), 29Purohit and Foster (2012), 30Mueller et al. (2015), 31Marchais-Oberwinkler et al. (2011), Mueller et al. (2015), 32Rege et al. (2016), 33Strott (2002), and 34Yang et al. (2016).

Ovarian steroidogenesis
Transformation of cholesterol to 17β-estradiol (E2) involves first the production of dehydroepiandrosterone (DHEA) in theca cells through the action of steroidogenic acute regulatory protein (StAR) that facilitates the transport of cholesterol into mitochondria, followed by CYP11A1 (rate-limiting) and CYP17A1 (Figure 2); the ovarian pathway is indicated by the yellow background; reviewed by (Miller and Auchus, 2011; Andersen and Ezcurra, 2014). CYP11A1 is a type I CYP localized in mitochondria that uses nicotine-adenine-dinucleotide-phosphate (NADPH) and ferredoxin (Fdx)/ferredoxin reductase (FdR) to cleave the cholesterol side chain and produce pregnenolone (P5). Type II CYP17A1, localized in the endoplasmic reticulum (EndRet), has both 17α-hydroxylase and 17,20-lyase activities. It uses NADPH and P450 oxidoreductase (POR) to first hydroxylate P5 to 17α-hydroxypregnenolone (17OHP5) (17α-hydroxylase action), followed by 17,20-lyase action to release DHEA. Gonad specific type 2 3β-hydroxysteroid dehydrogenase (3βHSD2) has 3β-dehydrogenase and Δ5 to Δ4 isomerase activities and converts DHEA to androstenedione (A4). Next, CYP19A1 catalyzes the oxidative demethylation of C19 androgens to C18 estrogens, with A-ring aromatisation; hence A4 is converted to estrone (E1). The final conversion of E1 (with low affinity for the estrogen-receptors -ERs) to E2 (high affinity for ERs and high estrogenic potency) is catalyzed by 17βHSD1 that reduces 17-keto to 17β-hydroxyl steroids. In the ovary, the 17-keto group of A4 can be reduced to 17β-hydroxyl by AKR1C3/17βHSD5 yielding testosterone (T) that is converted to E2 by CYP19A1. Upon ovulation, high 3βHSD2 levels in the corpus luteum lead to high progesterone (P) generation from P5.

Intracrine steroidogenesis
The expression of StAR, CYP11A1 and CYP17A1 is demonstrated in a limited number of peripheral tissues (see later and Tables 6–8). However, pregnenes, pregnanes, androstenes and androstanes generated from these initial steps (but also abundantly available as circulating precursors) can be further metabolized locally thus generating a plethora of compounds with various biological activities (estrogenic, androgenic, progestogenic and neuroactive; Tables 1, 2 and Figure 2). The Δ5 to Δ4 isomerization of androstenes (DHEA, androstenediol -A5- and 17αA5) and pregnenes (P5, 17OHP5) is catalyzed by 3βHSD1, which is the peripheral counterpart of ovarian 3βHSD2. Also 3βHSD2, whose expression was initially considered to be restricted to endocrine tissues, is detected peripherally in recent reports (Stoffel-Wagner, 2001; Tsai et al., 2001; Attar et al., 2009; Huhtinen et al., 2014; Osinski et al., 2018). Due to the high concentration of DHEA (both in blood and tissues), its conversion to A4 by 3βHSDs is relevant to the formation of downstream androgens and of estrogens. Additionally, 3βHSDs convert A5 and the isomer 17αA5 to T and epitestosterone (EpiT). Although minor, in the context of women's health, these pathways are relevant. A5, together with 3α and 3βDIOL (generated by AKR1Cs from DHT and AN, see below) activate both ERs and have estrogenic action (especially 3βDIOL, a potent ERβ binder). A5 possesses immune stimulatory activity whereas its 17α isomer (17αA5) has androgenic, antitumor and neuroactivity. Additionally, EpiT is a weak AR binder and a strong endogenous inhibitor of SRD5As (Loria and Graf, 2012). The endogenous occurrence of 17αA5 is demonstrated in humans (Laatikainen et al., 1971) but its route of synthesis is unclear (Shimizu, 1979). A 17αHSD able to convert A4 to EpiT and DHEA to 17αA5 is characterized in mice (Bellemare et al., 2005) but no human homologous is described yet. Similarly to the ovaries, androgen to estrogen conversion is catalyzed by CYP19A1.

A particularly important reaction is controlled by oxidative and reductive 17βHSDs, which interconvert 17-keto and 17β-hydroxysteroids. Since 17β-hydroxysteroids (T and E2) have higher affinity for the receptors than the keto-steroids (A4 and E1), this balance determines the final androgenic/estrogenic activity. Fourteen 17βHSDs exist, whose specificity is determined by tissue distribution, intracellular localization and biochemistry (Table 2); reviewed thoroughly in (Mindnich et al., 2004; Moeller and Adamski, 2006, 2009; Prehn et al., 2009; Miller and Auchus, 2011). Unpublished data also refer to a 15th 17βHSD (see Table 2; reported in Luu-The et al., 2008) with a putative role in androgen metabolism. With the exclusion of 17βHSD5 (AKR1C3, see below), all other 17βHSDs belong to the short-chain dehydrogenase (SRD) family.

Although all 17βHSDs have been postulated to use steroids as substrates based on cell-free or in vitro assays, recent investigations based on substrate specificity (Laplante et al., 2009) and knock-out (KO) models (Table 4) better clarified their roles. Type 1 17βHSD is the estrogenic enzyme and coverts E1 to E2 both in the ovary and in peripheral tissue. Type 2 17βHSD oxidizes 17-hydroxyl groups (E2 and T) to the 17-keto forms (E1 and A4), and possesses also a 20α-hydroxyl oxidative action, through which this enzyme generates P from 20αDHP. Type 6 17βHSD uses 5α-reduced androgens and has 17-hydroxyl oxidative activity (converting androsterone -AN- to androstanedione) and 3-hydroxyl oxidative activity (converting 3αDIOL to the most potent androgen dihydrotestosterone -DHT). Additional catalytic actions for 17βHSD6 (epimerase or 17-hydroxydehydrogenase) are demonstrated in vitro (Table 2). Type 14 17βHSD is postulated to have 17β-hydroxyl oxidative action on various steroids, type 7 is involved in cholesterol metabolism as indicated by KO mice (Table 4), whereas there is apparently little/no in vivo role of types 8, 9, 10, 11 and 12 17βHSDs on steroid metabolism (Table 2 and indicated by KO mice, Table 4). Recently, a novel SRD, DHRS11, was shown to possess in vitro 17-keto to 17β-hydroxyl reductive action (able to use E1, Δ5 or Δ4 androstenes, androstanes), plus reductive 3βHSD activity toward Δ4 pregnenes and other compounds (5β-steroids, bile acids; Table 2 and Figure 2; Endo et al., 2016).

Androgens and progestogens can be further metabolized by aldo-ketoreductases (AKRs) and 5α-reductases (SRD5As; Figure 2). Cytoplasmic AKRs (AKR1C1, 1C2, 1C3/17βHSD5 and 1C4) have broad substrate specificity with non-stereo-selective 3α/3βHSD, 17- and 20-ketosteroid reductase activities (Table 2; Penning et al., 2004; Steckelbroeck et al., 2010). Together with the fact that they have wide tissue distribution (only AKR1C4 is restricted), AKR1Cs contribute to make intracrine networks flexible and intricate (Rižner and Penning, 2014; Sinreih et al., 2014).

SRD5As convert 3-keto Δ4 androstene and pregnene to 5α-reduced steroids (androstanes and pregnanes), hence they are important in progestogen, androgen (DHT production) and neurosteroid metabolism (Di Costanzo et al., 2009). SRD5A1 and 3 are widely expressed, in contrast to SRD5A2. Human 5β-reductase activity, catalyzed by AKR1D1, is restricted to the liver, where 5β-steroids are directed to clearance/catabolism. However, some 5β-compounds are neuroactive and recent studies indicate the presence of AKR1D1 in placenta and myometrium (Jin et al., 2011). With the exclusion of their neuroactivity (Paragraph 4.6), 5β-steroids will not be further considered.

The sulphatase pathway is finally responsible for the balance between sulpho-conjugated and free steroids. Sulpho-conjugated steroids (-S) possess higher water solubility, increased stability and longer half-life than unconjugated compounds (e.g., 10–12 h vs. 20–30 min for estrogens), and although they cannot bind steroid-receptors, they serve as a reservoir for the formation of biologically active steroids (Reed et al., 2005). Sulphotransferases (SULTs) are phase-I detoxifying enzymes that use bis-phospho-nucleotide 3′-phospho-adenosine-5′-phosphate- (PAP)-sulfate as donor to conjugate 3β-hydroxyl steroids (e.g., estrogens, DHEA, P5, cholesterol; red circles in Figure 2) with a sulfate group (Strott, 2002; Rižner, 2016). Distinct SULTs have different specificities toward substrates, with SULT1E1 being the major estrogen sulphating enzyme (with little contribution of SULT1A1), and SULT2A1 being specific for DHEA (but also for P5, 17OHP5 and A5) (Table 2). Steroid sulphatase (STS) is a membrane-bound microsomal enzyme that catalyzes the hydrolysis of sulfate ester bonds from sulphated-steroids (cholesterol-S, P5-S, 17OHP5-S, DHEA-S, E1-S) (Mueller et al., 2015; Rižner, 2016), thus releasing unconjugated compounds.

Although sulphated-3α-hydroxysteroids are not thoroughly studied, they are detected in biospecimens (AN-S, 3αDIOL-S; Table 1 and orange circles in Figure 2). They are most likely produced by SULT2A1 (active on 3α-hydroxy bile acids) (Strott, 2002; Rižner, 2016) but no 3α-stereo specific sulphatase is known to date. Some intracellular sulphated-steroids are converted to other compounds without prior desulphation (Sánchez-Guijo et al., 2016).

In conclusions, intracrinology presents redundant and complex pathways, which generate compounds with various activities. Genetic variants in intracrine genes are associated with various diseases (classically endocrine and not; Table 5). Even in the absence of the enzymatic machinery to metabolize cholesterol (StAR, steroidogenic factor, CYP17A1 and CYP11A1), DHEA, P5 and especially their sulphated-conjugates have high blood concentrations (Table 1), and are used to generate all other steroids in peripheral tissues.

Drug development
Natural hormones have been historically used as drugs, and depending on definitions, approximately 90 marketed drugs share a steroidal core (see https://www.drugbank.ca). Steroids (T, E2, cortisol, DHEA), simple derivatives (ethinylestrogen, prednisolone) or more complex analogs (abiraterone, fulvestrant) are used in various conditions. This old-and-proven steroidal chemistry based approach is used even in modern era.

By targeting steroid intracrine metabolism, the effects of steroids can be modulated locally. Table 3 overviews the available drugs targeting intracrine enzymes and their developmental status. CYP19A1 (aromatase) inhibitors, currently at their third generation, started to be used for breast cancer during the 80's of last century (Lønning and Eikesdal, 2013), and was followed by drugs able to target other enzymes (CYP11A1, CYP17A1, SRD5As; Table 3).

Table 3 Drugs targeting intracrine enzymes.

	Inhibitor name (if known); (Drug Bank ID#)	
	Developmental phase&	Approved drugs	
Name	Discovery	Preclinical indication	Clinical indication	Inhibitor name	Indication	
CYP11A1	✓	✓	✓	Aminoglutethimide
(DB00357##)	Cushing's syndrome
Breast cancer	
CYP17A1	✓	✓	✓	Abiraterone
(DB05812)	Prostate cancer, metastatic, castration-resistant	
CYP19A1	✓	✓	Letrozole
(DB01006)(19, 22, 24)	Anastrozole	Breast cancer: adjuvant treatment, metastatic	
				(DB01217)		
				Letrozole		
				(DB01006)		
				Exemestane	Breast cancer, palliative	
				(DB00990)		
				Formestane1		
				Testolactone*		
				(DB00894)		
			Anastrozole
(DB01217) (20, 23)			
			Exemestane
(DB00990) 21			
			Advanced stage endometrial cancer, NSCLC∧, LAM∧∧			
3βHSD1	✓	✓	✓	Trilostane*
(DB01108)	Cushing's syndrome
(veterinary use)	
3βHSD2	✓	✓	✓	Trilostane*
(DB01108)	Cushing's syndrome
(veterinary use)	
17βHSD1	✓	Endometriosis2,3				
		Endometrial cancer4				
		Breast cancer5,6				
		Endometrial hyperplasia7				
17βHSD2	8,9					
17βHSD3&&		Prostate cancer10				
17βHSD7	11					
AKR1C1	12					
AKR1C2	12					
AKR1C3	✓	✓	ASP-952113
Prostate cancer**			
			BAY 1128688
Endometriosis***			
AKR1C4	12					
SRD5A1	✓	✓	✓	Dutasteride (DB01126)	Prostatic hyperplasia (benign)	
SRD5A2	✓	✓	✓	Finasteride (DB01216)	Prostatic hyperplasia (benign)	
				Dutasteride (DB01126)		
SRD5A3	✓	✓	✓	Dutasteride (DB01216)	Prostatic hyperplasia (benign)	
STS	✓	✓	Irosustat (DB02292)			
			Endometrial cancer 14,15			
			Breast cancer14−17			
			E2MATE/PLG2001			
			Endometriosis18			
SULT1E1	✓	✓	✓	Cyclizine (DB01176)	antistaminic for nausea/vomiting	
& ‘Clinical phase’, i.e., in phase I, II or III trial; ‘Preclinical phase’ refers to in vivo testing; ‘Discovery phase’ any previous phase with some candidate compounds.

# Drug Bank ID if the compound is deposited in Drug Bank database (www.drugbank.ca/drugs. Accessed on date: February 2018) (Wishart et al., 2018).

## Aminoglutethimide (ID: DB00357) is an important inhibitor of CYP11A1 with inhibitory activity on CYP19A1 as well.

* No longer on the market.

&& 17βHSD3 is testis specific and the reactions catalyzed by this enzyme are not reported in Figure 2.

** This trial for prostate cancer was prematurely terminated (www.clinicaltrials.gov, NCT01352208).

*** Phase I trial is concluded (www.clinicaltrials.gov, NCT02434640. Accessed on date: February 2018) and a phase II trial started 2016 (http://adisinsight.springer.com/drugs/800041929).

∧ NSCLC: non-small cell lung cancer

∧∧ LAM: lymphangioleiomyomatosis

1 Perez Carrion et al. (1994), 2Arnold and Einspanier (2013), 3Delvoux et al. (2014), 4Konings et al. (2017), 5Järvensivu et al. (2018), 6Husen et al. (2006), 7Saloniemi et al. (2010), 8Gargano et al. (2015), 9Soubhye et al. (2015) 10Day et al. (2013), 11 Wang et al. (2017), 12BroŽic et al. (2011), 13 Kikuchi et al. (2014), 14Purohit and Foster (2012), 15Pautier et al. (2017), 16Palmieri et al. (2017a), 17Palmieri et al. (2017b), 18Pohl et al. (2014), 19Ma et al. (2004), 20Rose et al. (2000), 21Lindemann et al. (2014), 22Slomovitz et al. (2015), 23 NCT00932152; 25Lu et al. (2017).

Table 4 Mouse models (knockouts - KO or transgenic-TG, i.e., ubiquitous expression of the gene, unless specified) for intracrine enzymes.

Gene∧	Modification MGI ID$	Phenotype	
SatAR	Null/KO1
MGI: 2388706	Endocrine (steroids) & reproductive endocrinology

- abnormal endocrine organs (adrenal, ovaries, prostate, testis).
- decreased steroids and increased adrenocorticotropin level.
- adrenocortical insufficiency.
- loss of negative feedback regulation at hypothalamic-pituitary levels.	
		Additional
Growth retardation neo/post natal lethality (incomplete penetrance). Reproductive system: abnormal uterus; incomplete spermatogenesis; abnormal genitalia.	
CYP11A1	Null/KO2
MGI:5464022	Endocrine (steroids) and reproductive endocrinology
- abnormal adrenal gland morphology.
- increased circulating adrenocorticotropin level.
- lack of steroid production.
- decreased corticosterone and aldosterone levels.	
	Null/KO3
MGI: 2183813	Additional
Neonatal lethality (rescued by steroid supplementation); abnormal mitochondrion morphology; abnormal lipid level. Reproductive system: abnormal genitalia, prostate, testis morphology and spermatogenesis; Nervous system: abnormal adrenaline and noradrenaline level; abnormal food intake, hypoactivity; postnatal growth retardation.	
CYP17A1	Null/KO4
MGI:3722780	Endocrine (steroids) & reproductive endocrinology
- increased circulating cholesterol level.
- decreased T level.
- early reproductive senescence.	
	Null/KO5
MGI:3047328 

Null/KO 
MGI:5605834	Additional
Homozygous embryonic lethality (Ed7, between implantation and somite formation). Reproductive system: abnormal sperm flagellum morphology/asthenozoospermia; reduced male fertility. Bone: abnormal bone structure, mineral content and density. Metabolism: increased total body fat; decreased lean body mass; increased circulating creatinine level; increased fasted circulating glucose level. Nervous system: abnormal sexual interaction.	
CYP19A1	Null/KO6
MGI:2179439	Endocrine (steroids) and reproductive endocrinology
- increased circulating cholesterol, T, DHT, FSH, LH and prolactin.
- decreased circulating E2 level.
- abnormal endometrium (thin, decreased uterus weight). 
- abnormal ovary (absence of follicles and corpus luteum, anovulation).	
	Null/KO7

MGI:2154536

Null/KO8
MGI:2389548	Additional
Reproductive system: ovary hemorrhage and cysts; increased seminal vesicle weight and abnormal seminiferous tubule epithelium and oligozoospermia; female infertility and reduced male fertility. Metabolism: increased fat; obesity and susceptibility to weight gain. Bone: decreased bone mineral density and bone mass; increased bone resorption, osteoclast cell number; abnormal compact and trabecular bone morphology. Metabolism: increased circulating glucose and triglyceride levels; impaired glucose tolerance; insulin resistance; hepatic steatosis; abnormal liver physiology. Nervous system: abnormal short term spatial reference memory; abnormal emotion/affect behavior; abnormal barbering behavior; increased grooming behavior; abnormal locomotor activation, bradykinesia; abnormal mating frequency.	
17βHSD1	Null/KO9
MGI:5576042 and 3799948	Endocrine (steroids) & reproductive endocrinology
- abnormal corpus luteum morphology and decreased number. 
- increased ovarian E1:E2 and A4:T ratios.
- increased LH level.
- reduced P level.	
		Additional
Increased circulating alkaline phosphatase level, pigmentation, abnormal retinal pigmentation, abnormal lens morphology, abnormal retina morphology, abnormal retinal pigmentation. Reproductive system: increased ovary weight; reduced female fertility. Metabolism: decreased circulating glucose level. Nervous system: abnormal behavior, response to light, sleep behavior, decreased exploration in new environment; abnormal motor coordination/balance.	
17bHSD1	TG10	Reproductive endocrinology
- female have increased T levels.
- increased E1E2 conversion.
- masculinization in females. 
- develop benign/malignant breast, ovarian and endometrial conditions.	
17βHSD2	Null/KO11
MGI:3773836	No clear reproductive endocrinology phenotype
Additional
Heterozygous mice: growth retardation at birth ant postnatal; premature death; renal degeneration. Reproductive system: 70% embryonic lethality (Ed11.5) due to placental defects (homozygous); small and abnormal placenta morphology; Nervous system: brain phenotype with enlarged ventricles; abnormal cortex morphology; impaired balance, coordination, abnormal sleep pattern, megacephaly.	
	TG12	Reproductive endocrinology
- low T level.	
		Additional
Growth retardation; delayed eye opening; impaired retinoic signaling. Reproductive system: disrupted spermatogenesis. Bone: decreased bone formation (pre-pubertal age); decreased IGF-I and osteocalcin levels.	
17βHSD4	Null/KO13	No clear reproductive endocrinology phenotype
Additional
Neonatal and postnatal lethality; postnatal growth retardation; abnormal mitochondrion morphology; abnormal bile salt level; hepatic steatosis. Reproductive system: abnormal testis and spermatid morphology; seminiferous tubule degeneration; small testis; abnormal gametogenesis; reduced male fertility. Nervous system: microgliosis; Purkinje cell degeneration; astrocytosis; axon degeneration; abnormal suckling behavior; increased anxiety-related response, tremors, ataxia, impaired coordination, hypoactivity, lethargy; abnormal gait. GIT: abnormal intestinal absorption. Metabolism: decreased body weight; abnormal lipid homeostasis and decreased fatty acid level.	
17βHSD7	Null/KO14
MGI:3811923	Endocrine (steroids)
Cholesterol biosynthesis.	
	Null/KO15
MGI:4456868	Additional
Decreased embryo size; embryo lethality due to heart malformations (Ed10.5); abnormal blood vessel and capillary morphology. Nervous system: brain malformations; forebrain hypoplasia; increased neural tube apoptosis.	
17βHSD9	Null/KO16

MGI: 2446073 

Null/KO17

MGI:2388375	No clear reproductive endocrinology phenotype


Additional
Visual defects; abnormal eye electrophysiology, delayed dark adaptation.	
17βHSD10	Null/KO18	No clear reproductive endocrinology phenotype
Additional
Mitochondria dysfunction; reduced plasma glucose and increase insulin levels. Nervous system: neuronal damage.	
	TG (brain specific)19	No clear reproductive endocrinology phenotype
Additional
Nervous system: Protect against ischemia, Parkinson, Alzheimer disease model	
17βHSD11	Null/KO20

MGI:5581418	No clear reproductive endocrinology phenotype
Additional
Increased total circulating protein level. Nervous system: hyperactivity.	
17βHSD12	Null/KO21	No clear reproductive endocrinology phenotype
Additional
Embryo lethality Ed 9.5; impaired organogenesis; reduced arachidonic acid synthesis. Reproductive system: ovarian dysfunction, fertility problems, smaller litters, significantly fewer numbers of ductal branches than wild type female mammary glands; ovulation problems. Nervous system: high embryo expression in neuronal structures.	
17βHSD13	Null/KO22

MGI:5007180	No clear phenotype associated.	
17βHSD14	Null/KO23
MGI:5007181	No clear reproductive endocrinology phenotype
Additional

Increased IgG2a level. Reproductive system: oligozoospermia, testis degeneration, male infertility. Nervous system: increased response to stress-induced hyperthermia.	
17βHSD15	Null/KO24

MGI:3526658 &
3586379	No clear reproductive endocrinology phenotype
Additional
Abnormal eye electrophysiology, delayed dark adaptation	
AKR1C3/ 17βHSD5*	Null/KO25
MGI:3527218	Reproductive endocrinology
- long gestation, parturition failure.
- increased levels of P.
- prolonged estrous and diestrous.	
	Null/KO26
MGI:3774264	Additional
Small litter size, the number of pups, especially live pups, was markedly decreased hematopoietic system phenotype. Nervous system: Some behavioral phonotype,	
SRD5A1	Null/KO27
MGI:1857454	Reproductive endocrinology
- parturition defects, rescued by 3α-DIOL supplementation.	
		Additional
Decreased litter size; small prostate.	
SRD5A2	Null/KO28
MGI:2178039	Reproductive endocrinology

- T accumulation in reproductive tissues.
- impaired androgen-dependent gene expression.
- parturition defects, rescued by 3α-DIOL supplementation.	
		Additional
Decreased litter size; small prostate.	
SRD5A3	Null/KO29
MGI:5520177	Mouse not thoroughly characterized
Embryonic lethality, abnormal heart morphology, abnormal neural tube closure	
SULT1E1	Null/KO30
MGI:3529586	Reproductive endocrinology
- elevated circulating estrogen levels.	
		Additional
Disturbed platelet physiology. Reproductive system: leyding cell hyperplasia and abnormal morphology; abnormal testis morphology; abnormal placentation and amniotic fluid composition.	
SULT2B1	Null/KO
MGI:5432568
(unpublished)	Endocrine (steroids)

disturbed cholesterol metabolism and levels.	
∧ No report/references was found for 17βHSD3, 17βHSD6, 17βHSD8, 3βHSD1, 3βHSD2, DHRS11, STS, SULT2A1, SULT1A1.

* The human AKR1C3/17βHSD5 KO refers to mice with disrupted AKR1C18, however, functional conservation between the four human AKR1Cs and the eight mouse AKR1Cs in unclear (Sudeshna et al., 2013).

$ Reference ID refers to the Mouse Genome Informatics (MGI; www.informatics.jax.org. Accessed on date: February 2018) (Blake et al., 2017).

1 Caron et al. (1997), 2Huang et al. (2012), 3Hu et al. (2002), 4Liu et al. (2005), 5Bair and Mellon (2004), 6Nemoto et al. (2000), 7 Fisher et al. (1998), 8Honda et al. (1998), 9Hakkarainen et al. (2015), 10Saloniemi et al. (2010) and Järvensivu et al. (2018), 11Rantakari et al. (2008), 12Zhongyi et al. (2007), 13Baes et al. (2000), 14Shehu et al. (2008), 15Jokela et al. (2010), 16Shang et al. (2002), 17Driessen et al. (2000) and Sahu et al. (2015); 18Li et al. (2010) and Rauschenberger et al. (2010); 19Li et al. (2010); Rauschenberger et al. (2010), 20Dickinson et al. (2016), 21Rantakari et al. (2010); Kemilainen et al. (2016); 22Tang et al. (2010), 23Tang et al. (2010), 24Kim et al. (2005), 25Piekorz et al. (2005), 26Ishida et al. (2007), 27Mahendroo et al. (1996), 28Mahendroo et al. (2001), 29Dickinson et al. (2016), 30Qian et al. (2001) and Tong et al. (2005).

Table 5 Diseases associated with gene variants in intracrine enzymes.

Name	Affected system or tissue Disease	Phenotype	OMIM ID# References	
StAR	Endocrine system
Lipoid adrenal hyperplasia	Deficiency of adrenal or gonadal steroids	OMIM: 2017101	
		All individuals are phenotypic females		
		Infant mortality (mineral- & glucocorticoid deficiency		
CYP11A1	Endocrine system
Congenital adrenal insufficiency, with 46XY sex reversal	Acute adrenal insufficiency in infancy or childhood	OMIM: 6137431	
		Abnormality of cholesterol metabolism		
		Absence of secondary sex characteristics		
	Reproductive (ass∧)	SNPs∧∧ associated with endometrial cancer	2	
	Bone (ass∧)	SNPs associated with skeletal adverse events to AI	3	
	CNV (ass∧)	SNPs associated with neurological disturbances	4	
CYP17A1	Endocrine system
Congenital adrenal insufficiency (17α-hydroxyl. deficiency)	Excessive corticosteroids leading to hypertension
Low aldosterone synthesis
Abnormal sex determination and secondary sex
characteristics, amenorrhea	OMIM: 2021101	
	GIT
(ass∧)	SNPs associated with risk of cancer in the CRC##	5	
	Reproductive
(ass∧)	SNPs associated with endometrial cancer	6	
CYP19A1	Reprod Endocrin**Aromatase deficiency	Pseudo hermaphroditism in female	OMIM: 613546	
		Cystic ovaries, delayed bone maturation, adiposity		
	Aromatase excess syndrome	Heterosexual precocity and gynecomastia in males	OMIM: 139300	
		Isosexual precocity in females		
	Reproductive
(ass∧)	SNPs associated with endometrial cancer and ovarian cancer risks, endometriosis risk and risk to develop preeclampsia	6−14	
	Bone
(ass∧)	SNPs associated with osteoporosis and fracture risk	15, 16	
	Lung
(ass∧)	SNPs associated with lung cancer	17	
	GIT
(ass∧)	SNPs associated with gastric cancer	18	
3βHSD1	Endocr syst*(ass∧)	SNPs associated with hypertension	19	
	Skin
(ass∧)	SNPs associated with acne susceptibility	20	
3βHSD2	Endocrine system & Reprod Endocrin
Congenital adrenal insufficiency (3β-HSD2 deficiency)	Impaired steroid biosynthesis	OMIM: 2018101	
		Low cortisol, aldosterone, P androgens, estrogens.		
		Male new-borns exhibit pseudo hermaphroditism		
		Incomplete masculinization of the external genitalia		
		Affected females can have partial verification		
	Urogenital
(ass∧)	SNPs associated with bladder cancer	21	
17βHSD1	Reproductive
(ass∧)	SNPs associated with E2 levels and with endometriosis, cancer risk, abortion	22−25	
17βHSD3	Reprod Endocrin
ketosteroidreductase deficiency of testis	Males: pseudo hermaphroditism, gynecomastia	OMIM: 2643001	
		Infertility		
17βHSD4	CNS and
Reprod Endocrin
Perrault syndrome 1	Ovarian dysgenesis, amenorrhea, low estrogens	OMIM: 233400	
		Sensorineural deafness,		
		Neurologic manifestations (mild mental retardation)		
	CNS
D-bifunctional protein deficiency	Abnormal peroxisomal fatty acid beta-oxidation	OMIM: 261515	
		Deterioration of nervous system functions		
		Infantile-onset of hypotonia, seizures, and abnormal facial features, death before the age of 2 years		
17βHSD6	Reproductive
(ass∧)	SNPs associated with PCOS***	26	
17βHSD9	Eye
Fundus albipunctatus	Fleck retina disease, night blindness, delayed cone and rod photopigment regeneration.	OMIM: 136880	
17βHSD10	CNS
HSD10 mitochondrial disease	X-linked neurodegenerative disorder	OMIM: 300438	
		Multisystemic features, mitochondrial dysfunction		
	Turner type X-linked mental retardation	Moderate to profound mental retardation Macrocephaly and variable skeletal features	OMIM: 300706	
17βHSD12	Reproductive
(ass∧)	(Male) SNPs associated with prostate cancer	27	
	Lung
(ass∧)	SNPs associated with pulmonary function	28	
17βHSD15	Eye and CNS
Retinal dystrophy, juvenile cataracts, short stature	Decreased visual acuity, retinitis pigmentosa	OMIM: 616108	
		Psychomotor delays from early childhood, lack of fine motor skills and coordination, learning difficulties, facial dysmorphism		
AKR1C1	Lymphocytes
(ass∧)	SNPs associated with non-Hodgkin lymphoma	29	
	Lung
(ass∧)	SNPs associated with lung cancer	29	
	CNS
(ass∧)	SNPs associated with panic disorders	29	
AKR1C2	Reprod Endocrin
46XY sex reversal 8	Males: ambiguous external genitalia, cryptorchidism	OMIM: 614279	
		Disturbed endocrine features		
	Endocr. syst. (ass∧)	SNPs associated with weight-gain predisposition	29	
	Lung
(ass∧)	SNPs associated with lung cancer	29	
AKR1C3	Reproductive
(ass∧)	SNPs associated with T levels and PCOS	29,30	
	Lymphocytes
(ass∧)	SNPs associated with large B cell lymphoma	29	
	Lung
(ass∧)	SNPs associated with lung cancer	29	
	Leukocytes
(ass∧)	SNPs associated with lung childhood leukemia	29	
	Urogenital
(ass∧)	SNPs associated with bladder cancer	29	
	CNS
(ass∧)	SNPs associated with amyotrophic lateral sclerosis	29	
AKR1C4	Reprod Endocrin
46XY sex reversal 8	Males: ambiguous external genitalia, cryptorchidism	OMIM 614279	
		Disturbed endocrine features		
	– (ass∧)	SNPs associated with responses to anthracycline	29	
	CNS
(ass∧)	SNPs associated with paranoia risk	29	
SRD5A1	Reproductive
(ass∧)	Haplotypes associated with PCOS and hirsutum	31	
SRD5A2	Reprod Endocrin
Pseudovaginal perineoscrotal hypospadias	Males: pseudo hermaphroditism, ambiguous genitalia, cryptorchidism, small prostate	OMIM: 264600	
		No Mullerian structures, masculinization at puberty		
		No breast development or menstruation at puberty		
		Abnormal plasma DHT (and T) level		
	Reproductive
(ass∧)	Haplotypes associated with PCOS	31	
	Bone
(ass∧)	SNPs associated with low bone mineral density	32	
SRD5A3	CNS
Type Iq congenital glycosylation disorder	Developmental delay, midline brain malformations	OMIM: 612379	
		Variable extents of visual loss		
	CNS
Kahrizi syndrome	Mental retardation, delayed motor development, speech impairment, coarse facial features	OMIM: 612713	
STS	Skin
X-linked ichthyosis	Cutaneous manifestations: dark brown, polygonal scales and generalized dryness	OMIM: 30810040	
	Bone
bone dysplasia	Chondrodysplasia punctata and bone dysplasia	33	
SULT1E1	Reproductive
(ass∧)	SNP associated with estrogen dependent diseases	34	
SULT2A1	Reproductive
(ass∧)	SNP associated with DHEA-S, androgens and PCOS	40,35	
SULT2B1	Skin
congenital autosomal recessive ichthyosis	Generalized desquamation, dry scaly skin, hyperkeratosis, erythema	OMIM: 604125	
SULT1A1	Reproductive
(ass∧)	SNPs associated with endometrial cancer	11,36	
	Bone
(ass∧)	SNPs associated with low bone mineral density	32	
	GIT
(ass∧)	SNPs associated with risk of cancer in the GIT	37−38	
	–
(ass∧)	SNPs associated with activity and termostability	37,39	
Selected papers reporting association between SNPs and diseases are reported. Association studies with enzymes involved in steroid signaling but not discusses in the present review exist (for some references, see Doherty et al., 2005; Freedman et al., 2009; Miller and Auchus, 2011; Mueller et al., 2015).

* Endocr syst: Endocrine system.

** Reprod Endocrin: Reproductive endocrinology.

*** PCOS: polycystic ovarian syndrome.

∧ ass: association studies, case controls.

∧∧ SNP: single nucleotide polymorphism.

# OMIM: Online Mendelian Inheritance in Man. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). (https://omim.org/. Accessed on date: February 2018).

## CRC: colorectal cancer.

1 Miller and Auchus (2011), 2Terry et al. (2010), 3Rodríguez-Sanz et al. (2015), 4Deng et al. (2016), 5Zeng et al. (2016), 6Olson et al. (2007), 7Berstein et al. (2006), 8Kitawaki et al. (2002), 9Lundin et al. (2012), 10Thompson et al. (2016), 11Gulyaeva et al. (2008), 12Setiawan et al. (2009), 13Zacher et al. (2016), 14Shimodaira et al. (2012), 15Fontein et al. (2014), 16Masi et al. (2001), 17Zhang et al. (2013), 18Cho et al. (2012), 19Shimodaira et al. (2010), 20Yang et al. (2013), 21Andrew et al. (2012), 22Tsuchiya et al. (2005), 23Huber et al. (2005), 24Setiawan et al. (2004), 25Shi et al. (2016), 26Jones et al. (2009), 27Audet-Walsh et al. (2012), 28Loth et al. (2014), 29Alshogran (2017), 30Qin et al. (2006), 31Goodarzi et al. (2006), 32Zarrabeitia et al. (2007), 33Wöhrle et al. (1990), 34Adjei et al. (2003), 35Goodarzi et al. (2007), 36Ashton et al. (2010), 37Lilla et al. (2007), 38Xiao et al. (2014), 39Sun et al. (2005), and 40Mueller et al. (2015).

Bold text indicates the system affected, italics text indicates the name of the disease.

More recently, there is a re-emerging interest in developing novel intracrine drugs. A number of compounds are in their clinical phases, like STS inhibitors (Maltais and Poirier, 2011; Woo et al., 2011; Purohit and Foster, 2012; Pohl et al., 2014; Pautier et al., 2017) or inhibitors of AKR1C3/17βHSD5, which are of particular interest because this enzyme has crucial role in androgen/estrogen and prostaglandin biosynthesis (Penning, 2017). Bayer's AKR1C3/17βHSD5 inhibitor BAY 1128688 has a modified estrogen core, it interferes with both pathways, and is in phase II clinical trial for endometriosis (Bothe et al., 2017). Astellas Pharma potent and selective AKR1C3/17βHSD5 inhibitor ASP-9521 had only modest effect in a phase II study on prostate cancer as single drug, but combination therapy approaches remain to be studied (Kikuchi et al., 2014; Loriot et al., 2014).

HSD inhibitors are being studied in the area of hormone-dependent diseases, with 11βHSD inhibitors being in clinical trials for metabolic disorders (Ye et al., 2017) and 17βHSD inhibitors approaching the clinical phase for a number of gynecological indications (Table 3; Abdelsamie et al., 2017).

Intracrinology in peripheral tissues
In this paragraph, intracrinology of endometrium, GIT, bone, lungs, and CNS is reviewed. To comprehensively understand the ability of these tissues and systems to generate estrogens and other steroids, we have performed a systematic search of all original papers published in English until June 2018 that described the levels of intracrine enzymes (those indicated in Table 2-mRNA, protein or activity) in healthy tissues. In total 177 if the four extra ref are allowed papers were reviewed, and for details of this search, see Supplemental panel: “Systematic Review.” The results of this systematic review are summarized in Tables 6–8 and are briefly overviewed in each section dedicated to the distinct tissues or systems. Reports describing the enzymes in cultured cells or cell lines were excluded (may have been discussed elsewhere, though). Each section follows then with a non-systematic overview of the role of intracrinology in pathophysiology. A brief non-systematic description of the intracrinology of the skin, immune system and adipose tissue is also given. We will not describe the intracrinology of breast, prostate and liver (where steroid catabolism is the most relevant aspect), and we redirect the reader to recent reviews (Foster et al., 2008a; Luu-The et al., 2008; Luu-The and Labrie, 2010; Labrie and Labrie, 2013; Labrie, 2015; Mueller et al., 2015; Zhao et al., 2016; Hilborn et al., 2017; Penning, 2017).

Table 6 Expression of intracrine enzymes in endometrium–results of the systematic search.

Name			Menopausal status		
		Technique#	Pre	Post	References	
StAR	mRNA	RT-PCR	yes	yes	Bukulmez et al., 2008a; Attar et al., 2009; Sinreih et al., 2017b&	
CYP11A1	mRNA	RT-PCR	yes	n.d.	Tsai et al., 2001; Rhee et al., 2003; Attar et al., 2009; Sinreih et al., 2013; Huhtinen et al., 2014	
		RT-PCR	no	n.d.	Rhee et al., 2003	
CYP17A1	mRNA	RT-PCR	yes	n.d.	Tsai et al., 2001; Attar et al., 2009; Huhtinen et al., 2014	
		RT-PCR	no	n.d.	Rhee et al., 2003	
		IHC	no	no	Watanabe et al., 1995	
CYP19A1	mRNA	RT-PCR	yes	yes	Dheenadayalu et al., 2002; Brosens et al., 2004; Matsuzaki et al., 2006; Pathirage et al., 2006; Smuc et al., 2006, 2009; Dassen et al., 2007; Bukulmez et al., 2008b; Attar et al., 2009; Smuc and Rizner, 2009; Lépine et al., 2010; Cornel et al., 2012; Huhtinen et al., 2012a; Delvoux et al., 2014; Sinreih et al., 2017a	
		RT-PCR	no	no	Bulun et al., 1993, 1994; Watanabe et al., 1995; Noble et al., 1996, 1997; Kitawaki et al., 1999; Bacallao et al., 2008; Colette et al., 2009	
		ISH	no	n.d.	Watanabe et al., 1995	
	Protein	IHC	yes	yes	Maentausta et al., 1990; Kitaoka et al., 2004; Maia et al., 2006, 2007; Hudelist et al., 2007; Vouk et al., 2011; Miller et al., 2012a	
		IHC	no	no	Watanabe et al., 1995; Kitawaki et al., 1999; Velasco et al., 2006; Acién et al., 2007; Jeon et al., 2007; Bukulmez et al., 2008b; Colette et al., 2009	
		WB	N.d.	yes	Knapp et al., 2013	
		activity	no	no	Bulun et al., 1993; Watanabe et al., 1995; Noble et al., 1997	
		activity	yes	yes	Tseng et al., 1982; Yamaki et al., 1985; Taga et al., 1990; Yamamoto et al., 1990a,b, 1993a,b; Jongen et al., 2005; Purohit et al., 2008	
3βHSD1	mRNA	RT-PCR	yes	yes	Rhee et al., 2003; Vani et al., 2007; Attar et al., 2009; Smuc et al., 2009; Gibson et al., 2013; Sinreih et al., 2013	
	Protein*	IHC	yes	n.d.	Rhee et al., 2003; Vani et al., 2007	
		IHC	no	no	Watanabe et al., 1995	
3βHSD2	mRNA	RT-PCR	yes	yes	Tsai et al., 2001; Attar et al., 2009; Huhtinen et al., 2014; Osinski et al., 2018	
17βHSDs						
oxidative activity			yes	yes	Tseng and Gurpide, 1974; Pollow et al., 1975a,b, 1976; Polow et al., 1975; Tseng et al., 1977; Lane, 1990; Kitawaki et al., 2000; Utsunomiya et al., 2001; Delvoux et al., 2007, 2009; Cornel et al., 2012	
reductive activity			yes	yes	Maentausta et al., 1990; Delvoux et al., 2007, 2009, 2014; Bacallao et al., 2008	
			no	no	Utsunomiya et al., 2001	
17βHSD1	mRNA	RT-PCR	yes	yes	Zeitoun et al., 1998; Dassen et al., 2007; Smuc et al., 2007, 2009; Bacallao et al., 2008; Huhtinen et al., 2012a; Colette et al., 2013; Delvoux et al., 2014; Sinreih et al., 2017a; Osinski et al., 2018	
		NB	yes	n.d.	Zeitoun et al., 1998	
		RT-PCR	no	no	Casey et al., 1994; Utsunomiya et al., 2001	
	Protein	IHC	yes	yes	Maentausta et al., 1990&; Mäentausta et al., 1991; Li et al., 2003; Dassen et al., 2007; Colette et al., 2013; Mori et al., 2015; He et al., 2016; Sinreih et al., 2017a	
		IHC	no	no	Utsunomiya et al., 2001	
17βHSD2	mRNA	RT-PCR	yes	yes	Mäentausta et al., 1991; Zeitoun et al., 1998; Kitawaki et al., 2000, 2002; Utsunomiya et al., 2001; Matsuzaki et al., 2006; Smuc et al., 2006, 2007, 2009; Carneiro et al., 2007; Dassen et al., 2007; Vani et al., 2007; Bacallao et al., 2008; Hevir et al., 2011b; Huhtinen et al., 2012a; Colette et al., 2013; Delvoux et al., 2014; Sinreih et al., 2017a; Osinski et al., 2018	
		NB	yes	n.d.	Zeitoun et al., 1998	
	Protein	IHC	yes	yes	Scublinsky et al., 1976; Ciuffi et al., 1982; Utsunomiya et al., 2001; Dassen et al., 2007; Colette et al., 2013; Cornel et al., 2017; Sinreih et al., 2017a	
17βHSD4	mRNA	RT-PCR	yes	yes	Dassen et al., 2007; Smuc et al., 2009; Huhtinen et al., 2012a; Delvoux et al., 2014	
		NB	yes	n.d.	Möller et al., 1999	
17βHSD6	mRNA	RT-PCR	yes	n.d.	Huang and Luu-The, 2000; Huhtinen et al., 2012a	
17βHSD7	mRNA	RT-PCR	yes	yes	Smuc et al., 2007, 2009; Smuc and Rizner, 2009; Lépine et al., 2010; Cornel et al., 2012; Huhtinen et al., 2012a; Delvoux et al., 2014	
17βHSD8	mRNA	RT-PCR	yes	yes	Smuc and Rizner, 2009; Smuc et al., 2009	
17βHSD10	mRNA	RT-PCR	yes	n.d.	Huhtinen et al., 2012a	
17βHSD12	mRNA	RT-PCR	yes	yes	Smuc and Rizner, 2009; Smuc et al., 2009; Lépine et al., 2010; Cornel et al., 2012; Huhtinen et al., 2012a; Delvoux et al., 2014	
17βHSD14	mRNA	RT-PCR	yes	n.d.	Huhtinen et al., 2012a; Sinreih et al., 2017a	
AKR1Cs						
AKR1C1	mRNA	RT-PCR	yes	yes	Rizner et al., 2006; Smuc and Rizner, 2009; Smuc et al., 2009; Hevir et al., 2011b; Sinreih et al., 2013	
AKR1C2	mRNA	RT-PCR	yes	yes	Hevir et al., 2011b; Sinreih et al., 2013	
AKR1C3/17
βHSD5	mRNA	RT-PCR	yes	yes	Penning et al., 2000; Rizner et al., 2006; Vani et al., 2007; Smuc and Rizner, 2009; Smuc et al., 2009; Hevir et al., 2011b; Cornel et al., 2012; Huhtinen et al., 2012a; Sinreih et al., 2013; Delvoux et al., 2014	
	Protein	IHC	yes	yes	Pelletier et al., 1999; Ito et al., 2006; Vani et al., 2007; Smuc and Rizner, 2009; Zakharov et al., 2010	
SRD5As						
SRD5A1	mRNA	RT-PCR	yes	yes	Carneiro et al., 2008; Hevir et al., 2011b; Sinreih et al., 2013; Huhtinen et al., 2014	
	Protein	IHC	yes	yes	Ito et al., 2002; Carneiro et al., 2008; Tanaka et al., 2015	
SRD5A2	mRNA	RT-PCR	yes	yes	Carneiro et al., 2008; Hevir et al., 2011b; Sinreih et al., 2013; Huhtinen et al., 2014	
	Protein	IHC	yes	yes	Ito et al., 2002; Carneiro et al., 2008; Tanaka et al., 2015	
SRD5A3		RT-PCR	yes	n.d.	Huhtinen et al., 2014	
Sulphatase pathway				
STS	mRNA	RT-PCR	yes	yes	Tanaka et al., 2003; Utsunomiya et al., 2004; Smuc et al., 2006, 2007, 2009; Dalla Valle et al., 2007; Dassen et al., 2007; Bacallao et al., 2008; Smuc and Rizner, 2009; Lépine et al., 2010; Colette et al., 2013; Huhtinen et al., 2014; Piccinato et al., 2016b; Sinreih et al., 2017a	
		RT-PCR	no	no	Miki et al., 2002	
		Comp-RT	yes	n.d.	Yanaihara et al., 2001	
	Protein	IHC	yes	yes	Yanaihara et al., 2001; Utsunomiya et al., 2004; Dassen et al., 2007; Cornel et al., 2017; Sinreih et al., 2017a	
		IHC	no	no	Miki et al., 2002	
		activity	yes	yes	Warren and French, 1965; Prost and Adessi, 1983; Adessi et al., 1984; Platia et al., 1984; Yamamoto et al., 1990a, 1993a; Tanaka et al., 2003; Bacallao et al., 2008; Purohit et al., 2008; Delvoux et al., 2009	
		IHC	no	no	Utsunomiya et al., 2004	
SULT1E1	mRNA	RT-PCR	yes	yes	Yamamoto et al., 1993a; Miki et al., 2002; Tanaka et al., 2003; Utsunomiya et al., 2004; Smuc et al., 2006, 2007; Dassen et al., 2007; Bacallao et al., 2008; Smuc and Rizner, 2009; Lépine et al., 2010; Hevir et al., 2011a, 2013; Colette et al., 2013; Piccinato et al., 2016b; Sinreih et al., 2017a	
		NB	yes	n.d.	Rubin et al., 1999	
	Protein	IHC	yes	yes	Miki et al., 2002; Utsunomiya et al., 2004; Hudelist et al., 2007; Cornel et al., 2017; Sinreih et al., 2017a	
		activity	yes	yes	Tanaka et al., 2003; Utsunomiya et al., 2004; Bacallao et al., 2008; Purohit et al., 2008	
SULT1A1	mRNA	RT-PCR	yes	yes	Hevir et al., 2011a, 2013	
SULT1A1		NB	yes	n.d.	Rubin et al., 1999***	
SULT2A1		NB	no	n.d.	Rubin et al., 1999	
SULT2B1	mRNA	RT-PCR	yes	yes	Hevir et al., 2011a, 2013	
Primary/original references were analyzed and reviews were excluded (and are cited ad hoc in the text). The table report only the enzymes whose expression was assessed in reviewed studies**.

# Technique abbreviations. For mRNA detection, NB: northern blot; ISH: in situ hybridisation; RT-PCR: reverse transcription semi or quantitative PCR; Comp-RT: competitive RT-PCR. For protein detection: IHC: immunohistochemistry; WB: western blotting. For enzyme activity measurement: activity.

* Most commercially available antibodies do not distinguish between 3βHSD1 and 3βHSD1.

** No publication was found describing the expression of 17βHSD9, 11, 13, 15, DHRS11 and AKR1C4.

*** The same study also detected expression of SULT1A3 (Rubin et al., 1999).

n.d.: not determined.

& Protein level was measured by radioimmunoassay.

Endometrium
The actions of steroid hormones in the endometrium are mediated by hormone-receptors via the classical mechanisms, although non-genomic and rapid signaling are also present (Groothuis et al., 2007; Zwart et al., 2011; Flach and Zwart, 2016; Hewitt et al., 2016). Estrogens and P control the menstrual cycle (Groothuis et al., 2007; Andersen and Ezcurra, 2014) and the endometrium during the window of implantation (WOI), occurring in the mid-luteal phase (Wang and Dey, 2006).

In rats, the WOI is characterized by high E2 plasma levels, and endometrial ERα and PR expression shows specific and varying cytosolic/nuclear patterns (Singh et al., 1996). ERα and PR expression decreases after ovulation and in preimplantation stages in both mice (Vasquez and DeMayo, 2013) and primates (Macaca mulatta) (Ghosh et al., 1999).

Rodent genetic models unraveled some molecular mechanisms underlying the estrogen-dependency of these processes. ERα-KO mice are infertile, no implantation occurs, endometrium is hypoplastic and estrogen response is absent (Couse and Korach, 1999; Walker and Korach, 2004). Not only its absence, but also sustained estrogen signaling has deleterious effects on endometrial receptivity, as recapitulated by mice with uterine COUP-TFII ablation. These mice exhibit increased estrogen signaling and asynchrony between embryo competency and uterine receptivity with consequent implantation defects. This effect is rescued by treatment with the antiestrogen ICI-182780 (Lee et al., 2010). Additionally, the duration of E2 exposure and its dosage affect endometrial receptivity and WOI length in mice (Ma et al., 2003).

Available human data, mostly obtained in the context of assisted reproduction technologies (ART), also indicate that steroid stimulation retards or shortens the luteal phase, the WOI, causes shifts in the appearance of pinopodes (a classical WOI marker) and causes asynchrony between ovarian and menstrual cycles (Devroey et al., 2004).

Intracrinology in healthy endometrium–systematic search
Initial studies on steroid hormone metabolism in the endometrium date back to 1965 with first demonstration of the STS activity, followed by investigation on the oxidative and reductive 17βHSD activities (Table 6).

Both pre and postmenopausal tissues possess oxidative and reductive 17βHSD activities and the expression of 17βHSD1, 2, 4, 6, 7, 8, 10, 12, 14, and AKR1C3/17βHSD5 was detected at the mRNA or protein levels. Sulphatase pathway (STS and SULT1E1; recently reviewed by Rižner, 2016), CYP19A1, 3βHSDs, SRD5As and AKR1Cs are also present, indicating that human endometrium can metabolize sulphated-compounds and DHEA to form androgens and estrogens.

Few 17βHSDs have been characterized by IHC. The low expression of 17βHSD1 poses sensitivity problems using standard detection methods (Cornel et al., 2017), and few authors reported endometrial absence of 17βHSD1 (Table 6). Type 1 17βHSD localizes in the cytoplasm of epithelial cells (Dassen et al., 2007; Colette et al., 2013; Mori et al., 2015; Sinreih et al., 2017a) and it is also detected in primary stroma cells cultured in vitro (Aghajanova et al., 2009; Mori et al., 2015). Type 2 17βHSD, AKR1C3/17βHSD5 and 3βHSD1 give strong reactivity in the glandular epithelium (Rhee et al., 2003; Ito et al., 2006; Dassen et al., 2007; Vani et al., 2007; Smuc and Rizner, 2009; Zakharov et al., 2010; Colette et al., 2013; Mori et al., 2015; Sinreih et al., 2017a).

CYP19A1 as well has low expression and some authors detected this enzyme only in association with diseases (see below and recently reviewed by Rižner, 2013). Although CYP19A1 immunoreactivity was initially associated with stroma cells (Watanabe et al., 1995), subsequent investigations showed also glandular expression (Kitawaki et al., 1999; Hudelist et al., 2007) and laser-capture-microdissected stroma/epithelial components detected CYP19A1 mRNA in both cell types (Matsuzaki et al., 2006).

The mRNA of those enzymes converting cholesterol to DHEA (CYP11A1, CYP17A1, StAR) and (ovarian) 3βHSD2 was reported in recent studies, suggesting that the endometrium can produce steroids from cholesterol (Table 6).

Intratissue steroid levels
Endometrial steroid levels were recently profiled by LC-MS. E2 levels differ between tissue and serum during the menstrual cycle, being up to five-times higher in tissue than in serum during the proliferative phase and 1.5-fold higher in the luteal period (Huhtinen et al., 2012a, 2014). T levels were lower in tissue than in serum with no cyclic changes. The levels P and P5 (and their 17-hydroxy derivatives) did not vary between serum and tissue, indicating that, contrarily to estrogens, progestogen intra-tissue levels are determined by passive diffusion from the blood (Huhtinen et al., 2014).

Intracrinology and reproduction
Animal models show not only that intracrine enzymes are expressed in the endometrium, but also they vary the expression levels during the endometrial phases and during implantation, as shown already during the 80's in rhesus monkeys for the oxidizing 17βHSD activity (Kreitmann et al., 1979).

In rodents, STS activity measured with [3H]E1-S in 6-days pregnant rats was lower around the implantation site compared with non-implantation sites (Loza, 1995). In situ hybridisation signal of 17βHSD7 mRNA varied spatio-temporally throughout implantation and early gestation, being initially detected on luminal epithelium around the implantation site and absent in decidua (embryonic day, Ed5.5). At Ed8 and Ed9.5, 17βHSD7 expression increased in the decidua capsularis (the part that interacts with the trophoblast) and later (after E9) in the junctional zone of the developing placenta and in the spongiotrophoblasts (Nokelainen et al., 2000).

A brilliant study in mice showed that decidualization is dependent on local E2 produced through CYP19A1. CYP19A1 expression increased during pregnancy and decidualization was unaffected by ovariectomy. In contrast, treatment with the aromatase inhibitor (AI) letrozole impaired decidualization and decreased decidual marker expression (e.g., PRP, BMP2 and CX43) (Das et al., 2009).

In human endometrium, 17βHSD2 and SULT1E1 are induced by P as their expression peaks in the luteal phase (Rubin et al., 1999; Tseng and Mazella, 2002; Utsunomiya et al., 2004; Dassen et al., 2007; Huhtinen et al., 2012a; Colette et al., 2013; Piccinato et al., 2016b). Since both enzymes decrease intra-tissue estrogen levels, their up-regulation is one of the mechanisms of the uterine antiestrogenic effects of P. The P-dependency of 17βHSD2 and SULT1E1 was recapitulated in vitro using explant cultures and primary cells (Tseng and Mazella, 2002; Dassen et al., 2007; Piccinato et al., 2016b). Luteal peak expression of other SULTs (1A1 and 2B1) was also reported (Rubin et al., 1999; Koizumi et al., 2010). Some reports also suggested that STS expression increased in the luteal phase (Tanaka et al., 2003; Piccinato et al., 2016b) with a potential role during decidualization (Tseng and Mazella, 2002). Mid-luteal phase endometrium shows also peaking expression of 3βHSD1 (mRNA and protein) (Rhee et al., 2003; Vani et al., 2007).

Two studies on human ectopic pregnancies explored the endometrium around the implanted blastocyst. Expression of 3βHSD1 (mRNA and protein) was highest in decidua obtained from ectopic pregnancies (Rhee et al., 2003) and in a study on 23 tubal pregnancies, 17βHSD1 showed highest immunoreactivity at the fetal-maternal interface (Li et al., 2003), suggestive for a role of these enzymes in the nidation site.

Endometriosis
Endometriosis, an estrogen-dependent benign disorder affecting up to 10% of reproductive-aged women, is associated with pelvic pain, infertility, decreased life-quality and important health care/social costs (Simoens et al., 2011, 2012; De Graaff et al., 2013, 2015, 2016; Vercellini et al., 2014). Endometriosis is characterized by the growth of endometrium-like tissue outside the uterus (ectopic locations), beside the ovaries (endometrioma), as peritoneal implants, or as deep-lesions infiltrating peritoneal organs (deep endometriosis).

The expression of intracrine enzymes in endometriosis was reviewed in 2012, (Huhtinen et al., 2012b) and among other studies, 20 papers published between 1996 and 2009 specifically described the levels of intracrine enzymes in eutopic and ectopic endometrium from patients and control women. With the exclusion of one study that included over 100 patients (Colette et al., 2009), the rest included small study populations, and in most cases, the various endometriosis types (ovarian, peritoneal and deep infiltrating) were pooled together. Various techniques were used (RT-qPCR, immunohistochemistry, enzyme activity assay). Overall, no clear conclusion could be drawn from these studies. Comparing endometriosis with controls, CYP19A1 was up-regulated (six studies), unchanged (three studies) and one study found no expression of this gene. With respect to oxidative and reductive 17βHSDs, 17βHSD1 was reported up-regulated (three studies), 17βHSD2 was reported down-regulated or unchanged and two studies reported an up-regulation of 17βHSD7 and 12 in endometriosis vs. controls (Huhtinen et al., 2012b).

Subsequent investigations also continued to report inconsistent results. No change in mRNA (Delvoux et al., 2014) or increased expression of CYP19A1 in ovarian endometriosis vs. controls (Huhtinen et al., 2012a) were reported. An increased expression of CYP19A1 was also described using in vitro spheroids derived from endometrial stroma cells from patients compared with controls (Mori et al., 2015).

The mRNA expression of 17βHSD1 was higher in endometriosis compared with normal tissue using patient biopsies as well as spheroid cultures derived from endometrial stroma cells of patients and controls (Delvoux et al., 2014; Mori et al., 2015). One study assessing the three endometriosis types separately (60 patients in total) described that the increased 17βHSD1 level was restricted to endometrioma during the secretory phase of the menstrual cycle (Huhtinen et al., 2012a), whereas a second study on 79 patients and 41 controls, found no change in 17βHSD1 level, but described an increased 17βHSD1/2 ratio (Colette et al., 2013).

Regarding 17βHSD2, recent investigations reported both unchanged (Delvoux et al., 2014) and down-regulated mRNA in patient biopsies compared with controls (Huhtinen et al., 2012a; Colette et al., 2013). No variations were found in 17βHSD4, 5, 7 and 12 (Smuc et al., 2009; Delvoux et al., 2014) but an increased level of 17βHSD6 mRNA was detected in endometriosis compared with controls (Huhtinen et al., 2012a).

A few studies reported detectable levels of the enzymes involved in the generation of DHEA from cholesterol (StAR, CYP11A1 and CYP17A1) in endometriosis (Tsai et al., 2001; Rhee et al., 2003; Bukulmez et al., 2008a; Attar et al., 2009; Sinreih et al., 2013, 2017b; Huhtinen et al., 2014), suggesting that, in contrast to eutopic endometrium, endometriosis is able to produce steroids from cholesterol. However, it has also been argued that the presence of paracrine confounders of ovarian origin in studies using endometriomas could bias the results (Noël et al., 2011).

The contribution of STS, SULT1E1 and other SULTs was investigated by numerous studies and also in this case, conclusions are unclear (recently reviewed, Rižner, 2016). A recent investigation using 78 specimens described increased STS levels in endometriosis vs. control samples and found that the overall balance between STS and SULT1E1 differed between eutopic and ectopic tissue, implying an unbalanced flux of sulpho-conjugated estrogens in this disease (Piccinato et al., 2016b). The same research group also described an aberrant regulation of the enzymes involved in the estrogen oxidative metabolism in endometriosis (Piccinato et al., 2016a).

Although the level of the single enzymes in the intracrine machinery varies with apparently no clear association with the disease condition, the intracrinological nature of endometriosis was recently proven by comparison between serum and tissue levels of steroids in 60 patients (eutopic and ectopic endometrium) and 16 controls. Although E2 changed cyclically in eutopic tissue, E2 levels remained constant in the lesions and inversely correlated with the mRNA level of 17βHSD2 and 17βHSD6 suggesting an impairment in E2 deactivation to E1. P levels were equal in serum and control tissues, but resulted higher in patients and correlated with high 3βHSD2 mRNA. T, low in the tissue of controls, was over 13-times more concentrated at ectopic locations and correlated with low expression of SRD5A3 (Huhtinen et al., 2012a, 2014).

Endometrial cancer (EC)
EC is the most common gynecological malignancy in western society and 80% of all cases are estrogen-driven (Amant et al., 2005; Morice et al., 2015). Major serum steroids are increased in patients with EC, including several substrates for intracrine E2 synthesis (Lépine et al., 2010; Audet-Walsh et al., 2011). In addition, tissue-steroid levels differ between cancer, normal tissue and serum and correlate with the levels of specific intracrine enzymes (see below) (Tanaka et al., 2015).

A systematic review recently explored all studies published between 1990 and 2017 assessing the expression of 17βHSD1, 2, STS, SULT1E1, and CYP19A1, with results that describe unbalanced intracrine regulation and important inter-patient variability (Cornel et al., 2018). Most studies compared cases with controls or tumor tissue with adjacent normal endometrium. Compared with normal tissue (from controls or adjacent to tumor), 17βHSD1 was found increased in EC (Cornel et al., 2012), decreased (Smuc and Rizner, 2009; Lépine et al., 2010) and undetected (Utsunomiya et al., 2001, 2003); 17βHSD2 was found decreased (Utsunomiya et al., 2003, 2004) or increased (Lépine et al., 2010; Cornel et al., 2012; Sinreih et al., 2013); AKR1C3/17βHSD5 was found unchanged (Cornel et al., 2012; Sinreih et al., 2013), increased (Ito et al., 2016) and decreased (Zakharov et al., 2010); 17βHSD7 both decreased (Smuc and Rizner, 2009) and unchanged (Lépine et al., 2010; Cornel et al., 2012) and 17βHSD12 was unchanged (Smuc and Rizner, 2009; Cornel et al., 2012) or increased in tumors vs. controls (Lépine et al., 2010). One recent report described decreased 17βHSD14 levels in tumor compared with adjacent tissue (Sinreih et al., 2017a). Controversial results apply to CYP19A1, described as increased (Watanabe et al., 1995; Utsunomiya et al., 2001, 2004; Smuc and Rizner, 2009) and unchanged (Jongen et al., 2005; Pathirage et al., 2006; Cornel et al., 2012). STS/SULT1E1 expression is also inconsistent in different studies (recently reviewed in Mueller et al., 2015; Rižner, 2016).

Recent studies exploring the association between enzyme levels and tumor characteristics found a correlation between STS with tumor grade and lymphovascular invasion (Sinreih et al., 2017a) and described an association between high CYP19A1 or 17βHSD1 and poor patient prognosis (Segawa et al., 2005; Cornel et al., 2017).

Other investigations emphasized the potential antiestrogenic and protective roles of androgens and P. Formation of DHT (via conversion of A4 to T by AKR1C3/17βHSD5 and of T to DHT by SRD5As) has potential antiestrogenic action because it devoids tissue from T (substrate of CYP19A1 yielding E2) and because it has direct endometrial antiproliferative effects via AR (Ito et al., 2016). Similar to the AKR1C3/17βHSD5 data reported earlier, results on SDR5A expression are inconclusive as SRD5A2 was down-regulated in a study on 47 tumor specimens compared with adjacent normal tissue (Sinreih et al., 2013), but both SRD5A1 and SRD5A2 resulted unchanged in another study on 122 tumors (although only five controls were studied) (Tanaka et al., 2015). This last study found however increased androgen levels (T and DHT) in tissue vs. blood. High DHT levels were restricted to samples with high SRD5A1 immunohistochemical staining. In addition, AR and SRD5A1 positivity was associated with good patient prognosis (Tanaka et al., 2015). The prognostic value of AR is confirmed by independent investigations (Tangen et al., 2016).

P is well-known for its antiestrogenic action, PR positivity is a good prognostic marker (Tangen et al., 2014) and P synthesis and metabolism are disturbed in EC (Sinreih et al., 2013). Interestingly, in a study on 47 tumors and adjacent normal tissues, EC had decreased StAR and CYP11A1 mRNA levels, indicative of diminished de novo steroid synthesis (Sinreih et al., 2013, 2017b). At the same time, EC showed decreased SRD5A2 and increased 17βHSD2 indicative of a diminished rate of conversion of P to 5αDHP and of 20αDHP to 5α-pregnan-20-ol-3-one, but increased conversion of 20αDHP to P (see Figure 2).

Other endometrial/gynecological disorders
Although literature is scarce, a potential role of intracrinology is postulated for ovarian cancer (Ito et al., 2016), for adenomyosis and fibroids (Rižner, 2016), for sarcoma, where CYP19A1 expression may have prognostic significance (Kitaoka et al., 2004) and among infertile women (Brosens et al., 2004).

Intracrine drug targets
Endometriosis: blocking the systemic estrogen signaling via P, or GnRH agonist is standard care (Vercellini et al., 2014). Blocking the intracrine E2 generation is the future approach with on-going preclinical/clinical research.

STS inhibition showed promising results. Irosustat (Table 3) inhibited up to 100% the formation of free steroids using ex-vivo material from 27 patients (Purohit et al., 2008) and STS inhibition showed good results in a mouse model of endometriosis, where decreased size and weight of the lesions was observed (Colette et al., 2011). A phase-I clinical trial on 24 volunteers proved the safety of the STS inhibitor E2MATE (PLG2001), which reduced STS activity by over 90% and induced changes in endometrial markers (both alone or co-administered with norethindrone acetate) (Pohl et al., 2014).

Inhibitors of 17βHSD1 are in preclinical phase, and promising results are described using a primate model of endometriosis, where decreased behavior/pain symptoms were reported (Arnold and Einspanier, 2013) and using ex-vivo material from endometriosis patient (over 70% of the patients showed over 80% of enzyme inhibition) (Delvoux et al., 2014).

AKR1C3/17βHSD5 inhibition can interfere with E2, androgen synthesis, and reduce prostaglandin-associated inflammation/proliferation and an inhibitor has recently entered a phase II trial for endometriosis (Table 3). Overall, AIs have limited efficacy for endometriosis (Ferrero et al., 2011; Dunselman et al., 2014),

EC: only in case of advanced stage/metastatic disease hormonal care is given (progestogen, tamoxifen or AIs). AIs alone have limited efficacy with low response rates (Rose et al., 2000; Ma et al., 2004; Lindemann et al., 2014). Promising data were obtained using dual regimen (AI and mTOR inhibitor; Slomovitz et al., 2015) and additional trials on combinatory regimen are on-going. STS inhibitors showed promising results in a mouse subcutaneous model of EC, with decreased tumor growth by 48–67% (Foster et al., 2008b). However, a phase II trial on advanced stage EC was stopped because of the absence of added benefit compared with progestogen treatment (Purohit and Foster, 2012; Pautier et al., 2017).

Preclinical studies on 17βHSD1 inhibitors showed promising results in a mouse model of endometrial hyperplasia (Saloniemi et al., 2010;Järvensivu et al., 2015) and in various models of EC (Konings et al., 2018).

Endometrium: conclusions
The ability to synthesize DHEA from cholesterol (reported by few studies) needs confirmation. However, the endometrium possesses the enzymatic machinery to metabolize sulphated-compounds and DHEA and form androgens and estrogens, (although this contention is wrangled by other authors: Labrie and Labrie, 2013; Labrie, 2015). Further, the endometrium can metabolize androgens and progestogens via AKR1Cs and SRD5As to produce a wide range of compounds, including estrogens (Table 6 and Figure 3). The morphological changes during the menstrual cycle are accompanied by cyclic changes in intracrine steroid and enzyme levels, indicating that steroid exposure needs to be cyclically regulated to support endometrial physiology.

Figure 3 Effect of steroids (mainly estrogens) and intracrine networks in central nervous system, lungs, digestive system, uterus and bone. Italics and by brackets are those metabolism/reactions that need conformation by independent authors (because validated at the mRNA level only or in few studies). * EC, epithelial cells; **SMC, smooth muscle cells; #Chol, cholesterol. The drawing was kindly generated by Dr. Margaretha A. Skowron (Department of Urology, University Düsseldorf, Germany) for this review.

Gastrointestinal tract (GIT) and digestive system (DS)
ERα and ERβ are expressed throughout the GIT and DS (esophagus, stomach, colon, gallbladder, pancreas) and epidemiological studies show important influence of sex hormones in DS physiology and disturbances, with a clear gender-dependency. In the duodenum, estrogens regulate bicarbonate secretion (Nayeb-Hashemi and Kaunitz, 2009; Tuo et al., 2011). This is an important defense mechanism of the mucosa against acids discharged from the stomach, and men develop duodenal ulcer two/three-times more often than premenopausal women (Wu et al., 2008). Such estrogen protective effect is recapitulated in animal studies exposed to estrogens and anti-estrogens, and is mediated by a rapid action (i.e., non genomic) of ERα on membrane ion channels (Smith et al., 2008).

ERα, ERβ and GPER mediate important effects on the pancreatic beta-cells during adaptation to insulin resistance periods (e.g., pregnancy, puberty, obesity; Nadal et al., 2011). In mice, ERα signaling regulates proliferation of beta-cell during development and after injury (Yuchi et al., 2015).

Men are also more likely than women to develop cancer in the esophagus, stomach and colon. Accordingly, estrogen treatment for prostate cancer decreases the incidence of gastric cancer and menopausal status in women is associated with colorectal cancer CRC risk (Freedman et al., 2007; Kennelly et al., 2008; Hogan et al., 2009; Duell et al., 2010). ERβ results oncoprotective at several GIT sites (Kennelly et al., 2008; Barzi et al., 2013; Caiazza et al., 2015) and low expression correlate with high CRC stage in mice and with poor differentiated gallbladder cancer in humans (Hogan et al., 2009).

The association between estrogens and DS cancer risk is however controversial. The Women's Health Initiative and other large studies showed that combined estrogens plus P hormone replacement therapy (HRT) decreases CRC risk, but increases that of gallbladder. In addition, CRC during HRT has a higher grade (Kennelly et al., 2008; Hogan et al., 2009; Rennert et al., 2009; Foster, 2013; Mueller et al., 2015). However, a recent randomized, placebo-controlled trial enrolling over 10,000 women receiving estrogens alone vs. placebo found no difference in CRC incidence (Lavasani et al., 2015). Such complexity is recapitulated in animal studies where estrogens and androgens can have distinct and opposite effects on colitis and CRC (Amos-Landgraf et al., 2014; Heijmans et al., 2014). Overall, the association between DS disturbances/cancers with estrogens depends on the moment in life, extent and nature (endogenous or exogenous) of exposure and is influenced by the relative balance of the receptors (Foster, 2013). Similarly, androgens influence DS pathophysiology via complex and unclear mechanisms involving classical, membrane signaling, level of free and SHBG bound T (Roshan et al., 2016).

The lack of clear conclusion and the fact that the levels of circulating endogenous estrogens in women do not influence CRC risk indicates that intracrine steroids may have a predominant role irrespective of their circulating levels (Sato et al., 2009; Falk et al., 2015).

Intracrinology in healthy GIT–systematic search
In total, 29 original papers were retrieved that described the levels of the intracrine enzymes in the GIT, published from the late 80's (Table 7 and Supplemental panel: “Systematic Review”).

Table 7 Expression of intracrine enzymes in the gastrointestinal tract (GIT)-results of the systematic search.

Gene	Detection	Gastrointestinal tract	
	Molecule	Technique#	St*	References	S.I.*	References	L.I.*	References	
CYP11A1	Protein	IHC	no	Saitoh et al., 1992	n.d.		n.d.		
CYP19A1	Protein	Activity	n.d.		n.d.		yes	English et al., 2000	
CYP19A1	Protein	IHC	no	Saitoh et al., 1992	n.d.		yes	English et al., 2000	
		WB	no	Saitoh et al., 1992	n.d.		n.d.		
HSD17B oxidative activity	n.d.		n.d.		yes	English et al., 1999	
HSD17B reductive activity	n.d.		n.d.		yes	English et al., 1999	
17βHSD1	mRNA	RT-PCR	no	Oduwole et al., 2003a	n.d.		yes	Rawłuszko et al., 2011	
		NB	n.d.		no	Casey et al., 1994	no	Casey et al., 1994	
		ISH	n.d.		no	Oduwole et al., 2002	no	Oduwole et al., 2002	
	Protein	WB	n.d.		n.d.		yes	Rawłuszko et al., 2011	
17βHSD2	mRNA	RT-PCR	yes	Oduwole et al., 2003a; Frycz et al., 2015	n.d.		n.d.		
		NB	n.d.		yes	Casey et al., 1994	yes	Casey et al., 1994	
		ISH	n.d.		yes	Oduwole et al., 2002	yes	Oduwole et al., 2002, 2003b	
	Protein	IHC	n.d.		n.d.		yes	English et al., 2000; Mueller et al., 2015	
		WB	yes	Frycz et al., 2015	n.d.		yes	English et al., 2000; Mueller et al., 2015	
17βHSD4	mRNA	NB	n.d.		yes	Möller et al., 1999	yes	Möller et al., 1999	
	Protein	IHC	n.d.		n.d.		yes	English et al., 2000; Mueller et al., 2015	
		WB	n.d.		n.d.		yes	English et al., 2000; Mueller et al., 2015	
17βHSD10	mRNA	RT-PCR	n.d.		n.d.		yes	De Preter et al., 2012	
17βHSD12	mRNA	RT-PCR	n.d.		yes	Sakurai et al., 2006	n.d.		
		NB	n.d.		yes	Sakurai et al., 2006	no	Sakurai et al., 2006	
	Protein	IHC	yes	Sakurai et al., 2006	yes	Sakurai et al., 2006	yes	Sakurai et al., 2006	
AKR1C3	mRNA	Comp-RT	yes	Frycz et al., 2016	n.d.		n.d.		
		NB	yes	Frycz et al., 2016	yes	Lin et al., 1997	yes	Lin et al., 1997	
	Protein	IHC	yes	Miller et al., 2012b; Chang et al., 2013	yes	Chang et al., 2013	yes	Chang et al., 2013	
SRD5A1	Protein	IHC	yes	Aumüller et al., 1996	yes	Aumüller et al., 1996	yes	Aumüller et al., 1996	
SRD5A2	Protein	IHC	yes	Aumüller et al., 1996	yes	Aumüller et al., 1996	yes	Aumüller et al., 1996	
STS	mRNA	RT-PCR	n.d.		no	Miki et al., 2002	yes	Dalla Valle et al., 2007	
		RT-PCR	–		–		no	Miki et al., 2002	
	Protein	IHC	n.d.		no	Miki et al., 2002	no	Miki et al., 2002; Sato et al., 2009	
	Protein	Activity	n.d.		n.d.		yes	Munroe and Chang, 1987	
SULT1E1	mRNA	RT-PCR	no	Nishimura and Naito, 2006	yes	Miki et al., 2002; Nishimura and Naito, 2006	yes	Miki et al., 2002; Teubner et al., 2007; Riches et al., 2009	
			–		–		no	Nishimura and Naito, 2006	
		NB	n.d.		yes	Her et al., 1996	n.d.		
	Protein	IHC	no	Chen et al., 2003; Teubner et al., 2007	yes	Miki et al., 2002; Teubner et al., 2007	yes	Miki et al., 2002; Teubner et al., 2007; Sato et al., 2009	
		WB	n.d.		yes	Her et al., 1996; Chen et al., 2003; Teubner et al., 2007; Riches et al., 2009	no	Chen et al., 2003	
		Activity	no	Chen et al., 2003; Teubner et al., 2007	yes	Teubner et al., 2007	yes	Teubner et al., 2007	
SULT2A1	mRNA	RT-PCR	no	Nishimura and Naito, 2006	yes	Nishimura and Naito, 2006	no	Nishimura and Naito, 2006	
		ISH	yes	Tashiro et al., 2000	n.d.		n.d.		
		NB	n.d.		yes	Her et al., 1996	n.d.		
	Protein	IHC	no	Teubner et al., 2007	yes	Teubner et al., 2007	yes	Teubner et al., 2007	
		WB	yes	Tashiro et al., 2000; Chen et al., 2003	yes	Her et al., 1996; Chen et al., 2003; Teubner et al., 2007; Riches et al., 2009	yes	Chen et al., 2003; Teubner et al., 2007; Riches et al., 2009	
		WB	n.d.		n.d.		no	Chen et al., 2003	
		Activity	yes	Tashiro et al., 2000	yes	Chen et al., 2003; Teubner et al., 2007	yes	Chen et al., 2003; Teubner et al., 2007	
		Activity	no	Teubner et al., 2007	–		–		
SULT1A1	mRNA	RT-PCR	yes	Nishimura and Naito, 2006	yes	Nishimura and Naito, 2006	yes	Nishimura and Naito, 2006	
	Protein	IHC	yes	Teubner et al., 2007	yes	Teubner et al., 2007	yes	Teubner et al., 2007	
		WB	yes	Teubner et al., 2007	yes	Teubner et al., 2007; Riches et al., 2009	yes	Teubner et al., 2007; Riches et al., 2009	
		Activity	yes	Teubner et al., 2007	yes	Teubner et al., 2007	yes	Teubner et al., 2007	
SULT2B1	mRNA	RT-PCR	no	Nishimura and Naito, 2006	yes	Nishimura and Naito, 2006	no	Nishimura and Naito, 2006	
		NB	n.d.		n.d.		no	Meloche and Falany, 2001	
Primary/original references were analyzed and reviews were excluded (and are cited ad hoc in the text). The table report only the enzymes whose expression was assessed in reviewed studies**.

* St: stomach; S.I.: small intestine; L.I.: large intestine.

# Technique abbreviations. For mRNA detection, NB: northern blot; ISH: in situ hybridisation; RT-PCR: reverse transcription quantitative (or semi-quantitative) PCR; Comp-RT: competitive RT-PCR assay; NB: northern blotting. For protein detection: IHC: immunohistochemistry; WB; western blotting; activity: enzyme activity measurement.

**No publication was found describing the expression of StAR, 3βHSD1, 3βHSD2, 17βHSD6, 7, 8, 9, 11, 13, 14 15, DHRS11, AKR1C1 AKR1C2 and AKR1C4.

n.d.: not determined.

Stomach intracrinology.
The stomach is an endocrine tissue, and in rodents it produces steroids starting at birth and throughout adulthood (Kobayashi et al., 2013). Human gastric mucosa expresses 17βHSD1, 2, 12 and AKR1C3/17βHSD5 (Table 7). The mRNA for 17βHSD2 in mucosa surface and glandular epithelium inversely correlates with age in both genders (Oduwole et al., 2003a). Luminal gastric mucosa has strong AKR1C3/17βHSD5 immunoreactivity that decreases toward the gastric pits (Chang et al., 2013). Weak immunoreactivity for 17βHSD12 localizes in the fundic glands and in the squamous epithelium of the esophagus (Sakurai et al., 2006).

Sulphatases in parietal cells of the gastric glands have a protective role in detoxification. Estrogenic SULT1E1 is not expressed whereas data for SULT2A1 are inconsistent. SULT2A1 was detected in the gastric mucosa in a study on seven subjects (Tashiro et al., 2000), but it was low/absent in other studies on 39 (Teubner et al., 2007) and 23 subjects (Chen et al., 2003).

Small intestine: duodenum–jejunum–ileum.
Due to its high exposure to food components and harmful xenobiotics, the duodenum expresses several phase I/II enzymes including DHEA/estrogenic SULT1E1, 2A1, 1A1 (Table 7). Protein and enzyme activity of SULT1E1 and 2A1 are present in human jejunum and ileum but absent in duodenum (Teubner et al., 2007), mRNA and protein levels vary with no relation either with age or gender (Her et al., 1996; Nishimura and Naito, 2006). In a study on 23 subjects, SULT1E1 and 2A1 varied inter-individually and between different intestine tracts (Chen et al., 2003). The duodenal mucosa expresses 17βHSD2, but not 17βHSD1 (Casey et al., 1994; Oduwole et al., 2003a) and shows strong luminal AKR1C3/17βHSD5 (Chang et al., 2013) and weak 17βHSD12 immunoreactivity (Sakurai et al., 2006) that decreases toward the Brunner's gland (Chang et al., 2013).

Large intestine: colon, cecum, rectum
The intracrinology of healthy colon mucosa and its relation to CRC was recently reviewed (Foster, 2013). Studies dating from 1987 demonstrated the presence of CYP19A1, 17βHSD reductive and oxidative enzymatic activities, plus the expression of 17βHSD1, 2, 4, CYP19A1, STS and SULT1E1 (Table 7). Most 17βHSDs tend to have higher levels at the surface than in cryptal epithelial cells as indicated for 17βHSD2 mRNA (Oduwole et al., 2002; Foster, 2013), and for the immunoreactivity of AKR1C3/17βHSD5 (very strong; Chang et al., 2013) and 17βHSD12 (weak; Sakurai et al., 2006).

Pancreas
Radiolabelled substrates demonstrated the presence of CYP19A1 and SRD5A activities in human pancreatic tissue (Iqbal et al., 1983), which expresses 17βHSD2, 12, STS, SULT1E1 (Casey et al., 1994; Miki et al., 2002; Sakurai et al., 2006; Dalla Valle et al., 2007). High levels of AKR1C3/17βHSD5 localized in pancreatic ductules (acini and islets of Langerhans resulted negative; Chang et al., 2013).

Association with diseases
SNPs in genes controlling estrogen synthesis, response and deactivation are associated with GIT cancers (Freedman et al., 2009; Cho et al., 2012; Zeng et al., 2016) and AKR1C4 is a candidate gene in hereditary CRC (Gylfe et al., 2013; Table 5). Also variations in the expression of these genes associate with GIT disturbances. Low 17βHSD10 levels are associated with aberrant butyrate β-oxidation and ulcerative colitis (De Preter et al., 2012). The epithelial 17βHSD2 level is low in case of stomach, duodenal cancer and chronic gastritis, though it is high in regenerating epithelium close to active gastritis and ulcers (Oduwole et al., 2003a). In a study on 34 gastric tumors and adjacent healthy tissue, the mRNA and protein levels of 17βHSD2 and AKR1C3/17βHSD5 were down-regulated in cancer (Frycz et al., 2015, 2016). Some studies showed lower oxidative 17βHSD activity and mRNA level of 17βHSD2 (and 4) in CRC vs. adjacent normal tissue, suggesting a protective role of estrogen deactivation. However, another study on 35 women and 39 men found that high 17βHSD2 levels were associated with poor prognosis in female patients with distal CRC (reviewed in Foster, 2013). Also 17βHSD1 level measured by RT-qPCR and western blotting in specimens from 52 patients was lower in CRC than adjacent normal mucosa (Rawłuszko et al., 2011). CRC show also higher CYP19A1 mRNA compared with adjacent normal mucosa (n = 31) (Sato et al., 2012).

Although no clear target for drugs has been identified in the intracrine network, intracrine enzymes showed some values as biomarkers. In CRC, high STS/SULT1E1 ratio correlates with poor prognosis (Foster, 2013) and AKR1C3/17βHSD5 expression with lymph-node metastasis (Nakarai et al., 2015). In addition, AKR1C1 and AKR1C3/17βHSD5 associate with cisplatin resistance in CRC, hence inhibitors of these AKR1Cs may be used to re-sensitize patients to chemotherapy (Matsunaga et al., 2013). In a study were the levels of E1, E2 and DHEA-S were measured in CRC specimens and adjacent normal mucosa of men and women by LC-MS, intra-tumor estrogens were elevated and (in particular E1) correlated with poor prognosis. In line with an unfavorable role of intra-tissue estrogens, absence on STS was associated with long survival (Sato et al., 2009).

GIT: conclusions
Human GIT/DS is unable to metabolize cholesterol and there is no clear evidence that it expresses 3βHSDs, hence DHEA cannot be used to generate androgens and estrogens (Table 7 and Figure 3). Several SULTs are expressed throughout GIT and involved in detoxification and STS is regulated by estrogen in vitro via non-classical GPER signaling (Gilligan et al., 2017).

The role of steroids in pathology is complex, with divergent effects that depend on time, length and extent of exposure. In line with this, intracrine networks have unclear roles in pathogenesis. In the GIT these networks are strongly involved in the metabolisms of fatty acids and bile acids (outside the scope of this review).

Bone tissue and skeletal system
Bones consist of mineralized connective tissue with structural and supportive functions. The hard exterior part (cortical bone) and the trabecular and spongy cancellous tissue filling the bone interior are identical but differ in the level of mineralization. Osteoblasts, derived from multipotent mesenchymal stem cells, build the bone tissue through deposition of Type-I collagen and through the release of ions that combine chemically forming the bone mineral. Osteoclasts differentiate from hematopoietic stem cells and cause resorption of the mineralized bone mass. The balance between osteoblasts and osteoclasts regulates mineral deposition and resorption. Sex steroid hormones contribute to control bone development during puberty, contribute to bone physiology, bone mass maintenance and regulate the rate of mineral bone deposition and resorption (Svoboda et al., 2010).

The presence of the ERs as well as other hormone-receptors in normal osteoblastic cells, osteoclasts and osteoblasts is documented (Gruber et al., 2002) and estrogens and androgens stimulate bone formation and inhibit bone resorption in both males and females. During human puberty and throughout adulthood, E2 and T induce osteoblast proliferation (Kassem et al., 1998), which is mediated by IGF and GH (Riggs et al., 2002; Svoboda et al., 2010). Such human effects are well recapitulated in animal models. ERα-KO (Vidal et al., 2000) and CYP19A1-KO mice (Oz et al., 2000) exhibit low BMD in both genders and E2 treatment rescues the CYP19A1-KO phenotype (Miyaura et al., 2001). Additionally, ovariectomy stimulates osteoclast differentiation through (indirect) increased levels of IL-1, 6 and TNF in osteoblasts and other bone-derived stromal cells (Gruber et al., 2002; Svoboda et al., 2010).

Accelerated bone loss and increased osteoporotic fractures are associated with postmenopausal estrogen deficiency and low sex steroid levels elicit similar manifestations in men (Compston, 2001; Riggs et al., 2002; Syed and Khosla, 2005). Free E2 levels are associated with low lumbar spine and femoral neck bone mineral density (BMD) in both genders (Zarrabeitia et al., 2007) and estrogen therapy reduces bone loss and the risk of fracture in women with osteoporosis (Gruber et al., 2002).

Intracrinology in healthy bone–systematic search
Bone expresses CYP19A1 and 17βHSD1, and mRNA in situ hybridisation and immunohistochemistry signals were seen in lining cells, osteoblasts, chondrocytes of articular cartilage, and adipocytes adjacent to bone trabeculae in both male and female tibiae. CYP19A1 mRNA was also widely present in various bones (ribs, femurs) with inter-individual variability, but no relation with gender or age (Sasano et al., 1997). STS and 17βHSD activities were demonstrated by recovery of [3H]E1 and [3H]E2 after incubating femur-head fragments with [3H]E1-S (15 women and 12 men with osteoarthritis indicated for hip replacement). No gender-related differences were observed and E2 formation from androgens was lower than that from E1-S, indicating a predominant role of the sulphatase pathway in bone estrogen supply (Muir et al., 2004). Subsequent studies also demonstrated the presence of CYP11A1, CYP17A1, 17βHSD reductive and oxidative activity in bone tissues (Table 8). Overall, however, only six papers describing the level of intracrine enzymes in bone tissues were retrieved by the systemic search (Table 8) and most studies on bone intracrinology used in vitro cell cultures. In vitro studies were not included in our systematic review, but those on bone are briefly described in the next paragraph. These studies demonstrate the presence of a complex intracrine networks.

Table 8 Expression of intracrine enzymes in bone, lungs and central nervous system (CNS) – results of the systematic search.

Gene	Detection	Bone	References	Lung	References	CNS	References	
	Molecule	Technique#							
StAR	mRNA	RT-PCR	n.d.		yes∧	Pezzi et al., 2003	n.d.		
CYP11A1	mRNA	RT-PCR	yes	Rodríguez-Sanz et al., 2015	yes∧	Pezzi et al., 2003	yes	Stoffel-Wagner, 2001	
		Comp-RT	n.d.		n.d.		yes	Beyenburg et al., 1999; Watzka et al., 1999	
	Protein	WB	yes*	Rodríguez-Sanz et al., 2015			n.d.		
CYP17A1	mRNA	RT-PCR	yes	Rodríguez-Sanz et al., 2015	no∧	Pezzi et al., 2003	yes	Stoffel-Wagner, 2001	
		RT-PCR	–		–		no	Steckelbroeck et al., 2004b	
	Protein	WB	yes*	Rodríguez-Sanz et al., 2015	n.d.		n.d.		
		IHC	n.d.		n.d.		no	Steckelbroeck et al., 2004b	
		Activity	n.d.		n.d.		no	Steckelbroeck et al., 2004b	
CYP19A1	mRNA	RT-PCR	yes	Oz et al., 2001	yes	Pezzi et al., 2003; Aresti et al., 2014; Kohno et al., 2014; Konings et al., 2017	yes	Sasano et al., 1998; Stoffel-Wagner et al., 1998a; Stoffel-Wagner, 2001; Yague et al., 2006	
		Comp-RT	n.d.		n.d.		yes	Stoffel-Wagner et al., 1999a	
		ISH	yes	Sasano et al., 1997	n.d.		n.d.		
	Protein	IHC	yes	Sasano et al., 1997; Oz et al., 2001	yes	Verma et al., 2013; Siegfried and Stabile, 2014; Taniuchi et al., 2014; Konings et al., 2017	yes	Naftolin et al., 1996; Yague et al., 2006, 2010	
		ELISA	n.d.		yes	Aresti et al., 2014; Skjefstad et al., 2016; Tanaka et al., 2016	n.d.		
		Activity	yes	Schweikert et al., 1995	yes	Taniuchi et al., 2014	yes	Naftolin and MacLusky, 1982; Stoffel-Wagner, 2001	
3βHSD1	mRNA	RT-PCR	n.d.		yes∧	Pezzi et al., 2003	no	Stoffel-Wagner, 2001	
3βHSD2	mRNA	RT-PCR	n.d.		no∧	Pezzi et al., 2003	no	Stoffel-Wagner, 2001	
17βHSDs							
HSD17B oxidative activity	yes	Muir et al., 2004	n.d.		yes	Steckelbroeck et al., 1999, 2003; Stoffel-Wagner, 2001	
HSD17B reductive activity	yes	Muir et al., 2004	n.d.	Tsai et al., 2001; Attar et al., 2009; Huhtinen et al., 2014	yes	Steckelbroeck et al., 1999, 2003; Stoffel-Wagner, 2001	
17βHSD1	mRNA	RT-PCR	n.d.		yes	Takeyama et al., 2000; Drzewiecka et al., 2015; Konings et al., 2017)	yes	Stoffel-Wagner et al., 1999a; Stoffel-Wagner, 2001	
		Comp-RT	n.d.		n.d.		yes	Beyenburg et al., 2000	
	mRNA	ISH	yes	Sasano et al., 1997	n.d.		n.d.		
17βHSD1	Protein	Comp-RT	n.d.		n.d.		yes	Stoffel-Wagner et al., 1999b; Beyenburg et al., 2000	
		IHC	yes	Sasano et al., 1997	yes	Verma et al., 2013; Drzewiecka et al., 2015; Konings et al., 2017	n.d.		
		WB	n.d.		yes	Drzewiecka et al., 2015	n.d.		
17βHSD2	mRNA	RT-PCR	n.d.		yes	Takeyama et al., 2000; Simard et al., 2010; Konings et al., 2017	no	Stoffel-Wagner, 2001	
		Comp-RT	n.d.		n.d.		n.d.	Stoffel-Wagner et al., 1999b; Beyenburg et al., 2000	
		NB	n.d.		n.d.		no	Casey et al., 1994	
	Protein	IHC	n.d.		yes	Verma et al., 2013	n.d.		
		WB			n.d.		n.d.		
17βHSD3	mRNA	RT-PCR	n.d.		n.d.		yes	Stoffel-Wagner, 2001	
		Comp-RT	n.d.		n.d.		yes	Stoffel-Wagner et al., 1999b; Beyenburg et al., 2000	
17βHSD4	mRNA	RT-PCR	n.d.		yes	Konings et al., 2017	yes	Stoffel-Wagner et al., 1999a; Stoffel-Wagner, 2001; Steckelbroeck et al., 2003	
		Comp-RT	n.d.		n.d.		yes	Stoffel-Wagner et al., 1999b; Beyenburg et al., 2000	
		NB	n.d.		yes	Möller et al., 1999	yes	Möller et al., 1999	
17βHSD6	mRNA	RT-PCR	n.d.				yes	Huang and Luu-The, 2000; Steckelbroeck et al., 2003	
17βHSD7	mRNA	RT-PCR	n.d.		yes	Törn et al., 2003; Konings et al., 2017	yes	Steckelbroeck et al., 2003	
17βHSD8	mRNA	RT-PCR	n.d.		yes	Ohno et al., 2008	yes	Steckelbroeck et al., 2003	
17βHSD9	mRNA	RT-PCR	n.d.		n.d.		yes	Steckelbroeck et al., 2003	
17βHSD10	mRNA	RT-PCR	n.d.		n.d.		yes	Steckelbroeck et al., 2003; He and Yang, 2006; Hovorkova et al., 2008	
	Protein	IHC	n.d.		n.d.		yes	He et al., 2005b	
		C-ELISA	n.d.		n.d.		yes	Hovorkova et al., 2008	
17βHSD11	mRNA	RT-PCR	n.d.		yes	Chai et al., 2003	yes	Steckelbroeck et al., 2003	
	mRNA	NB	n.d.		yes	Chai et al., 2003	n.d.		
	Protein	IHC	n.d.		yes	Brereton et al., 2001	n.d.		
17βHSD12	mRNA	RT-PCR	n.d.		yes	Sakurai et al., 2006; Konings et al., 2017	yes	Sakurai et al., 2006	
	mRNA	NB	n.d.		yes	Sakurai et al., 2006	yes	Sakurai et al., 2006	
	mRNA	NB	n.d.		n.d.		no	Casey et al., 1994	
	Protein	IHC	n.d.		Yes$	Sakurai et al., 2006	n.d.		
AKR1C activity		n.d.		n.d.		yes	Steckelbroeck et al., 2010	
AKR1C1	mRNA	RT-PCR	n.d.		n.d.		yes	Penning et al., 2000; Stoffel-Wagner et al., 2003; Steckelbroeck et al., 2010	
AKR1C2	mRNA	RT PCR	n.d.		n.d.		yes	Penning et al., 2000	
		Comp-RT	n.d.		n.d.		yes	Stoffel-Wagner et al., 2003; Steckelbroeck et al., 2004a, 2010	
AKR1C3	mRNA	RT PCR	n.d.		yes	Simard et al., 2010; Konings et al., 2017	n.d.		
		Comp-RT	n.d.		n.d.		yes	Stoffel-Wagner et al., 2000, 2003; Steckelbroeck et al., 2001, 2004a; Stoffel-Wagner, 2001	
		NB	n.d.		n.d.	Lin et al., 1997	n.d.		
	Protein	IHC	n.d.		yes	Miller et al., 2012b; Chang et al., 2013	n.d.		
AKR1C4	mRNA	RT-PCR	n.d.		n.d.		no	Steckelbroeck et al., 2010	
		Comp-RT	n.d.		n.d.		no	Stoffel-Wagner et al., 2000, 2003; Steckelbroeck et al., 2004a	
SRD5A1	mRNA	Comp-RT	n.d.		n.d.		yes	Stoffel-Wagner et al., 1998b, 2000, 2003	
	Protein	IHC	n.d.		yes	Aumüller et al., 1996	yes	Aumüller et al., 1996	
		activity	n.d.		n.d.		yes	Stoffel-Wagner et al., 1998b; Steckelbroeck et al., 2001	
SRD5A2	mRNA	Comp-RT	n.d.		n.d.		no	Stoffel-Wagner et al., 1998b, 2000	
	Protein	IHC	n.d.		yes	Aumüller et al., 1996	yes	Aumüller et al., 1996	
STS	mRNA	RT-PCR	n.d.		yes	Konings et al., 2017	yes	Steckelbroeck et al., 2004b	
		RT-PCR	–		no	Miki et al., 2002	no	Miki et al., 2002	
	Protein	IHC	n.d.		yes	Iida et al., 2013	yes	Steckelbroeck et al., 2004b	
		IHC	–		no	Miki et al., 2002	no	Miki et al., 2002	
		Activity	yes	Muir et al., 2004	yes	Milewich et al., 1983; Munroe and Chang, 1987	yes	Platia et al., 1984	
SULT1E1	mRNA	RT-PCR	yes	Svoboda et al., 2007	yes	Miki et al., 2002; Konings et al., 2017	yes	Miki et al., 2002; Nishimura and Naito, 2006	
		RT-PCR	n.d.		n.d.		no	Salman et al., 2011	
		NB	n.d.		n.d.		n.d.		
	Protein	IHC	n.d.		yes	Miki et al., 2002; Iida et al., 2013	yes	Miki et al., 2002	
		IHC	n.d.		–		no	Salman et al., 2011	
		WB	n.d.		yes	Riches et al., 2009	n.d.		
		Activity	n.d.		yes	Jones et al., 1992	no	Miki et al., 2002	
SULT2A1	mRNA	RT-PCR	n.d.		n.d.		no	Nishimura and Naito, 2006; Salman et al., 2011
3/4 Table VII continues	
	Protein	IHC	n.d.		yes	Riches et al., 2009	no	Steckelbroeck et al., 2004b; Salman et al., 2011	
		Activity	n.d.		n.d.		no	Steckelbroeck et al., 2004b.	
SULT1A1	mRNA	RT-PCR	n.d.		n.d.		yes	Nishimura and Naito, 2006; Salman et al., 2011	
	Protein	IHC	n.d.		n.d.		yes	Nishimura and Naito, 2006; Salman et al., 2011	
		WB	n.d.		yes	Riches et al., 2009	n.d.		
SULT2B1	mRNA	RT-PCR	n.d.		yes	He et al., 2004, 2005a	yes	Nishimura and Naito, 2006; Salman et al., 2011	
		NB	n.d.		yes	He et al., 2004, 2005a	no	Meloche and Falany, 2001	
		NB	–		no	Meloche and Falany, 2001	–		
	Protein	IHC	n.d.		yes	He et al., 2004, 2005a	yes	Nishimura and Naito, 2006; Salman et al., 2011	
Primary/original references were analyzed and reviews were excluded (and are cited ad hoc in the text). The table report only the enzymes whose expression was assessed in reviewed studies**.

# Technique abbreviations. For mRNA detection, NB: northern blot; ISH: in situ hybridisation; RT-PCR: reverse transcription quantitative (or semi-quantitative) PCR; Comp-RT: competitive RT-PCR assay; NB: northern blotting. For protein detection: IHC: immunohistochemistry; C-ELISA: competitive ELISA assay; WB: western blotting; activity: enzyme activity measurement.

* CYP11A1 and CYP17A1 activities were detected in primary cells of bone.

**No publication was found describing the expression of 17βHSD13, 14, 15 and DHRS11.

∧ Detected in fetal lung tissue.

$ IHC signal in bronchial epithelium.

Bone intracrinology: in vitro and in vivo
From early ‘90s, various isotopic techniques demonstrated the presence of CYP19A1, 17βHSD reductive/oxidative, 3βHSD and STS activities and the mRNA expression of 17βHSD1, 2, 4, STS, SULT1E1, CYP19A1 and SDR5A in human osteoblastic (e.g., HOS, U20S, HTB-96 and MG63) and osteosarcoma cell lines like CRL-1543 (Purohit et al., 1992; Fujikawa et al., 1997; Jakob et al., 1997; Dong et al., 1998; Saito and Yanaihara, 1998; Janssen et al., 1999; Muir et al., 2004; Svoboda et al., 2007; Dias and Selcer, 2014).

In vitro evidence using osteoblastic cells show that E2 has mitogenic effects, which is blocked by the ERα antagonist fulvestrant. Since both E1-S and DHEA-S elicit effects similar to E2, which are blocked by STS inhibition (Selcer and Difrancesca, 2012; Dias and Selcer, 2014), these studies demonstrate that conjugated steroids are activated and that DHEA is converted to E2. Studies in rat osteoblast with [14C]T demonstrated that T is converted by SRD5As and AKR1Cs to 3α/3βDIOLs, which induce proliferation via activation of ER (and not AR) (Enríquez et al., 2013).

In vitro models of osteoblast differentiation showed that various differentiation stages are accompanied by declines in STS, CYP19A1 and 17βHSD1 (Janssen et al., 1999; Dias and Selcer, 2016).

In rats, during and after sexual maturation, in situ hybridization showed that ERα and ERβ localize in osteoblasts, osteoclasts and osteocytes covering the tibia metaphysis (responsible for elongation of long bones), and co-localize with STS. Starting at sexual maturation (e.g., 7-week-old), ERs also co-localize with CYP19A1, 17βHSD1, 2 and SRD5A1 (van der Eerden et al., 2004). In addition, male transgenic mice overexpressing 17βHSD2 show disturbed IGF-I/steroid actions in bone, with growth retardation, decreased bone formation at prepuberty and decreased serum levels of IGF-I, osteocalcin and T (Shen et al., 2008).

Diseases and treatments
Genetic variants of estrogen and intracrine pathways are associated with bone disturbances (Table 5). Defects in the CYP19A1 and ERα are associated with low BMD and other skeletal disturbances (e.g., high stature, delayed bone age) and estrogen therapy ameliorates some bone abnormalities caused by CYP19A1 deficiencies in men (Smith et al., 1994; Morishima et al., 1995; Carani et al., 1997; Mullis et al., 1997; Bilezikian et al., 1998). In lumbar vertebrae, CYP19A1 levels correlate with changes in osteoporotic degree (Sasano et al., 1997).

Inhibitors of 17βHSD2 attracted attention as potential drugs to oppose the effects of low E2 on BMD, fracture and osteoporosis. Ovariectomised female macaques receiving a 17βHSD2 inhibitor display desirable bone balance, bone strength and lower bone resorption compared with untreated controls (Bagi et al., 2008). Several compounds targeting this enzyme have been developed and their use and challenges in osteoporosis were recently reviewed (Soubhye et al., 2015).

In a study on 35 chondrosarcoma biopsies (a malignant bone cancer occurring in middle aged patients), ERα (mRNA and IHC) and CYP19A1 (mRNA and activity) were demonstrated in the majority of the samples, and the AI exemestane impaired the E2- and androgen-induced proliferation of primary chondrosarcoma cells (Cleton-Jansen et al., 2005). Although AIs were proposed as novel drugs to treat this condition (Bovée et al., 2005), a pilot study on six patients with progressive disease showed no benefit of exemestane in progression-free survival compared with untreated patients (Meijer et al., 2011).

In a study of 28 osteosarcoma specimens (one of the most common bone cancers developing at young age) strong ERβ and PR immunoreactivity was seen in over 80% of the samples (and also correlated with Ki67). ERα and AR staining was seen in 30% of the samples, whereas CYP19A1 was undetected (Dohi et al., 2008). In another study, 20 osteosarcoma specimens, including 11 good responders to chemotherapy and nine poor responders, were subjected to cDNA microarray and 17βHSD10 resulted unregulated in the poor responder group. Results were further confirmed by IHC on 69 archival biopsies, hence targeting 17βHSD10 may be a valuable approach for drug (re)sensitisation (Salas et al., 2009).

Additional intracrine imbalances are described in bone diseases, such as higher androgen reducing 17βHSD activity in benign vs. malignant tumors, declines of CYP19A1 from normal bone to osteosarcoma and expression of SULT1E1 in the majority of the skeletal benign and malignant lesions, originated in bones or from primary tumors elsewhere (Svoboda et al., 2007).

Bone tissue: conclusions
In vitro, animal and human studies show that intracrinology controls bone development, benign and malignant conditions, and offer novel potential drug targets (Table 8 and Figure 3). Steroids can be synthesized in situ from cholesterol (Rodríguez-Sanz et al., 2015) and can be recruited from the serum via the sulphatase pathway. DHEA is substrate for androgen and estrogen production. The action of androgens is partly mediated by their conversion to estrogens via CYP19A1 or to estrogenic 3α/βDIOLs (Vanderschueren et al., 2008).

Lungs
Sex steroids play an important role in lung development and homeostasis. Androgens, progestogens and estrogens are present and exert genomic and non-genomic actions via their hormone-receptors. Classical ERs (with ERβ as predominant form) and membrane GPER are expressed (Couse et al., 1997; Prossnitz and Barton, 2011; Konings et al., 2017). Sex steroids remain active in the lungs throughout lifetime and modulate lung function in both a beneficial or detrimental way, extensively reviewed (González-Arenas and Agramonte-Hevia, 2012; Townsend et al., 2012; Sathish et al., 2015).

E2 and P regulate epithelial sodium channel expression in alveolar epithelial cells (Luo et al., 2015). In alveolar smooth muscle cells, E2 induces bronchodilation via the reduction of intracellular Ca2+ (Townsend et al., 2010).

Both human and animal studies support a promoting role for estrogens and inhibitory role for androgens in lung development and maturation. During gestation and neonatal period, AR is expressed in mesenchymal and epithelial cells. Androgens inhibit the production of surfactants, which starts later in male than in female neonatal lungs (Carey et al., 2007), but also support the developing lung during branching morphogenesis (Kimura et al., 2003).

Lung intracrinology in lungs–systematic search
Adult human lungs express CYP19A1 and most 17βHSDs (1, 2, 4, 7, 8, 11, 12, 17βHSD5/AKR1C3; Table 8). STS, SULT and 17βHSD1, 12 and 17βHSD5/AKR1C3 immunoreactivity localizes in the bronchial epithelium (weak for types 1 and 12, strong for type 17βHSD5) and alveolar macrophages (Sakurai et al., 2006; Miller et al., 2012b; Chang et al., 2013; Konings et al., 2017).

Intracrinology controls lung development and maturation as shown in various animal models (Boucher et al., 2009) and intracrine enzymes are expressed already during fetal stages. Human fetal lungs possess StAR, CYP11A1, 3βHSD1 mRNA (Pezzi et al., 2003), SULT1E1 activity (Jones et al., 1992) and show 17βHSD1 and 2 mRNAs expression at 13 and 20 weeks of gestational age (Takeyama et al., 2000). High mRNA levels of AR, 17βHSD2 and 17βHSD5/AKR1C3 in mid-late gestation period and adult lungs indicate the present of androgen metabolism (Simard et al., 2010). Immunoreactivity for 17βHSD11 is detected in bronchioles of 14 and 31 weeks old fetuses, whereas other structures are negative (e.g., alveoli, ciliated epithelium, acini of the trachea). The expression of 17βHSD11 increases during the second half of pregnancy and maintains similar patterns in neonatal (14 days) and adult lugs (Brereton et al., 2001).

Intracrinology and lung diseases
Altered intracrinology is involved in lung disorders already from neonatal stages toward adulthood, and SNPs in intracrine genes are associated with the onset of diseases (Zhang et al., 2013). Higher concentration of estrogens were measured by LC-MS in women with multiple-synchronous-lung adenocarcinoma compared with single adenocarcinoma (Ikeda et al., 2016) and in neoplastic tissue compared with adjacent normal lungs (Niikawa et al., 2008; Verma et al., 2013). Type 1 17βHSD mRNA, protein and activity are present in various non-small-cell-lung-cancer (NSCLC) cell lines where the mitogenic effect of E1 is abrogated by 17βHSD1 knockdown (Drzewiecka and Jagodzinski, 2012; Verma et al., 2013). In specimens from 48 NSCLC patients, 17βHSD1 expression was associated with squamous cell carcinoma and stage 3A disease (Drzewiecka et al., 2015). In another study on 103 NSCLC specimens, high 17βHSD1 immunoreactivity was associated with low intratumoural E1 and high E2:E1 ratio, whereas higher 17βHSD2 immunoreactivity was associated with high intratumoural E1. Multivariate regression analysis also demonstrated that increased 17βHSD1 immunoreactivity in tumors was an independent negative prognostic factor (Verma et al., 2013).

CYP19A1 is expressed in lung cancer and has potential therapeutic value (Niikawa et al., 2008; Verma et al., 2011; Siegfried and Stabile, 2014). A recent IHC study on 335 NSCLC specimens found an inverse association between CYP19A1 expression with disease specific survival (Skjefstad et al., 2016). Similar data, although restricted to women only, were confirmed in an independent study on 150 primary lung adenocarcinoma specimens, where CYP19A1 was found as the main driver of local estrogen supply (Tanaka et al., 2016). Another study on 110 lung adenocarcinoma specimens found an association between CYP19A1 mRNA (RT-qPCR) and poor prognosis in females, never-smokers and harboring EGFR mutations (Kohno et al., 2014). However, a recent mRNA study on 96 NSCLC patients showed that CYP19A1 in combination with ER is a good prognostic marker (Aresti et al., 2014).

STS and SULT1E1 immunoreactivity is detected in the majority of NSCLC cases, and STS is a good prognostic marker (Iida et al., 2013).

Lymphangioleiomyomatosis (LAM) is a rare, potentially fatal disease affecting predominantly young women. It is strongly hormone sensitive and it is hypothesized to originate from the uterus as lung metastasis (Prizant and Hammes, 2016). The levels of ERs, PR, AR, CYP19A1, STS, 17βHSD1 and SRD5A2 were recently assessed among 30 LAM biopsies. CYP19A1 expression resulted a useful classification marker with implication for potential therapy (Adachi et al., 2015). A recent study on specimens from 73 patients with chronic obstructive pulmonary disease (COPD) and 48 controls described an association between both CYP19A1 and 17βHSD1 with COPD (Konings et al., 2017). CYP19A1 is also implicated in interstitial pneumonia interstitial pneumonia, where local E2 concentration and CYP19A1 activity and immunoreactivity were elevated in diseased compared with normal tissue (Taniuchi et al., 2014).

Potential novel treatments
Blocking the estrogen signaling showed promising preclinical results in animal models of lung cancer (Verma et al., 2011). In humans, antiestrogen treatments (ER antagonists, GnRH, oophorectomy, P) have been used in LAM (Taveira-DaSilva and Moss, 2014) and lung cancer patients (Verma et al., 2011; Kohno et al., 2014). A phase II study on advanced NSCLC patients non-responsive to platinum-based drugs tested the dual-regimen mTOR/CYP19A1 inhibitors. Unfortunately, this study was prematurely terminated due to high toxicity (Singhal et al., 2015) and one additional trial using ER antagonist plus AI (fulvestrant and anastrozole) as consolidation therapy in postmenopausal women with advanced NSCLC (NCT00932152) was terminated due to poor recruitment.

Better results were obtained using the AI letrozole as single agent or in combination with rapamycin in a phase II trial on 17 postmenopausal women with LAM (NCT01353209). AI treatment was safe and well tolerated also in the dual drug regimen (Lu et al., 2017).

Lungs: conclusions
Steroids are involved in lung maturation, development and in susceptibility to diseases. Most 17βHSDs, STS/SULT1E1, CYP19A1 are expressed indicating the lung's ability to metabolize androgens, estrogens and progestogens. Evidence of 3βHSDs is limited to fetal tissues (Table 8 and Figure 3). Approaches aimed at decreasing local estrogens may offer future novel treatments for various lung diseases.

Brain and central nervous system (CNS)
One of the first CNS actions of sex steroids to be described is the hypothalamus-pituitary-gonadal axes control (Andersen and Ezcurra, 2014). The identification of steroid-receptors outside the hypothalamus, like hippocampus (controlling memory), prefrontal cortex, cerebellum and dopaminergic system regulation indicated that sex steroids have complex and widespread effects in the CNS. They control aggressive behavior, cognitive functions, mood, food intake, appetite, addiction, blood pressure, fine motor skills, motor coordination, pain circuit and both estrogens and androgens are neuroprotective (López and Tena-Sempere, 2015; Soma et al., 2015; McEwen and Milner, 2017). Estrogen deprivation in animals and humans is associated with development of metabolic disorders and estrogen administration has a general catabolic effect (López and Tena-Sempere, 2015). Animal experiments and KO models show that ERα mediates the major actions of estrogens in the CNS, like the metabolic control functions (Musatov et al., 2007) and the negative-feedback on the hypothalamus-pituitary-gonadal axes (Couse et al., 2003). However, both nuclear and non-nuclear ERs are relevant in distinct CNS regions (Almey et al., 2015; López and Tena-Sempere, 2015; McEwen and Milner, 2017).

Local steroid synthesis in the CNS is demonstrated in animal studies. CYP19A1-KO mice have increased ischemic damages compared with ovariectomised wild-type mice, indicating a local action of CYP19A1 (McEwen and Milner, 2017). Similar conclusions were drawn for the estrogen protective effects on stroke, Alzheimer (AD), Parkinson diseases, aggressive behavior (Soma et al., 2015; McEwen and Milner, 2017) and mice with ablation in various 17βHSDs show neuronal defects (Table 4). In rodents, CNS regions like the hippocampus and the hypothalamus express the enzymes involved in the local generation of steroids, like StAR, CYP11A1, CYP17A1, 3βHSD1, CYP19A1, 17βHSD1, SRD5A1 and 2 (mRNA and protein by immunohistochemistry or western blot), and can produce pregnenolone, DHEA, androgens and estrogens from cholesterol, as confirmed by HPLC using radiolabelled substrates and tissue cultures of brain slices (Mukai et al., 2006; Murakami et al., 2006). CYP enzymes of rat hippocampus co-localize in pyramidal neurons (CA1–CA3 regions) and granule cells (dentate gyrus) (Mukai et al., 2006; Murakami et al., 2006). Regulation of intracrine enzymes varies during development and sexual maturation, as indicated by mRNA expression (RT-qPCR) of 20 intracrine enzymes analyzed in rat hippocampus post-natal and throughout early (1 week) development (Kimoto et al., 2010).

Intracrinology in the CNS is particularly relevant because, beside the traditional pathway via the receptors, several steroids have neuroactivity and are allosteric modulators of GABAA receptors (Figure 2). Such actions are possessed also by steroids that are unable to activate the steroid hormone receptors, such as 3β- and 3α-hydroxyl sulpho-conjugates (P5-S and DHEA-S), 5β-reduced steroids (5βAN, etiocholanolone and 5β-THP isomers; Table 1), which are all GABAA negative modulators (in contrast to unconjugated 3α-hydroxysteroids) (Stoffel-Wagner, 2001; Belelli and Lambert, 2005; Agís-Balboa et al., 2006; Gibbs et al., 2006; Reddy, 2010; Steckelbroeck et al., 2010).

Intracrinology in CNS–systematic search
Intracrine enzymes are widely expressed in human CNS (Table 8) and intratissue concentrations of steroids in distinct regions differ between regions and from the levels in the blood (Mukai et al., 2006; Murakami et al., 2006; Jäntti et al., 2010). In contrast to rodents, however, the presence of the complete steroid biosynthetic pathway is not clearly demonstrated in the human CNS and contrasting data were reported (Table 8). CYP11A1 mRNA was detected in the temporal, frontal neocortex and subcortical white matter of men, women and children (Stoffel-Wagner, 2001). Low mRNA levels of CYP17A1 were detected in the hippocampus, amygdala, caudate nucleus, cerebellum, corpus callosum, spinal cord and thalamus (Stoffel-Wagner, 2001; Yu et al., 2002), but other authors found no expression of this enzyme (Steckelbroeck et al., 2004b, 2010; MacKenzie et al., 2008). No 3βHSD1 or 2 was detected in temporal lobes, hippocampus, thalamus and amygdala (Stoffel-Wagner, 2001; Steckelbroeck et al., 2010), although other authors detected low levels in amygdala, caudate nucleus, cerebellum, corpus callosum, hippocampus, spinal cord and thalamus (Yu et al., 2002).

The temporal lobes (both neocortex and white matter) have 17βHSD oxidative and reductive activities, CYP19A1 mRNA expression and activity, which is also present in hippocampus (Stoffel-Wagner et al., 1999a; Stoffel-Wagner, 2001). Temporal lobe specimens from 10 men to 12 women indicated that 17βHSD estrogen-oxidative and DHEA-reductive metabolisms are predominant, thus producing E1 and A5, respectively (Stoffel-Wagner, 2001). Regarding the different 17βHSDs, type 1, 3, and 4 mRNAs (but not type 2) were demonstrated by competitive reverse transcription-PCR in specimens from 34 women, 32 men and 10 children (Casey et al., 1994; Beyenburg et al., 2000). Subsequent studies confirmed the expression of types 4, 7, 8, 10, 11 17βHSD and AKR1C3/17βHSD5 in temporal lobes and hippocampus (Stoffel-Wagner, 2001; Steckelbroeck et al., 2003). In particular 17βHSD10 is involved in the deactivation of THP to 5αDHP, and it is an important regulator of neurological functions (Yang et al., 2016).

Production of 5α-androstane and pregnane neurosteroids is mediated by the action of SRD5As and AKR1Cs (Figure 2). SRD5A1 (not type 2) mRNA and enzyme activity were demonstrated in temporal neocortex and subcortical white matter, hippocampus, cerebellum, hypothalamus (Steckelbroeck et al., 2001; Stoffel-Wagner, 2001), and AKR1C4 mRNA was detected in both hippocampus and temporal lobe (Stoffel-Wagner, 2001). AKR1C1 and AKR1C2 are widely expressed in CNS and since no specific inhibitors directed against AKR1C1 to 4 could completely inhibit AKR1C brain activity, the involvement of an unidentified enzyme is suggested (Steckelbroeck et al., 2010). Isomeric 5β-neurosteroids require the action of AKR1D1, and it is unknown whether AKR1D1 is expressed in CNS, or liver 5β-steroids reach peripheral regions via the circulation (Jin et al., 2011).

The sulphatase pathway in the CNS is relevant because (although recent studies are revisiting this paradigm; Qaiser et al., 2017), sulphated-steroids do not cross the blood-brain barrier. Therefore, sulphated neurosteroids like DHEA-S and P5-S need to be generated locally, and in line with this, their level in the CNS is independent from the level in the blood (Rajkowski et al., 1997) and varies throughout distinct brain regions (especially hippocampus and hypothalamus) (Jäntti et al., 2010).

STS and SULTs are widely expressed, with no gender-related differences (Table 8) (Kríz et al., 2008a,b; Mueller et al., 2015). SULT1A1 has high expression especially in specimens isolated from cerebellum, occipital and frontal lobes (Salman et al., 2009). No brain region expresses SULT2A1, whereas contrasting data exist for SULT2B1 and SULT1E1 (Table 8).

Diseases and treatments
Steroid metabolism is deviated in schizophrenia (Bicikova et al., 2013) and aberrations and unbalances of intracrine enzymes are associated with neurological disorders (Luchetti et al., 2011 and see Table 5). In a study of 49 patients with AD, prefrontal cortex mRNA levels of 17βHSD1, CYP19A1 and AKR1C2 increased at late stages (Luchetti et al., 2011). STS and SULT activities, measured by radioimmunoassay and GC-MS in 55 human brain tumor specimens, varied between tumor types (Kríz et al., 2008b). Immunoreactivity for AKR1C3/17βHSD5 was low in medulloblastomas (n = 10 analyzed), high in 37 glial neoplasms and 18 meningiomas and was absent in intracranial schwannoma (n = 7) (Park et al., 2010). A recent screening of a chemical library of steroid inhibitors using three low grade pediatric glioma cell lines found that inhibition of 17βHSD3 blocked cell growth and induced apoptosis in vitro (Ajeawung et al., 2013)

Type 10 17βHSD is associated with AD and is a potential target in diseases like AD, Parkinson, and an X-linked mental retardation, that may arise from the impaired degradation of branched chain fatty acid, isoleucine or aberrant neurosteroid (THP) metabolism (Lim et al., 2011; Yang et al., 2016).

STS has been implicated in ADHD and a recent mouse study indicates that genetic and pharmacological manipulations of the STS axis influence the inhibitory processes and give rise to improvements in response control (Davies et al., 2014). A recent animal experiment using a model of autoimmune encephalomyelitis showed high SULT1A1 mRNA expression in laser-captured-micro-dissected white matter astrocytes, suggesting that deactivation of estrogens (and other phenolic substrates) may be responsible for the resistance to anti-neuro-inflammatory treatments in these cells and could be possibly used as new treatments to protect CNS from inflammatory injuries (Guillot et al., 2015).

CNS: conclusions
CNS can synthesize steroids from cholesterol, although this is restricted to few brain regions. Steroid metabolism in the CNS is particular complex due to the formation of both 5α-/β-reduced and sulpho-conjugated neurosteroids (Table 8 and Figure 3).

Intracrinology in other tissues and systems
Steroid metabolism is also important in the immune system, skin and adipose tissue. A thorough review of these systems is outside the scope of this study, however, a brief mention is given below.

Immune system and inflammation
Beside corticosteroids, several other steroids affect the immune system and inflammation. A5 induces white blood cells and platelets production in bone marrow (Chen et al., 2004); estrogens and androgens control B-lymphocyte development in a sex-dependent way and modulate autoimmune diseases (McCarthy, 2000; Calippe et al., 2010; Sakiani et al., 2013).

Lipopolysaccharide-mediated proinflammatory pathway in macrophages and NF-κB activation are blocked by estrogens, which induce T-helper (Th) type 2 responses, whereas androgens stimulate type 1 responses (Iwasa et al., 2015). DHEA and DHEA-S also regulate the maturation of Th1 or Th2 cells. It was shown that plasma Th2 lymphocytes and its major secreted cytokine IL6 increase with age, and this is reversed in mice upon administration of DHEA or DHEA-S (Reed et al., 2005). Such effect was recapitulated in vitro by DHEA but not DHEA-S implicating the involvement of macrophage STS in lymphoid tissues where Th cell maturation occurs. In line with this, the effect of DHEA-S, but not DHEA, was impaired in vivo by an STS inhibitor (Reed et al., 2005). These data prompted to propose STS inhibition as a therapeutic approach for diseases associated with inappropriate immune responses and excess Th1 cytokines such as rheumatoid arthritis (Reed et al., 2005). Whether the action of DHEA is secondary to its conversion to androgens or estrogens is currently unclear. STS activity of peripheral blood leukocytes is higher in women during the follicular phase of the menstrual cycle than in women in the luteal phase or in men and it becomes highest during pregnancy, suggesting a role for P in regulating STS activity (Reed et al., 2005; Mueller et al., 2015). In vitro studies also demonstrated that STS activity is induced by cytokines such as IL6 and TNF (Mueller et al., 2015).

Opposite deregulation of the sulphatase pathway is seen in other chronic inflammatory diseases/cell types. Vascular smooth muscle cells show higher STS activity in women with mild atherosclerosis compared with women with severe disease (and male), whereas SULT1E1 activity is lower in women with severe disease (Mueller et al., 2015).

CYP19A1 is also expressed in macrophages (Konings et al., 2017) and KO mice have increased numbers of peripheral blood and bone marrow cells and inflammatory renal lesions (Shim et al., 2004). CYP19A1 inhibitors exacerbate the autoimmune lesions in a murine model of Sjögren syndrome and estrogen administration reverses such phenotype (Iwasa et al., 2015; Park et al., 2015). Opposite effects are observed in prostate, where elevated intracrine estrogens due to CYP19A1 overexpression induce inflammation and pre-malignant pathology (Ellem et al., 2009) as well as in adipose tissue (Reed et al., 2005).

Skin
The skin is the largest human organ and first barrier against pathogens where important immune functions interconnected with intracrine steroid metabolism take place (Slominski et al., 2013). Keratinocytes and sebocytes express ERs, intracrine enzymes, and the activity of sebaceous glands is influenced by steroids as indicated by the sebum production at andrenarche (Slominski et al., 2013). CYP17A1, CYP19A1, 17βHSD1, 2, 3, 4 (and enzymes metabolizing corticosteroid - outside the scope of this review) are detected in human skin. Some genes are under the influence of vitamin D and sebocytes can synthesize T from adrenal precursors (Hughes et al., 1997; Thiboutot et al., 1998; Slominski et al., 2013). Low 17βHSD oxidative metabolism characterizes sebaceous glands from skin areas prone to develop acne compared with other locations, suggesting a protective role of the oxidative metabolism against androgen excess (Fritsch et al., 2001). Sulphatase pathway is present in the skin (Reed et al., 2005; Simard et al., 2005), and genetic variants in STS and SULTs are associated with skin disturbances, most likely because of unbalanced steroid accumulation (Table 5).

Adipose tissue
The adipose tissue is one of the most complex endocrine organs that besides secreting leptin and adiponectin, is a site of steroid metabolism, it establishes interaction with the CNS for glucose and lipid metabolism control, energy homeostasis and inflammation. The implication of sex steroids in adipose tissue is demonstrated by the different fat distribution that characterizes men and women (Mauvais-Jarvis et al., 2013; Varlamov et al., 2014; López and Tena-Sempere, 2015, 2016; Palmer and Clegg, 2015). ER-KO and CYP19A1-KO mice develop obesity with human-like phenotypes (López and Tena-Sempere, 2015). Estrogens protect against metabolic syndrome and men lacking endogenous estrogens (CYP19A1 or ER-α deficiency) develop hypertriglyceridemia, glucose intolerance and insulin resistance (Kim et al., 2014). In adipose tissue of men, 17βHSD2 levels and androgen inactivation correlate with BMI (Fouad Mansour et al., 2015). A mouse study also showed that increased unsulphated-estrogen availability due to loss of SULT1E1 improved metabolic function in a model of type 2 diabetes, which leads to speculations about a potential role of SULT1E1 inhibition for this disease - at least in women (Gao et al., 2012).

Fat consists of different tissue types (white and brown) and different regional depots with distinct physiological, intracrinological characteristics and distinct relations with pathologies and metabolic disorders (Blouin et al., 2009; Mauvais-Jarvis et al., 2013). White adipose tissue is mainly subcutaneous (abdomen) or visceral (surrounding the inner organs), this last being associated with metabolic risks. A plethora of investigations demonstrated the ability of adipose tissue to aromatise androgens into estrogens and that the intra-tissue steroid levels are higher than the levels in blood (Bélanger et al., 2002). Androgenic and estrogenic 17βHSD activity and the mRNA for 17βHSD1, 2, 3, 7, 12, AKR1C3/17βHSD5 were detected in both intra-abdominal and subcutaneous fat (Bélanger et al., 2002; Quinkler et al., 2004; Bellemare et al., 2009; Wang et al., 2013).

Both subcutaneous and visceral fat tissue of women expresses the androgenic 17βHSD3 (generally considered testis specific) indicating that adipose tissue in women is substantially androgenic. Such characteristic in the visceral depot increased with increasing BMI, suggesting a link between central obesity and metabolic diseases (Corbould et al., 2002).

Additionally, several enzymes (AKR1C2, AKR1C3/17βHSD5, CYP19A1, STS and SULT1E1) vary throughout adipocyte differentiation and maturation (Quinkler et al., 2004; Bellemare et al., 2009; Blouin et al., 2009; Mueller et al., 2015).

Conclusions and recommendations
Intracrinology consists of a complex and intricate network of alternative and redundant pathways that generate, deactivate steroids in peripheral tissues and ultimately control steroid exposure in a tissue specific manner. A number of compounds have that ability to bind and activate more than one nuclear receptors thus exerting multiple biological actions. Blood steroids represent a reservoir of substrates that support these intracrine networks. Studies retrieved by the systematic search demonstrated that most investigations rely on RT-PCR or IHC to detect enzyme and protein, and frequently without multiple-technique confirmation of the data. Since both techniques present limitations, and antibodies for IHC often perform sub-optimally (detection limit is not sufficient to detect some intracrine enzymes, crossreactivity between isoforms) these techniques are not always suitable to infer the real biological role of a reaction/enzyme.

However, the recent technological advances in steroid profiling together with an improved knowledge of intracrine enzymes and the possibility to validate data using multiple approaches (RNA, protein, activity, steroid profiling) create today unprecedented opportunities to expand our understanding of intracrinology, its relation with endocrinology and to exploit this knowledge in patient care. Improved multiplex platforms allowing to profile in peripheral tissues all steroids depicted in Figure 2 are awaited and will elucidate the relevant tissue-specific networks. It is envisaged that novel prognostic markers and drug targets will become of clinical relevance soon.

We should however be aware that the redundant actions of intracrine enzymes, their substrate promiscuity, the existence of alternative pathways and the patient-to-patient variability might result in drug insensitivity. Dual/triple inhibitors will help solving this problem. In addition, in order to optimize research on novel drugs, the classical preclinical drug discovery pipelines (safety, pharmacokinetics and dynamics), should encompass parallel research lines to learn how to pre-select potentially responsive patients.

Finally, since we know that steroidal and intracrine drugs might have profound effects on the CNS, it is desirable to have in depth research on the neurological effects of potential novel drugs during the nonclinical phase of drug development. This will facilitate to select suitable compounds to the clinical development.

Author contributions
GK drafted the study, prepared figures, tables, intermediate versions, final version and approved final version. LB drafted part of the study, contributed to intermediate versions and approved final version. KC drafted part of the study, contributed to intermediate versions and approved final version. BD contributed to intermediate versions and approved final version. TL drafted part of the study, contributed to intermediate versions and approved final version. PK contributed to intermediate versions and approved final version. MB contributed to intermediate versions and approved final version. RK contributed to intermediate versions and approved final version. SX drafted part of the study, contributed to intermediate versions and approved final version. AR drafted the study, prepared figures, tables, intermediate versions, final version and approved final version.

Conflict of interest statement
PK and TL are employees of Forendo Pharma Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We are grateful to Dr. Margaretha A Skowron (Department of Urology, University Düsseldorf, Germany) for graphic arts.

We also would like to thank the management and curator of the online databases we made use of, namely: the database of chemical molecules PubChem (www.ncbi.nlm.nih.gov; pubchem.ncbi.nlm.nih.gov) maintained by the National Center for Biotechnology Information (NCBI; National Library of Medicine/United States National Institutes of Health - NIH); Chemical Abstracts Service (CAS), maintained by the American Chemical Society (www.cas.org); Human Metabolome Data Base (HMDB, www.hmdb.ca), funded and maintained by Genome Canada; Chemical Book (www.chemicalbook.com), funded by industrial partners; Chemical Entities of Biological Interest (ChEBI; www.ebi.ac.uk/chebi/init.do), curated by the European Bioinformatics Institute of the European Molecular Biology Laboratory (EMBL); drug and drug target database Drugbank (www.drugbank.ca/drugs), University of Alberta and The Metabolomics Innovation Centre; GeneCards (www.genecards.org), developed and maintained by the Crown Human Genome Center at the Weizmann Institute of Science; Online Mendelian Inheritance in Man® (OMIM®, https://omim.org/), McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD); Mouse Genome Informatics (MGI; www.informatics.jax.org), Mouse Genome Database at the Mouse Genome Informatics website, The Jackson Laboratory, Bar Harbor, Maine.

Funding. The present study was sponsored by the Dutch Cancer Society (KWF Kankerbestrijding: www.kwf.nl), contract number UM-13-5782 granted to AR.

Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2018.00940/full#supplementary-material

Click here for additional data file.

 Abbreviations
[3H]tritiated hydrogen

[14C]radioactive carbon

ADAlzheimer disease

ADHDattention deficit hyperactivity disorder

AIaromatase inhibitor

AKRaldo-ketoreductase

ARandrogen-receptor

ARTassisted reproduction technology

BMDbone mineral density

BMP-2bone morphogenetic protein 2

COPDchronic obstructive pulmonary disease

COUP-TFIIchicken-ovalbumin-upstream-promoter-transcription-factor II

CNScentral nervous system

CRCcolorectal cancer

CX43connexin 43

DSdigestive system

Edembryonic day

ECendometrial cancer

EndRetendoplasmic reticulum

ERestrogen-receptor

Fdxferredoxin

FdRferredoxin reductase

GC-MSgas-chromatography tandem mass-spectrometry

GnRHgonadotropin releasing hormone

GHgrowth hormone

GITgastrointestinal tract

GPERG protein-coupled estrogen-receptor

HPLChigh performance liquid-chromatography

HRThormone-replacement-therapy

hCGhuman chorionic gonadotropin

IGF1insulin-like growth factor 1

IHCimmunohistochemistry

IL-1interleukin-1

IL-6interleukin-6

KOknock-out

LC-MSliquid-chromatography tandem mass-spectrometry

mTORmammalian target of rapamycin

NAPDHnicotine-adenine-dinucleotide-phosphate

NSCLCnon-small cell lung cancer

PAINphenomena of pan-assay interfering compounds

PAPbis-phospho-nucleotide-3′-phospho-adenosine-5′-phosphate

PCOCpoly cystic ovarian syndrome

PORP450 oxidoreductase

RT-qPCRreverse-transcriptase quantitative polymerase-chain-reaction

SF1steroidogenic factor 1

SHBGsex hormone binding globulin

SNPsingle nucleotide polymorphism

SRDshort-chain dehydrogenase

ThT-helper

TNFtumor necrosis factor

VEGFvascular endothelial growth factor

WBwestern blot/blotting

WOIwindow of implantation.
==== Refs
References
Abdelsamie A. S. van Koppen C. J. Bey E. Salah M. Börger C. Siebenbürger L.  . (2017 ). 17β-HSD1 inhibitor with sub-nanomolar IC50 for a proof-of-principle study . Eur. J. Med. Chem. 
127 , 944 –957 . 10.1016/j.ejmech.2016.11.004 27852458 
Acién P. Velasco I. Gutiérrez M. Martínez-Beltrán M.   (2007 ). Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings . Fertil. Steril. 
88 , 32 –38 . 10.1016/j.fertnstert.2006.11.188 17336977 
Adachi K. Miki Y. Saito R. Hata S. Yamauchi M. Mikami Y.  . (2015 ). Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis . Hum. Pathol. 
46 , 1685 –1693 . 10.1016/j.humpath.2015.02.019 26298231 
Adessi G. L. Prost O. Agnani G. Petitjean A. Burnod J.   (1984 ). Estrone sulfatase activity in normal and abnormal endometrium . Arch. Gynecol. 
236 , 13 –18 . 10.1007/BF02114864 6508360 
Adjei A. A. Thomae B. A. Prondzinski J. L. Eckloff B. W. Wieben E. D. Weinshilboum R. M.   (2003 ). Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: Gene resequencing and functional genomics . Br. J. Pharmacol. 
139 , 1373 –1382 . 10.1038/sj.bjp.0705369 12922923 
Aghajanova L. Hamilton A. Kwintkiewicz J. Vo K. C. Giudice L. C.   (2009 ). Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis . Biol. Reprod. 
80 , 105 –114 . 10.1095/biolreprod.108.070300 18815356 
Agís-Balboa R. C. Pinna G. Zhubi A. Maloku E. Veldic M. Costa E.  . (2006 ). Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis . Proc. Natl. Acad. Sci. U.S.A. 
103 , 14602 –14607 . 10.1073/pnas.0606544103 16984997 
Ajeawung N. F. Maltais R. Jones C. Poirier D. Kamnasaran D.   (2013 ). Viability screen on pediatric low grade glioma cell lines unveils a novel anti-cancer drug of the steroid biosynthesis inhibitor family . Cancer Lett. 
330 , 96 –105 . 10.1016/j.canlet.2012.11.034 23201138 
Almey A. Milner T. A. Brake W. G.   (2015 ). Estrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females . Horm. Behav. 
74 , 125 –138 . 10.1016/j.yhbeh.2015.06.010 26122294 
Alshogran O. Y.   (2017 ). Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes . Expert Opin. Drug Metab. Toxicol. 
13 , 1063 –1073 . 10.1080/17425255.2017.1376648 28871815 
Amant F. Moerman P. Neven P. Timmerman D. Van Limbergen E. Vergote I.   (2005 ). Endometrial cancer . Lancet 
366 , 491 –505 . 10.1016/S0140-6736(05)67063-8 16084259 
Amos-Landgraf J. M. Heijmans J. Wielenga M. C. Dunkin E. Krentz K. J. Clipson L.   (2014 ). Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones . Proc. Natl. Acad. Sci. U.S.A. 
111 , 16514 –16519 . 10.1073/pnas.1323064111 25368192 
Andersen C. Y. Ezcurra D.   (2014 ). Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins . Reprod. Biol. Endocrinol. 
12 :128 . 10.1186/1477-7827-12-128 25543693 
Andrew A. S. Hu T. Gu J. Gui J. Ye Y. Marsit C. J.  . (2012 ). HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer . PLoS ONE 
7 :e51301 . 10.1371/journal.pone.0051301 23284679 
Aresti U. Carrera S. Iruarrizaga E. Fuente N. Marrodan I. de Lobera A. R.   (2014 ). Estrogen receptor 1 gene expression and its combination with estrogen receptor 2 or aromatase expression predicts survival in non-small cell lung cancer . PLoS ONE 
9 :e109659 
10.1371/journal.pone.0109659 25310221 
Arnold C. Einspanier A.   (2013 ). Medical treatment improves social behavior in a primate endometriosis model (Callithrix jacchus) . J. Med. Primatol. 
42 , 112 –119 . 10.1111/jmp.12042 23432639 
Ashton K. A. Proietto A. Otton G. Symonds I. McEvoy M. Attia J.  . (2010 ). Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk . Cancer Epidemiol. 
34 , 328 –337 . 10.1016/j.canep.2010.03.005 20381444 
Attar E. Tokunaga H. Imir G. Yilmaz M. B. Redwine D. Putman M.  . (2009 ). Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis . J. Clin. Endocrinol. Metab. 
94 , 623 –631 . 10.1210/jc.2008-1180 19001523 
Audet-Walsh É. Bellemare J. Lacombe L. Fradet Y. Fradet V. Douville P.  . (2012 ). The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy . Eur. Urol. 
62 , 88 –96 . 10.1016/j.eururo.2011.12.021 22209174 
Audet-Walsh E. Lepine J. Gregoire J. Plante M. Caron P. Tetu B.  . (2011 ). Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics . J. Clin. Endocrinol. Metab. 
96 , E330 –E339 . 10.1210/jc.2010-2050 21147881 
Aumüller G. Eicheler W. Renneberg H. Adermann K. Vilja P. Forssmann W. G.   (1996 ). Immunocytochemical evidence for differential subcellular localization of 5 alpha-reductase isoenzymes in human tissues . Acta Anat. (Basel). 
156 , 241 –252 . 10.1159/000147852 9078395 
Bacallao K. Leon L. Gabler F. Soto E. Romero C. Valladares L.  . (2008 ). In situ estrogen metabolism in proliferative endometria from untreated women with polycystic ovarian syndrome with and without endometrial hyperplasia . J. Steroid Biochem. Mol. Biol. 
110 , 163 –169 . 10.1016/j.jsbmb.2008.03.031 18467089 
Baes M. Huyghe S. Carmeliet P. Declercq P. E. Collen D. Mannaerts G. P.   (2000 ). Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids . J. Biol. Chem. 
275 , 16329 –16336 . 10.1074/jbc.M001994200 10748062 
Bagi C. M. Wood J. Wilkie D. Dixon B.   (2008 ). Effect of 17β-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys . J. Musculoskelet. Neuronal Interact. 
8 , 267 –280 .18799860 
Bair S. R. Mellon S. H.   (2004 ). Deletion of the mouse P450c17 gene causes early embryonic lethality . Mol. Cell. Biol. 
24 , 5383 –5390 . 10.1128/MCB.24.12.5383-5390.2004 15169901 
Balk S. P. Knudsen K. E.   (2008 ). AR, the cell cycle, and prostate cancer . Nucl. Recept. Signal. 
6 :e001 .18301781 
Barzi A. Lenz A. M. Labonte M. J. Lenz H. J.   (2013 ). Molecular pathways: estrogen pathway in colorectal cancer . Clin. Cancer Res. 
19 , 5842 –5848 . 10.1158/1078-0432.CCR-13-0325 23965904 
Bélanger C. Luu-The V. Dupont P. Tchernof A.   (2002 ). Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity . Horm. Metab. Res. 
34 , 737 –745 . 10.1055/s-2002-38265 12660892 
Belelli D. Lambert J. J.   (2005 ). Neurosteroids: endogenous regulators of the GABA(A) receptor . Nat. Rev. Neurosci. 
6 , 565 –575 . 10.1038/nrn1703 15959466 
Bellemare V. Faucher F. Breton R. Luu-The V.   (2005 ). Characterization of 17α-hydroxysteroid dehydrogenase activity (17α-HSD) and its involvement in the biosynthesis of epitestosterone . BMC Biochem. 
6 :12 . 10.1186/1471-2091-6-12 16018803 
Bellemare V. Laberge P. Noel S. Tchernof A. Luu-The V.   (2009 ). Differential estrogenic 17β-hydroxysteroid dehydrogenase activity and type 12, 17β-hydroxysteroid dehydrogenase expression levels in preadipocytes and differentiated adipocytes . J. Steroid Biochem. Mol. Biol. 
114 , 129 –134 . 10.1016/j.jsbmb.2009.01.002 19429442 
Berstein L. Zimarina T. Imyanitov E. Kovalevskij A. Maximov S. Pujol P.  . (2006 ). Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes . Maturitas 
54 , 352 –355 . 10.1016/j.maturitas.2006.04.017 16730930 
Beyenburg S. Stoffel-Wagner B. Watzka M. Blumcke I. Bauer J. Schramm J.  . (1999 ). Expression of cytochrome P450scc mRNA in the hippocampus of patients with temporal lobe epilepsy . Neuroreport 
10 , 3067 –3070 . 10.1097/00001756-199909290-00035 10549824 
Beyenburg S. Watzka M. Blumcke I. Schramm J. Bidlingmaier F. Elger C. E.  . (2000 ). Expression of mRNAs encoding for 17β-hydroxisteroid dehydrogenase isozymes 1, 2, 3 and 4 in epileptic human hippocampus . Epilepsy Res. 
41 , 83 –91 . 10.1016/S0920-1211(00)00130-3 10924871 
Bicikova M. Hill M. Ripova D. Mohr P. Hampl R.   (2013 ). Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia . J. Steroid Biochem. Mol. Biol. 
133 , 77 –83 . 10.1016/j.jsbmb.2012.08.009 22944140 
Bilezikian J. P. Morishima A. Bell J. Grumbach M. M.   (1998 ). Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency . N. Engl. J. Med. 
339 , 599 –603 . 10.1056/NEJM199808273390905 9718379 
Blake J. A. Eppig J. T. Kadin J. A. Richardson J. E. Smith C. L. Bult C. J.  . (2017 ). Mouse Genome Database (MGD)-2017: community knowledge resource for the laboratory mouse . Nucleic Acids Res. 
45 , D723 –D729 . 10.1093/nar/gkw1040 27899570 
Blouin K. Nadeau M. Mailloux J. Daris M. Lebel S. Luu-The V.  . (2009 ). Pathways of adipose tissue androgen metabolism in women: depot differences and modulation by adipogenesis . Am. J. Physiol. Endocrinol. Metab. 
296 , E244 –E255 . 10.1152/ajpendo.00039.2008 18984855 
Bothe U. Busemann M. Steinmeyer A. Droescher P. Fischer O. M. Peters M.   (2017 ). First time disclosure of BAY 1128688: a novel AKR1C3 inhibitor for the treatment of endometriosis,  in 254th ACS National Meeting & Exposition  (Washington, DC ).
Boucher E. Provost P. R. Plante J. Tremblay Y.   (2009 ). Androgen receptor and 17β-HSD type 2 regulation in neonatal mouse lung development . Mol. Cell. Endocrinol. 
311 , 109 –119 . 10.1016/j.mce.2009.06.012 19576262 
Bovée J. V. Cleton-Jansen A. M. Taminiau A. H. Hogendoorn P. C.   (2005 ). Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment . Lancet Oncol. 
6 , 599 –607 . 10.1016/S1470-2045(05)70282-5 16054571 
Brereton P. Suzuki T. Sasano H. Li K. Duarte C. Obeyesekere V.  . (2001 ). Pan1b (17βHSD11)-enzymatic activity and distribution in the lung . Mol. Cell. Endocrinol. 
171 , 111 –117 . 10.1016/S0303-7207(00)00417-2 11165019 
Brosens J. Verhoeven H. Campo R. Gianaroli L. Gordts S. Hazekamp J.  . (2004 ). High endometrial aromatase P450 mRNA expression is associated with poor IVF outcome . Hum. Reprod. 
19 , 352 –356 . 10.1093/humrep/deh075 14747179 
BroŽic P. Turk S. Rizner T. L. Gobec S.   (2011 ). Inhibitors of aldo-keto reductases AKR1C1-AKR1C4 . Curr. Med. Chem. 
18 , 2554 –2565 . 10.2174/092986711795933713 21568892 
Bukulmez O. Hardy D. B. Carr B. R. Auchus R. J. Toloubeydokhti T. Word R. A.  . (2008a ). Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis . J. Clin. Endocrinol. Metab. 
93 , 3471 –3477 . 10.1210/jc.2008-0248 18559914 
Bukulmez O. Hardy D. B. Carr B. R. Word R. A. Mendelson C. R.   (2008b ). Inflammatory status influences aromatase and steroid receptor expression in endometriosis . Endocrinology 
149 , 1190 –1204 . 10.1210/en.2007-0665 18048499 
Bulun S. E. Economos K. Miller D. Simpson E. R.   (1994 ). CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors . J. Clin. Endocrinol. Metab. 
79 , 1831 –1834 .7989490 
Bulun S. E. Mahendroo M. S. Simpson E. R.   (1993 ). Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua . J. Clin. Endocrinol. Metab. 
76 , 1458 –1463 .7684741 
Caiazza F. Ryan E. J. Doherty G. Winter D. C. Sheahan K.   (2015 ). Estrogen receptors and their implications in colorectal carcinogenesis . Front. Oncol. 
5 :19 . 10.3389/fonc.2015.00019 25699240 
Calippe B. Douin-Echinard V. Delpy L. Laffargue M. Lelu K. Krust A.  . (2010 ). 17β-estradiol promotes TLR4-triggered proinflammatory mediator production through direct estrogen receptor alpha signaling in macrophages in vivo . J. Immunol. 
185 , 1169 –1176 . 10.4049/jimmunol.0902383 20554954 
Carani C. Qin K. Simoni M. Faustini-Fustini M. Serpente S. Boyd J.  . (1997 ). Effect of testosterone and estradiol in a man with aromatase deficiency . N. Engl. J. Med. 
337 , 91 –95 . 10.1056/NEJM199707103370204 9211678 
Carey M. A. Card J. W. Voltz J. W. Arbes S. J. Jr.Germolec D. R. Korach K. S.  . (2007 ). It's all about sex: gender, lung development and lung disease . Trends Endocrinol. Metab. 
18 , 308 –313 . 10.1016/j.tem.2007.08.003 17764971 
Carneiro M. M. Morsch D. M. Camargos A. F. Reis F. M. Spritzer P. M.   (2008 ). Androgen receptor and 5α-reductase are expressed in pelvic endometriosis . BJOG 
115 , 113 –117 . 10.1111/j.1471-0528.2007.01521.x 17983420 
Carneiro M. M. Morsch D. M. Camargos A. F. Spritzer P. M. Reis F. M.   (2007 ). Expression of 17β-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis . Gynecol. Endocrinol. 
23 , 188 –192 . 10.1080/09513590701200850 17505937 
Caron K. M. Soo S. C. Wetsel W. C. Stocco D. M. Clark B. J. Parker K. L.   (1997 ). Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia . Proc. Natl. Acad. Sci. U.S.A. 
94 , 11540 –11545 . 10.1073/pnas.94.21.11540 9326645 
Casey M. L. MacDonald P. C. Andersson S.   (1994 ). 17 beta-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium . J. Clin. Invest. 
94 , 2135 –2141 . 10.1172/JCI117569 7962560 
Chai Z. Brereton P. Suzuki T. Sasano H. Obeyesekere V. Escher G.   (2003 ). 17β-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells . Endocrinology 
144 , 2084 –2091 . 10.1210/en.2002-221030 12697717 
Chang T. S. Lin H. K. Rogers K. A. Brame L. S. Yeh M. M. Yang Q.  . (2013 ). Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung . Int. J. Clin. Exp. Pathol. 
6 , 2419 –2429 .24228104 
Chen F. Knecht K. Leu C. Rutledge S. J. Scafonas A. Gambone C.  . (2004 ). Partial agonist/antagonist properties of androstenedione and 4-androsten-3β,17β-diol . J. Steroid Biochem. Mol. Biol. 
91 , 247 –257 . 10.1016/j.jsbmb.2004.04.009 15336702 
Chen G. Zhang D. Jing N. Yin S. Falany C. N. Radominska-Pandya A.   (2003 ). Human gastrointestinal sulfotransferases: identification and distribution . Toxicol. Appl. Pharmacol. 
187 , 186 –197 . 10.1016/S0041-008X(02)00073-X 12662902 
Cho L. Y. Yang J. J. Ko K. P. Ma S. H. Shin A. Choi B. Y.  . (2012 ). Genetic susceptibility factors on genes involved in the steroid hormone biosynthesis pathway and progesterone receptor for gastric cancer risk . PLoS ONE 
7 :e47603 . 10.1371/journal.pone.0047603 23110082 
Ciuffi M. Savino L. Santini D. Buzzoni P. Scarselli G. Mazzei T.   (1982 ). Estradiol and progestin receptors, 17-beta-hydroxysteroid-dehydrogenase and histopathologic grade in endometrial carcinoma . Tumori 
68 , 217 –221 . 10.1177/030089168206800305 6958113 
Cleton-Jansen A. M. van Beerendonk H. M. Baelde H. J. Bovee J. V. Karperien M. Hogendoorn P. C.   (2005 ). Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma . Clin. Cancer Res. 
11 , 8028 –8035 . 10.1158/1078-0432.CCR-05-1253 16299232 
Colette S. Defrere S. Lousse J. C. Van Langendonckt A. Gotteland J. P. Loumaye E.  . (2011 ). Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model . Hum. Reprod. 
26 , 1362 –1370 . 10.1093/humrep/der079 21441545 
Colette S. Defrere S. Van Kerk O. Van Langendonckt A. Dolmans M. M. Donnez J.   (2013 ). Differential expression of steroidogenic enzymes according to endometriosis type . Fertil. Steril. 
100 , 1642 –1649 . 10.1016/j.fertnstert.2013.08.003 24012197 
Colette S. Lousse J. C. Defrere S. Curaba M. Heilier J. F. Van Langendonckt A.  . (2009 ). Absence of aromatase protein and mRNA expression in endometriosis . Hum. Reprod. 
24 , 2133 –2141 . 10.1093/humrep/dep199 19493871 
Compston J. E.   (2001 ). Sex steroids and bone . Physiol. Rev. 
81 , 419 –447 . 10.1152/physrev.2001.81.1.419 11152762 
Corbould A. M. Bawden M. J. Lavranos T. C. Rodgers R. J. Judd S. J.   (2002 ). The effect of obesity on the ratio of type 3, 17β-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women . Int. J. Obes. Relat. Metab. Disord. 
26 , 165 –175 . 10.1038/sj.ijo.0801886 11850747 
Cornel K. M. Krakstad C. Delvoux B. Xanthoulea S. Jori B. Bongers M. Y.  . (2017 ). High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer . Mol. Cell. Endocrinol. 
442 , 51 –57 . 10.1016/j.mce.2016.11.030 27923582 
Cornel K. M. Kruitwagen R. F. Delvoux B. Visconti L. Van de Vijver K. K. Day J. M.  . (2012 ). Overexpression of 17β-Hydroxysteroid Dehydrogenase Type 1 Increases the exposure of endometrial cancer to 17β-Estradiol . J. Clin. Endocrinol. Metab. 
97 , E591 –E601 . 10.1210/jc.2011-2994 22362820 
Cornel K. M. C. Bongers M. Y. Kruitwagen R. P. F. M. Romano A.   (2018 ). Local estrogen metabolism (intracrinology) in endometrial cancer: a systematic review . Mol. Cell. Endocrinol . Accepted for publication.
Couse J. F. Korach K. S.   (1999 ). Estrogen receptor null mice: what have we learned and where will they lead us? 
Endocr. Rev. 
20 , 358 –417 .10368776 
Couse J. F. Lindzey J. Grandien K. Gustafsson J. A. Korach K. S.   (1997 ). Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse . Endocrinology 
138 , 4613 –4621 . 10.1210/endo.138.11.5496 9348186 
Couse J. F. Yates M. M. Walker V. R. Korach K. S.   (2003 ). Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERα but not ERβ . Mol. Endocrinol. 
17 , 1039 –1053 . 10.1210/me.2002-0398 12624116 
Dalla Valle L. Toffolo V. Nardi A. Fiore C. Armanini D. Belvedere P.  . (2007 ). The expression of the human steroid sulfatase-encoding gene is driven by alternative first exons . J. Steroid Biochem. Mol. Biol. 
107 , 22 –29 . 10.1016/j.jsbmb.2007.05.004 17601726 
Das A. Mantena S. R. Kannan A. Evans D. B. Bagchi M. K. Bagchi I. C.   (2009 ). De novo synthesis of estrogen in pregnant uterus is critical for stromal decidualization and angiogenesis . Proc. Natl. Acad. Sci. U.S.A. 
106 , 12542 –12547 . 10.1073/pnas.0901647106 19620711 
Dassen H. Punyadeera C. Kamps R. Delvoux B. Van Langendonckt A. Donnez J.  . (2007 ). Estrogen metabolizing enzymes in endometrium and endometriosis . Hum. Reprod. 
22 , 3148 –3158 . 10.1093/humrep/dem310 17921479 
Davies W. Humby T. Trent S. Eddy J. B. Ojarikre O. A. Wilkinson L. S.   (2014 ). Genetic and pharmacological modulation of the steroid sulfatase axis improves response control; comparison with drugs used in ADHD . Neuropsychopharmacology 
39 , 2622 –2632 . 10.1038/npp.2014.115 24842408 
Day J. M. Foster P. A. Tutill H. J. Schmidlin F. Sharland C. M. Hargrave J. D.  . (2013 ). STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model . Endocr. Relat. Cancer 
20 , 53 –64 . 10.1530/ERC-12-0231 23132791 
De Graaff A. A. D'Hooghe T. M. Dunselman G. A. Dirksen C. D. Hummelshoj L. Consortium W. E.  . (2013 ). The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey . Hum. Reprod. 
28 , 2677 –2685 . 10.1093/humrep/det284 23847114 
De Graaff A. A. Dirksen C. D. Simoens S. De Bie B. Hummelshoj L. D'Hooghe T. M.  . (2015 ). Quality of life outcomes in women with endometriosis are highly influenced by recruitment strategies . Hum. Reprod. 
30 , 1331 –1341 . 10.1093/humrep/dev084 25908657 
De Graaff A. A. Van Lankveld J. Smits L. J. Van Beek J. J. Dunselman G. A.   (2016 ). Dyspareunia and depressive symptoms are associated with impaired sexual functioning in women with endometriosis, whereas sexual functioning in their male partners is not affected . Hum. Reprod. 
31 , 2577 –2586 . 10.1093/humrep/dew215 27619771 
De Preter V. Arijs I. Windey K. Vanhove W. Vermeire S. Schuit F.  . (2012 ). Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway . Inflamm. Bowel Dis. 
18 , 1127 –1136 . 10.1002/ibd.21894 21987487 
Delvoux B. D'Hooghe T. Kyama C. Koskimies P. Hermans R. J. Dunselman G. A.  . (2014 ). Inhibition of type 1, 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions . J. Clin. Endocrinol. Metab. 
99 , 276 –284 . 10.1210/jc.2013-2851 24187399 
Delvoux B. Groothuis P. D'Hooghe T. Kyama C. Dunselman G. Romano A.   (2009 ). Increased production of 17β-estradiol in endometriosis lesions is the result of impaired metabolism . J. Clin. Endocrinol. Metab. 
94 , 876 –883 . 10.1210/jc.2008-2218 19088158 
Delvoux B. Husen B. Aldenhoff Y. Koole L. Dunselman G. Thole H.  . (2007 ). A sensitive HPLC method for the assessment of metabolic conversion of estrogens . J. Steroid Biochem. Mol. Biol. 
104 , 246 –251 . 10.1016/j.jsbmb.2007.03.006 17481886 
Deng H. Z. You C. Xing Y. Chen K. Y. Zou X. B.   (2016 ). A Family-Based Association Study of CYP11A1 and CYP11B1 Gene Polymorphisms With Autism in Chinese Trios . J. Child Neurol. 
31 , 733 –737 . 10.1177/0883073815620672 26690694 
Devroey P. Bourgain C. Macklon N. S. Fauser B. C.   (2004 ). Reproductive biology and IVF: ovarian stimulation and endometrial receptivity . Trends Endocrinol. Metab. 
15 , 84 –90 . 10.1016/j.tem.2004.01.009 15036255 
Dheenadayalu K. Mak I. Gordts S. Campo R. Higham J. Puttemans P.   (2002 ). Aromatase P450 messenger RNA expression in eutopic endometrium is not a specific marker for pelvic endometriosis . Fertil. Steril. 
78 , 825 –829 . 10.1016/S0015-0282(02)03324-1 12372463 
Di Costanzo L. Penning T. M. Christianson D. W.   (2009 ). Aldo-keto reductases in which the conserved catalytic histidine is substituted . Chem. Biol. Interact. 
178 , 127 –133 . 10.1016/j.cbi.2008.10.046 19028475 
Dias N. J. Selcer K. W.   (2014 ). Steroid sulfatase mediated growth Sof human MG-63 pre-osteoblastic cells . Steroids 
88 , 77 –82 . 10.1016/j.steroids.2014.07.001 25042472 
Dias N. J. Selcer K. W.   (2016 ). Steroid sulfatase in the human MG-63 preosteoblastic cell line: Antagonistic regulation by glucocorticoids and NFkappaB . Mol. Cell. Endocrinol. 
420 , 85 –96 . 10.1016/j.mce.2015.11.029 26631368 
Dickinson M. E. Flenniken A. M. Ji X. Teboul L. Wong M. D. White J. K.  . (2016 ). High-throughput discovery of novel developmental phenotypes . Nature 
537 , 508 –514 . 10.1038/nature19356 27626380 
Doherty J. A. Weiss N. S. Freeman R. J. Dightman D. A. Thornton P. J. Houck J. R.  . (2005 ). Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer . Cancer Epidemiol. Biomarkers Prev. 
14 , 357 –366 . 10.1158/1055-9965.EPI-04-0479 15734958 
Dohi O. Hatori M. Suzuki T. Ono K. Hosaka M. Akahira J.  . (2008 ). Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma . Cancer Sci. 
99 , 518 –523 . 10.1111/j.1349-7006.2007.00673.x 18081879 
Dong Y. Qiu Q. Q. Debear J. Lathrop W. F. Bertolini D. R. Tamburini P. P.   (1998 ). 17β-hydroxysteroid dehydrogenases in human bone cells . J. Bone Miner. Res. 
13 , 1539 –1546 . 10.1359/jbmr.1998.13.10.1539 9783542 
Driessen C. A. Winkens H. J. Hoffmann K. Kuhlmann L. D. Janssen B. P. Van Vugt A. H.  . (2000 ). Disruption of the 11-cis-retinol dehydrogenase gene leads to accumulation of cis-retinols and cis-retinyl esters . Mol. Cell. Biol. 
20 , 4275 –4287 . 10.1128/MCB.20.12.4275-4287.2000 10825191 
Drzewiecka H. Galecki B. Jarmolowska-Jurczyszyn D. Kluk A. Dyszkiewicz W. Jagodzinski P. P.   (2015 ). Increased expression of 17-beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer . Lung Cancer 
87 , 107 –116 . 10.1016/j.lungcan.2014.12.012 25564397 
Drzewiecka H. Jagodzinski P. P.   (2012 ). Conversion of estrone to 17-beta-estradiol in human non-small-cell lung cancer cells in vitro . Biomed. Pharmacother. 
66 , 530 –534 . 10.1016/j.biopha.2012.02.006 22705334 
Duell E. J. Travier N. Lujan-Barroso L. Boutron-Ruault M. C. Clavel-Chapelon F. Palli D.  . (2010 ). Menstrual and reproductive factors, exogenous hormone use, and gastric cancer risk in a cohort of women from the European Prospective Investigation Into Cancer and Nutrition . Am. J. Epidemiol. 
172 , 1384 –1393 . 10.1093/aje/kwq321 21051447 
Dunselman G. A. Vermeulen N. Becker C. Calhaz-Jorge C. D'Hooghe T. De Bie B.  . (2014 ). ESHRE guideline: management of women with endometriosis . Hum. Reprod. 
29 , 400 –412 . 10.1093/humrep/det457 24435778 
Ellem S. J. Wang H. Poutanen M. Risbridger G. P.   (2009 ). Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy . Am. J. Pathol. 
175 , 1187 –1199 . 10.2353/ajpath.2009.081107 19700748 
Endo S. Miyagi N. Matsunaga T. Hara A. Ikari A.   (2016 ). Human dehydrogenase/reductase (SDR family) member 11 is a novel type of 17β-hydroxysteroid dehydrogenase . Biochem. Biophys. Res. Commun. 
472 , 231 –236 . 10.1016/j.bbrc.2016.01.190 26920053 
English M. A. Hughes S. V. Kane K. F. Langman M. J. Stewart P. M. Hewison M.   (2000 ). Oestrogen inactivation in the colon: analysis of the expression and regulation of 17β-hydroxysteroid dehydrogenase isozymes in normal colon and colonic cancer . Br. J. Cancer 
83 , 550 –558 . 10.1054/bjoc.2000.1324 10945506 
English M. A. Kane K. F. Cruickshank N. Langman M. J. Stewart P. M. Hewison M.   (1999 ). Loss of estrogen inactivation in colonic cancer . J. Clin. Endocrinol. Metab. 
84 , 2080 –2085 . 10.1210/jcem.84.6.5772 10372714 
Enríquez J. Larrea F. Santillan R. Hernandez A. Herrero B. Perez-Palacios G.  . (2013 ). Neonatal rat osteoblasts bioconvert testosterone to non-phenolic metabolites with estrogen-like effects on bone cell proliferation and differentiation . Horm. Mol. Biol. Clin. Investig. 
13 , 41 –49 . 10.1515/hmbci-2012-0035 25436712 
Falk R. T. Dallal C. M. Lacey J. V. Jr.Bauer D. C. Buist D. S. Cauley J. A.   (2015 ). Estrogen metabolites are not associated with colorectal cancer risk in postmenopausal women . Cancer Epidemiol. Biomarkers Prev. 
24 , 1419 –1422 . 10.1158/1055-9965.EPI-15-0541 26104910 
Ferrero S. Gillott D. J. Venturini P. L. Remorgida V.   (2011 ). Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review . Reprod. Biol. Endocrinol. 
9 , 89 . 10.1186/1477-7827-9-89 21693038 
Fisher C. R. Graves K. H. Parlow A. F. Simpson E. R.   (1998 ). Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene . Proc. Natl. Acad. Sci. U.S.A. 
95 , 6965 –6970 . 10.1073/pnas.95.12.6965 9618522 
Flach K. D. Zwart W.   (2016 ). The first decade of estrogen receptor cistromics in breast cancer . J. Endocrinol. 
229 
R43 –56 . 10.1530/JOE-16-0003 26906743 
Fontein D. B. Houtsma D. Nortier J. W. Baak-Pablo R. F. Kranenbarg E. M. van der Straaten T. R.  . (2014 ). Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial . Breast Cancer Res. Treat. 
144 , 599 –606 . 10.1007/s10549-014-2873-2 24590773 
Foster P. A.   (2013 ). Oestrogen and colorectal cancer: mechanisms and controversies . Int. J. Colorectal Dis. 
28 , 737 –749 . 10.1007/s00384-012-1628-y 23319136 
Foster P. A. Reed M. J. Purohit A.   (2008a ). Recent developments of steroid sulfatase inhibitors as anti-cancer agents . Anticancer. Agents Med. Chem. 
8 , 732 –738 . 10.2174/187152008785914815 18855575 
Foster P. A. Woo L. W. Potter B. V. Reed M. J. Purohit A.   (2008b ). The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer . Endocrinology 
149 , 4035 –4042 . 10.1210/en.2008-0223 18450955 
Fouad Mansour M. Pelletier M. Boulet M. M. Mayrand D. Brochu G. Lebel S.  . (2015 ). Oxidative activity of 17β-hydroxysteroid dehydrogenase on testosterone in male abdominal adipose tissues and cellular localization of 17β-HSD type 2 . Mol. Cell. Endocrinol. 
414 , 168 –176 . 10.1016/j.mce.2015.06.016 26123590 
Freedman N. D. Ahn J. Hou L. Lissowska J. Zatonski W. Yeager M.  . (2009 ). Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer . Carcinogenesis 
30 , 71 –77 . 10.1093/carcin/bgn258 19015200 
Freedman N. D. Chow W. H. Gao Y. T. Shu X. O. Ji B. T. Yang G.  . (2007 ). Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women . Gut 
56 , 1671 –1677 . 10.1136/gut.2007.129411 17627962 
Fritsch M. Orfanos C. E. Zouboulis C. C.   (2001 ). Sebocytes are the key regulators of androgen homeostasis in human skin . J. Invest. Dermatol. 
116 , 793 –800 . 10.1046/j.1523-1747.2001.01312.x 11348472 
Frycz B. A. Murawa D. Borejsza-Wysocki M. Marciniak R. Murawa P. Drews M.  . (2015 ). Expression of 17β-hydroxysteroid dehydrogenase type 2 is associated with some clinicopathological features in gastric cancer . Biomed. Pharmacother. 
70 , 24 –27 . 10.1016/j.biopha.2014.12.042 25776474 
Frycz B. A. Murawa D. Borejsza-Wysocki M. Wichtowski M. Spychala A. Marciniak R.  . (2016 ). Transcript level of AKR1C3 is down-regulated in gastric cancer . Biochem. Cell Biol. 
94 , 138 –146 . 10.1139/bcb-2015-0096 27019068 
Fujikawa H. Okura F. Kuwano Y. Sekizawa A. Chiba H. Shimodaira K.  . (1997 ). Steroid sulfatase activity in osteoblast cells . Biochem. Biophys. Res. Commun. 
231 , 42 –47 . 10.1006/bbrc.1996.6038 9070216 
Gangloff A. Shi R. Nahoum V. Lin S. X.   (2003 ). Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17β-hydroxysteroid dehydrogenase . FASEB J. 
17 , 274 –276 . 10.1096/fj.02-0397fje 12490543 
Gao J. He J. Shi X. Stefanovic-Racic M. Xu M. O'Doherty R. M.  . (2012 ). Sex-specific effect of estrogen sulfotransferase on mouse models of type 2 diabetes . Diabetes 
61 , 1543 –1551 . 10.2337/db11-1152 22438574 
Gargano E. M. Allegretta G. Perspicace E. Carotti A. Van Koppen C. Frotscher M.  . (2015 ). 17β-Hydroxysteroid dehydrogenase Type 2 inhibition: discovery of selective and metabolically stable compounds inhibiting both the human enzyme and its murine ortholog . PLoS ONE 
10 :e0134754 . 10.1371/journal.pone.0134754 26230928 
Ghosh D. Dhara S. Kumar A. Sengupta J.   (1999 ). Immunohistochemical localization of receptors for progesterone and oestradiol-17 beta in the implantation site of the rhesus monkey . Hum. Reprod. 
14 , 505 –514 . 10.1093/humrep/14.2.505 10100002 
Gibbs T. T. Russek S. J. Farb D. H.   (2006 ). Sulfated steroids as endogenous neuromodulators . Pharmacol. Biochem. Behav. 
84 , 555 –567 . 10.1016/j.pbb.2006.07.031 17023038 
Gibson D. A. McInnes K. J. Critchley H. O. Saunders P. T.   (2013 ). Endometrial Intracrinology–generation of an estrogen-dominated microenvironment in the secretory phase of women . J. Clin. Endocrinol. Metab. 
98 , E1802 –E1806 . 10.1210/jc.2013-2140 24014622 
Gilligan L. C. Gondal A. Tang V. Hussain M. T. Arvaniti A. Hewitt A. M.  . (2017 ). Estrone sulfate transport and steroid sulfatase activity in colorectal cancer: implications for hormone replacement therapy . Front. Pharmacol. 
8 :103 . 10.3389/fphar.2017.00103 28326039 
González-Arenas A. Agramonte-Hevia J.   (2012 ). Sex steroid hormone effects in normal and pathologic conditions in lung physiology . Mini Rev. Med. Chem. 
12 , 1055 –1062 . 10.2174/138955712802762194 22827216 
Goodarzi M. O. Antoine H. J. Azziz R.   (2007 ). Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome . J. Clin. Endocrinol. Metab. 
92 , 2659 –2664 . 10.1210/jc.2006-2600 17426092 
Goodarzi M. O. Shah N. A. Antoine H. J. Pall M. Guo X. Azziz R.   (2006 ). Variants in the 5α-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women . J. Clin. Endocrinol. Metab. 
91 , 4085 –4091 . 10.1210/jc.2006-0227 16849416 
Groothuis P. G. Dassen H. H. Romano A. Punyadeera C.   (2007 ). Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human . Hum. Reprod. Update 
13 , 405 –417 . 10.1093/humupd/dmm009 17584823 
Gruber C. J. Tschugguel W. Schneeberger C. Huber J. C.   (2002 ). Production and actions of estrogens . N. Engl. J. Med. 
346 , 340 –352 . 10.1056/NEJMra000471 11821512 
Guillot F. Garcia A. Salou M. Brouard S. Laplaud D. A. Nicot A. B.   (2015 ). Transcript analysis of laser capture microdissected white matter astrocytes and higher phenol sulfotransferase 1A1 expression during autoimmune neuroinflammation . J. Neuroinflammation 
12 , 130 . 10.1186/s12974-015-0348-y 26141738 
Gulyaeva L. F. Mikhailova O. N. PustyInyak V. O. Kim I. V. IV.Gerasimov A. V. Krasilnikov S. E.  . (2008 ). Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia . Adv. Exp. Med. Biol. 
617 , 359 –366 . 10.1007/978-0-387-69080-3_34 18497059 
Gylfe A. E. Katainen R. Kondelin J. Tanskanen T. Cajuso T. Hanninen U.  . (2013 ). Eleven candidate susceptibility genes for common familial colorectal cancer . PLoS Genet. 
9 :e1003876 . 10.1371/journal.pgen.1003876 24146633 
Hakkarainen J. Jokela H. Pakarinen P. Heikela H. Katkanaho L. Vandenput L.  . (2015 ). Hydroxysteroid (17β)-dehydrogenase 1-deficient female mice present with normal puberty onset but are severely subfertile due to a defect in luteinization and progesterone production . FASEB J. 
29 , 3806 –3816 . 10.1096/fj.14-269035 26018678 
He D. Frost A. R. Falany C. N.   (2005a ). Identification and immunohistochemical localization of Sulfotransferase 2B1b (SULT2B1b) in human lung . Biochim Biophys Act. 
1724 , 119 –126 . 10.1016/j.bbagen.2005.03.018 15878639 
He D. Meloche C. A. Dumas N. A. Frost A. R. Falany C. N.   (2004 ). Different subcellular localization of sulphotransferase 2B1b in human placenta and prostate . Biochem. J. 
379 , 533 –540 . 10.1042/bj20031524 14741047 
He W. Gauri M. Li T. Wang R. Lin S. X.   (2016 ). Current knowledge of the multifunctional 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) . Gene 
588 , 54 –61 . 10.1016/j.gene.2016.04.031 27102893 
He X. Y. Wegiel J. Yang Y. Z. Pullarkat R. Schulz H. Yang S. Y.   (2005b ). Type 10, 17β-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of gamma-aminobutyric acid type A receptors . Mol. Cell. Endocrinol. 
229 , 111 –117 . 10.1016/j.mce.2004.08.011 15607535 
He X. Y. Yang S. Y.   (2006 ). Roles of type 10, 17β-hydroxysteroid dehydrogenase in intracrinology and metabolism of isoleucine and fatty acids . Endocr. Metab. Immune Disord. Drug Targets 
6 , 95 –102 . 10.2174/187153006776056639 16611167 
Heijmans J. Wielenga M. C. Rosekrans S. L. van Lidth de Jeude J. F. Roelofs J. Groothuis P.  . (2014 ). Oestrogens promote tumorigenesis in a mouse model for colitis-associated cancer . Gut 
63 , 310 –316 . 10.1136/gutjnl-2012-304216 23408349 
Her C. Szumlanski C. Aksoy I. A. Weinshilboum R. M.   (1996 ). Human jejunal estrogen sulfotransferase and dehydroepiandrosterone sulfotransferase: immunochemical characterization of individual variation . Drug Metab. Dispos. 
24 , 1328 –1335 .8971138 
Hevir N. Ribic-Pucelj M. Lanisnik Rizner T.   (2013 ). Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: a source of excessive hydroxy-estrogens and ROS? 
Mol. Cell. Endocrinol. 
367 , 74 –84 . 10.1016/j.mce.2012.12.019 23277161 
Hevir N. Sinkovec J. Rizner T. L.   (2011a ). Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT . Mol. Cell. Endocrinol. 
331 , 158 –167 . 10.1016/j.mce.2010.09.011 20887769 
Hevir N. Vouk K. Sinkovec J. Ribic-Pucelj M. Rizner T. L.   (2011b ). Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis . Chem. Biol. Interact. 
191 , 217 –226 . 10.1016/j.cbi.2011.01.003 21232532 
Hewitt S. C. Winuthayanon W. Korach K. S.   (2016 ). What's new in estrogen receptor action in the female reproductive tract . J. Mol. Endocrinol. 
56 
R55 –71 . 10.1530/JME-15-0254 26826253 
Hilborn E. Stal O. Jansson A.   (2017 ). Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer . Oncotarget 
8 , 30552 –30562 . 10.18632/oncotarget.15547 28430630 
Hogan A. M. Collins D. Baird A. W. Winter D. C.   (2009 ). Estrogen and gastrointestinal malignancy . Mol. Cell. Endocrinol. 
307 , 19 –24 . 10.1016/j.mce.2009.03.016 19524122 
Honda S. Harada N. Ito S. Takagi Y. Maeda S.   (1998 ). Disruption of sexual behavior in male aromatase-deficient mice lacking exons 1 and 2 of the cyp19 gene . Biochem. Biophys. Res. Commun. 
252 , 445 –449 . 10.1006/bbrc.1998.9672 9826549 
Hovorkova P. Kristofikova Z. Horinek A. Ripova D. Majer E. Zach P.  . (2008 ). Lateralization of 17β-hydroxysteroid dehydrogenase type 10 in hippocampi of demented and psychotic people . Dement. Geriatr. Cogn. Disord. 
26 , 193 –198 . 10.1159/000151778 18765932 
Hu M. C. Hsu N. C. El Hadj N. B. Pai C. I. Chu H. P. Wang C. K.  . (2002 ). Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1 . Mol. Endocrinol. 
16 , 1943 –1950 . 10.1210/me.2002-0055 12145347 
Huang C. C. Shih M. C. Hsu N. C. Chien Y. Chung B. C.   (2012 ). Fetal glucocorticoid synthesis is required for development of fetal adrenal medulla and hypothalamus feedback suppression . Endocrinology 
153 , 4749 –4756 . 10.1210/en.2012-1258 22962254 
Huang X. F. Luu-The V.   (2000 ). Molecular characterization of a first human 3(α->β)-hydroxysteroid epimerase . J. Biol. Chem. 
275 , 29452 –29457 . 10.1074/jbc.M000562200 10896656 
Huber A. Keck C. C. Hefler L. A. Schneeberger C. Huber J. C. Bentz E. K.  . (2005 ). Ten estrogen-related polymorphisms and endometriosis: a study of multiple gene-gene interactions . Obstet. Gynecol. 
106 , 1025 –1031 . 10.1097/01.AOG.0000185259.01648.41 16260521 
Hudelist G. Czerwenka K. Keckstein J. Haas C. Fink-Retter A. Gschwantler-Kaulich D.  . (2007 ). Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: evidence for unbalanced estradiol production in endometriosis . Reprod. Sci. 
14 , 798 –805 . 10.1177/1933719107309120 18089598 
Hughes S. V. Robinson E. Bland R. Lewis H. M. Stewart P. M. Hewison M.   (1997 ). 1,25-dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes . Endocrinology 
138 , 3711 –3718 . 10.1210/endo.138.9.5406 9275056 
Huhtinen K. Desai R. Stahle M. Salminen A. Handelsman D. J. Perheentupa A.  . (2012a ). Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels . J. Clin. Endocrinol. Metab. 
97 , 4228 –4235 . 10.1210/jc.2012-1154 22969138 
Huhtinen K. Saloniemi-Heinonen T. Keski-Rahkonen P. Desai R. Laajala D. Stahle M.  . (2014 ). Intra-tissue steroid profiling indicates differential progesterone and testosterone metabolism in the endometrium and endometriosis lesions . J. Clin. Endocrinol. Metab. 
99 
E2188 –2197 . 10.1210/jc.2014-1913 25137424 
Huhtinen K. Stahle M. Perheentupa A. Poutanen M.   (2012b ). Estrogen biosynthesis and signaling in endometriosis . Mol. Cell. Endocrinol. 
358 , 146 –154 . 10.1016/j.mce.2011.08.022 21875644 
Husen B. Huhtinen K. Poutanen M. Kangas L. Messinger J. Thole H.   (2006 ). Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme . Mol. Cell. Endocrinol. 
248 , 109 –113 . 10.1016/j.mce.2005.11.042 16406284 
Ihlenfeldt W. D. Bolton E. E. Bryant S. H.   (2009 ). The PubChem chemical structure sketcher . J. Cheminform. 
1 :20 . 10.1186/1758-2946-1-20 20298522 
Iida S. Kakinuma H. Miki Y. Abe K. Sakurai M. Suzuki S.  . (2013 ). Steroid sulphatase and oestrogen sulphotransferase in human non-small-cell lung carcinoma . Br. J. Cancer 
108 , 1415 –1424 . 10.1038/bjc.2013.84 23531699 
Ikeda K. Shiraishi K. Yoshida A. Shinchi Y. Sanada M. Motooka Y.  . (2016 ). Synchronous multiple lung adenocarcinomas: estrogen concentration in peripheral lung . PLoS ONE 
11 :e0160910 . 10.1371/journal.pone.0160910 27526096 
Iqbal M. J. Greenway B. Wilkinson M. L. Johnson P. J. Williams R.   (1983 ). Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue . Clin. Sci. 
65 , 71 –75 . 10.1042/cs0650071 6851420 
Ishida M. Choi J. H. Hirabayashi K. Matsuwaki T. Suzuki M. Yamanouchi K.  . (2007 ). Reproductive phenotypes in mice with targeted disruption of the 20α-hydroxysteroid dehydrogenase gene . J. Reprod. Dev. 
53 , 499 –508 . 10.1262/jrd.18125 17272929 
Ito K. Miki Y. Suzuki T. McNamara K. M. Sasano H.   (2016 ). In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production . Endocr. Relat. Cancer 
23 
R323 –335 . 10.1530/ERC-15-0470 27287451 
Ito K. Suzuki T. Akahira J. Moriya T. Kaneko C. Utsunomiya H.  . (2002 ). Expression of androgen receptor and 5α-reductases in the human normal endometrium and its disorders . Int. J. Cancer 
99 , 652 –657 . 10.1002/ijc.10394 12115497 
Ito K. Utsunomiya H. Suzuki T. Saitou S. Akahira J. Okamura K.  . (2006 ). 17β-hydroxysteroid dehydrogenases in human endometrium and its disorders . Mol. Cell. Endocrinol. 
248 , 136 –140 . 10.1016/j.mce.2005.11.038 16406263 
Iwasa A. Arakaki R. Honma N. Ushio A. Yamada A. Kondo T.  . (2015 ). Aromatase controls Sjogren syndrome-like lesions through monocyte chemotactic protein-1 in target organ and adipose tissue-associated macrophages . Am. J. Pathol. 
185 , 151 –161 . 10.1016/j.ajpath.2014.09.006 25447050 
Jakob F. Siggelkow H. Homann D. Kohrle J. Adamski J. Schutze N.   (1997 ). Local estradiol metabolism in osteoblast- and osteoclast-like cells . J. Steroid Biochem. Mol. Biol. 
61 , 167 –174 . 10.1016/S0960-0760(97)80009-X 9365187 
Janssen J. M. Bland R. Hewison M. Coughtrie M. W. Sharp S. Arts J.  . (1999 ). Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function . J. Cell. Biochem. 
75 , 528 –537 . 10.1002/(SICI)1097-4644(19991201)75:3<528::AID-JCB16>3.0.CO;2-3 10536374 
Jäntti S. E. Tammimaki A. Raattamaa H. Piepponen P. Kostiainen R. Ketola R. A.   (2010 ). Determination of steroids and their intact glucuronide conjugates in mouse brain by capillary liquid chromatography-tandem mass spectrometry . Anal. Chem. 
82 , 3168 –3175 . 10.1021/ac902321z 20345173 
Järvensivu P. Heinosalo T. Hakkarainen J. Kronqvist P. Saarinen N. Poutanen M.   (2018 ). HSD17B1 expression induces inflammation-aided rupture of mammary gland myoepithelium . Endocr. Relat. Cancer 
25 , 393 –406 . 10.1530/ERC-17-0476 29371331 
Järvensivu P. Saloniemi-Heinonen T. Awosanya M. Koskimies P. Saarinen N. Poutanen M.   (2015 ). HSD17B1 expression enhances estrogen signaling stimulated by the low active estrone, evidenced by an estrogen responsive element-driven reporter gene in vivo . Chem. Biol. Interact. 
234 , 126 –134 . 10.1016/j.cbi.2015.01.008 25617485 
Jeon Y. T. Park S. Y. Kim Y. B. Kim J. W. Park N. H. Kang S. B.   (2007 ). Aromatase expression was not detected by immunohistochemistry in endometrial cancer . Ann. N. Y. Acad. Sci. 
1095 , 70 –75 . 10.1196/annals.1397.010 17404019 
Jin Y. Mesaros A. C. Blair I. A. Penning T. M.   (2011 ). Stereospecific reduction of 5β-reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1-AKR1C4 in the metabolism of testosterone and progesterone via the 5β-reductase pathway . Biochem. J. 
437 , 53 –61 . 10.1042/BJ20101804 21521174 
Jokela H. Rantakari P. Lamminen T. Strauss L. Ola R. Mutka A. L.  . (2010 ). Hydroxysteroid (17β) dehydrogenase 7 activity is essential for fetal de novo cholesterol synthesis and for neuroectodermal survival and cardiovascular differentiation in early mouse embryos . Endocrinology 
151 , 1884 –1892 . 10.1210/en.2009-0928 20185768 
Jones A. L. Hume R. Bamforth K. J. Coughtrie M. W.   (1992 ). Estrogen and phenol sulfotransferase activities in human fetal lung . Early Hum. Dev. 
28 , 65 –77 . 10.1016/0378-3782(92)90007-4 1582375 
Jones M. R. Mathur R. Cui J. Guo X. Azziz R. Goodarzi M. O.   (2009 ). Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6, 17β-hydroxysteroid dehydrogenase gene . J. Clin. Endocrinol. Metab. 
94 , 5034 –5038 . 10.1210/jc.2009-0931 19837928 
Jongen V. H. Thijssen J. H. Hollema H. Donker G. H. Santema J. G. Van der Zee A. G.  . (2005 ). Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer? 
Int. J. Gynecol. Cancer 
15 , 529 –536 . 10.1111/j.1525-1438.2005.15320.x 15882181 
Kancheva L. Hill M. Vcelakova H. Vrbikova J. Pelikanova T. Starka L.   (2007 ). The identification and simultaneous quantification of neuroactive androstane steroids and their polar conjugates in the serum of adult men, using gas chromatography-mass spectrometry . Steroids 
72 , 792 –801 . 10.1016/j.steroids.2007.06.006 17716701 
Kassem M. Okazaki R. Harris S. A. Spelsberg T. C. Conover C. A. Riggs B. L.   (1998 ). Estrogen effects on insulin-like growth factor gene expression in a human osteoblastic cell line with high levels of estrogen receptor . Calcif. Tissue Int. 
62 , 60 –66 . 10.1007/s002239900395 9405735 
Kemilainen H. Adam M. Maki-Jouppila J. Damdimopoulou P. Damdimopoulos A. E. Kere J.  . (2016 ). The hydroxysteroid (17β) dehydrogenase family gene HSD17B12 Is involved in the prostaglandin synthesis pathway, the ovarian function, and regulation of fertility . Endocrinology 
157 , 3719 –3730 . 10.1210/en.2016-1252 27490311 
Kennelly R. Kavanagh D. O. Hogan A. M. Winter D. C.   (2008 ). Oestrogen and the colon: potential mechanisms for cancer prevention . Lancet Oncol. 
9 , 385 –391 . 10.1016/S1470-2045(08)70100-1 18374292 
Kikuchi A. Furutani T. Azami H. Watanabe K. Niimi T. Kamiyama Y.  . (2014 ). In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3) . Invest. New Drugs 
32 , 860 –870 . 10.1007/s10637-014-0130-5 24981575 
Kim J. H. Cho H. T. Kim Y. J.   (2014 ). The role of estrogen in adipose tissue metabolism: insights into glucose homeostasis regulation . Endocr. J. 
61 , 1055 –1067 . 10.1507/endocrj.EJ14-0262 25109846 
Kim S. Thiessen P. A. Bolton E. E. Chen J. Fu G. Gindulyte A.  . (2016 ). PubChem substance and compound databases . Nucleic Acids Res. 
44 , D1202 –D1213 . 10.1093/nar/gkv951 26400175 
Kim T. S. Maeda A. Maeda T. Heinlein C. Kedishvili N. Palczewski K.  . (2005 ). Delayed dark adaptation in 11-cis-retinol dehydrogenase-deficient mice: a role of RDH11 in visual processes in vivo . J. Biol. Chem. 
280 , 8694 –8704 . 10.1074/jbc.M413172200 15634683 
Kimoto T. Ishii H. Higo S. Hojo Y. Kawato S.   (2010 ). Semicomprehensive analysis of the postnatal age-related changes in the mRNA expression of sex steroidogenic enzymes and sex steroid receptors in the male rat hippocampus . Endocrinology 
151 , 5795 –5806 . 10.1210/en.2010-0581 21047951 
Kimura Y. Suzuki T. Kaneko C. Darnel A. D. Akahira J. Ebina M.  . (2003 ). Expression of androgen receptor and 5α-reductase types 1 and 2 in early gestation fetal lung: a possible correlation with branching morphogenesis . Clin. Sci. 
105 , 709 –713 . 10.1042/CS20030236 12892557 
Kitaoka Y. Kitawaki J. Koshiba H. Inoue S. Ishihara H. Teramoto M.  . (2004 ). Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcomas: correlation with clinical parameters . J. Steroid Biochem. Mol. Biol. 
88 , 183 –189 . 10.1016/j.jsbmb.2003.11.013 15084350 
Kitawaki J. Kado N. Ishihara H. Koshiba H. Kitaoka Y. Honjo H.   (2002 ). Endometriosis: the pathophysiology as an estrogen-dependent disease . J. Steroid Biochem. Mol. Biol. 
83 , 149 –155 . 10.1016/S0960-0760(02)00260-1 12650711 
Kitawaki J. Koshiba H. Ishihara H. Kusuki I. Tsukamoto K. Honjo H.   (2000 ). Progesterone induction of 17β-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium . J. Clin. Endocrinol. Metab. 
85 , 3292 –3296 . 10.1210/jcem.85.9.6829 10999824 
Kitawaki J. Kusuki I. Koshiba H. Tsukamoto K. Fushiki S. Honjo H.   (1999 ). Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis . Fertil. Steril. 
72 , 1100 –1106 . 10.1016/S0015-0282(99)00424-0 10593388 
Knapp P. Chabowski A. Blachnio-Zabielska A. Walentowicz-Sadlecka M. Grabiec M. Knapp P. A.   (2013 ). Expression of estrogen receptors (alpha, beta), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus . Adv. Med. Sci. 
58 , 96 –103 . 10.2478/v10039-012-0055-1 23625281 
Kobayashi H. Yoshida S. Sun Y. J. Shirasawa N. Naito A.   (2013 ). Postnatal development of gastric aromatase and portal venous estradiol-17β levels in male rats . J. Endocrinol. 
218 , 117 –124 . 10.1530/JOE-13-0074 23606751 
Kohno M. Okamoto T. Suda K. Shimokawa M. Kitahara H. Shimamatsu S.  . (2014 ). Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations . Clin. Cancer Res. 
20 , 3613 –3622 . 10.1158/1078-0432.CCR-13-2683 24803578 
Koizumi M. Momoeda M. Hiroi H. Hosokawa Y. Tsutsumi R. Osuga Y.  . (2010 ). Expression and regulation of cholesterol sulfotransferase (SULT2B1b) in human endometrium . Fertil. Steril. 
93 , 1538 –1544 . 10.1016/j.fertnstert.2009.01.075 19243756 
Konings G. F. Cornel K. M. Xanthoulea S. Delvoux B. Skowron M. A. Kooreman L.  . (2018 ). Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach . J. Pathol. 
244 , 203 –214 . 10.1002/path.5004 29144553 
Konings G. F. Reynaert N. L. Delvoux B. Verhamme F. M. Bracke K. R. Brusselle G. G.  . (2017 ). Increased levels of enzymes involved in local estradiol synthesis in chronic obstructive pulmonary disease . Mol. Cell. Endocrinol. 
443 , 23 –31 . 10.1016/j.mce.2016.12.001 27940297 
Kreitmann O. Kreitmann-Gimbal B. Bayard F. Hodgen G. D.   (1979 ). 17 beta-hydroxysteroid dehydrogenase in monkey endometrium: characterization of enzyme activity, and effects of estradiol alone or in combination with progesterone . Steroids 
34 , 693 –703 . 10.1016/0039-128X(79)90139-9 120040 
Kríz L. Bicikova M. Hampl R.   (2008a ). Roles of steroid sulfatase in brain and other tissues . Physiol. Res. 
57 , 657 –668 .17949251 
Kríz L. Bicikova M. Mohapl M. Hill M. Cerny I. Hampl R.   (2008b ). Steroid sulfatase and sulfuryl transferase activities in human brain tumors . J. Steroid Biochem. Mol. Biol. 
109 , 31 –39 . 10.1016/j.jsbmb.2007.12.004 18249534 
Laatikainen T. Laitinen E. A. Vihko R.   (1971 ). Secretion of free and sulfate-conjugated neutral steroids by the human testis. Effect of administration of human chorionic gonadotropin . J. Clin. Endocrinol. Metab. 
32 , 59 –64 . 10.1210/jcem-32-1-59 5539027 
Labrie F.   (1991 ). Intracrinology . Mol. Cell. Endocrinol. 
78 , C113 –C118 . 10.1016/0303-7207(91)90116-A 1838082 
Labrie F.   (2015 ). All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause . J. Steroid Biochem. Mol. Biol. 
145 , 133 –138 . 10.1016/j.jsbmb.2014.06.001 24923731 
Labrie F. Labrie C.   (2013 ). DHEA and intracrinology at menopause, a positive choice for evolution of the human species . Climacteric 
16 , 205 –213 . 10.3109/13697137.2012.733983 23126249 
Lane G.   (1990 ). The histochemistry of isocitric and oestradiol-17 beta dehydrogenases in the endometrium of postmenopausal women treated with oestrogens and progestogens . Histochem. J. 
22 , 45 –50 . 10.1007/BF01962878 2312347 
Laplante Y. Rancourt C. Poirier D.   (2009 ). Relative involvement of three 17β-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors . Mol. Cell. Endocrinol. 
301 , 146 –153 . 10.1016/j.mce.2008.08.026 18812208 
Lavasani S. Chlebowski R. T. Prentice R. L. Kato I. Wactawski-Wende J. Johnson K. C.  . (2015 ). Estrogen and colorectal cancer incidence and mortality . Cancer 
121 , 3261 –3271 . 10.1002/cncr.29464 26036212 
Lee D. K. Kurihara I. Jeong J. W. Lydon J. P. DeMayo F. J. Tsai M. J.  . (2010 ). Suppression of ERα activity by COUP-TFII is essential for successful implantation and decidualization . Mol. Endocrinol. 
24 , 930 –940 . 10.1210/me.2009-0531 20219888 
Lépine J. Audet-Walsh E. Gregoire J. Tetu B. Plante M. Menard V.  . (2010 ). Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways . J. Clin. Endocrinol. Metab. 
95 , 2689 –2698 . 10.1210/jc.2010-2648 20371658 
Li C. Chen P. Palladino A. Narayan S. Russell L. K. Sayed S.  . (2010 ). Mechanism of hyperinsulinism in short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency involves activation of glutamate dehydrogenase . J. Biol. Chem. 
285 , 31806 –31818 . 10.1074/jbc.M110.123638 20670938 
Li Y. Qin L. Xiao Z. J. Wang Y. L. Herva R. Leng J. H.  . (2003 ). Expression of P450 aromatase and 17β-hydroxysteroid dehydrogenase type 1 at fetal-maternal interface during tubal pregnancy . J. Steroid Biochem. Mol. Biol. 
87 , 241 –246 . 10.1016/j.jsbmb.2003.09.013 14698204 
Lilla C. Risch A. Verla-Tebit E. Hoffmeister M. Brenner H. Chang-Claude J.   (2007 ). SULT1A1 genotype and susceptibility to colorectal cancer . Int. J. Cancer 
120 , 201 –206 . 10.1002/ijc.22156 17013894 
Lim Y. A. Grimm A. Giese M. Mensah-Nyagan A. G. Villafranca J. E. Ittner L. M.  . (2011 ). Inhibition of the mitochondrial enzyme ABAD restores the amyloid-beta-mediated deregulation of estradiol . PLoS ONE 
6 :e28887 . 10.1371/journal.pone.0028887 22174920 
Lin H. K. Jez J. M. Schlegel B. P. Peehl D. M. Pachter J. A. Penning T. M.   (1997 ). Expression and characterization of recombinant type 2, 3 α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution . Mol. Endocrinol. 
11 , 1971 –1984 .9415401 
Lindemann K. Malander S. Christensen R. D. Mirza M. R. Kristensen G. B. Aavall-Lundqvist E.  . (2014 ). Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO) . BMC Cancer 
14 :68 . 10.1186/1471-2407-14-68 24498853 
Liu Y. Yao Z. X. Bendavid C. Borgmeyer C. Han Z. Cavalli L. R.   (2005 ). Haploinsufficiency of cytochrome P450, 17β-hydroxylase/17,20 lyase (CYP17) causes infertility in male mice . Mol. Endocrinol. 
19 , 2380 –2389 . 10.1210/me.2004-0418 15890676 
Lønning P. E. Eikesdal H. P.   (2013 ). Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved . Endocr. Relat. Cancer 
20 , R183 –R201 . 10.1530/ERC-13-0099 23625614 
López M. Tena-Sempere M.   (2015 ). Estrogens and the control of energy homeostasis: a brain perspective . Trends Endocrinol. Metab. 
26 , 411 –421 . 10.1016/j.tem.2015.06.003 26126705 
López M. Tena-Sempere M.   (2016 ). Estradiol and brown fat . Best Pract. Res. Clin. Endocrinol. Metab. 
30 , 527 –536 . 10.1016/j.beem.2016.08.004 27697213 
Loria R. M. Graf M. R.   (2012 ). 17α-androstenediol-mediated oncophagy of tumor cells by different mechanisms is determined by the target tumor . Ann. N. Y. Acad. Sci. 
1262 , 127 –133 . 10.1111/j.1749-6632.2012.06602.x 22823444 
Loriot Y. Fizazi K. Jones R. J. Van den Brande J. Molife R. L. Omlin A.  . (2014 ). Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study . Invest. New Drugs 
32 , 995 –1004 . 10.1007/s10637-014-0101-x 24771350 
Loth D. W. Soler Artigas M. Gharib S. A. Wain L. V. Franceschini N. Koch B.  . (2014 ). Genome-wide association analysis identifies six new loci associated with forced vital capacity . Nat. Genet. 
46 , 669 –677 . 10.1038/ng.3011 24929828 
Loza M. C.   (1995 ). Hydrolysis of estrone sulfate in uterine minces of the 6-days pregnant rat . J. Steroid Biochem. Mol. Biol. 
52 , 277 –280 . 10.1016/0960-0760(94)00177-N 7696149 
Lu C. Lee H. S. Pappas G. P. Dilling D. F. Burger C. D. Shifren A.  . (2017 ). A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis . Ann. Am. Thorac. Soc. 
14 , 919 –928 . 10.1513/AnnalsATS.201610-824OC 28570161 
Luchetti S. Bossers K. Van de Bilt S. Agrapart V. Morales R. R. Frajese G. V.  . (2011 ). Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease . Neurobiol. Aging 
32 , 1964 –1976 . 10.1016/j.neurobiolaging.2009.12.014 20045216 
Lundin E. Wirgin I. Lukanova A. Afanasyeva Y. Krogh V. Axelsson T.  . (2012 ). Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer . Cancer Epidemiol. 
36 , 445 –452 . 10.1016/j.canep.2012.04.006 22633539 
Luo L. Deng J. Wang D. X. He J. Deng W.   (2015 ). Regulation of epithelial sodium channel expression by oestradiol and progestogen in alveolar epithelial cells . Respir. Physiol. Neurobiol. 
216 , 52 –62 . 10.1016/j.resp.2015.06.001 26051998 
Luu-The V. Belanger A. Labrie F.   (2008 ). Androgen biosynthetic pathways in the human prostate . Best Pract. Res. Clin. Endocrinol. Metab. 
22 , 207 –221 . 10.1016/j.beem.2008.01.008 18471780 
Luu-The V. Labrie F.   (2010 ). The intracrine sex steroid biosynthesis pathways . Prog. Brain Res. 
181 , 177 –192 . 10.1016/S0079-6123(08)81010-2 20478438 
Ma B. B. Oza A. Eisenhauer E. Stanimir G. Carey M. Chapman W.  . (2004 ). The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the National Cancer Institute of Canada Clinical Trials Group . Int. J. Gynecol. Cancer 
14 , 650 –658 . 10.1111/j.1048-891X.2004.14419.x 15304161 
Ma W. G. Song H. Das S. K. Paria B. C. Dey S. K.   (2003 ). Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation . Proc. Natl. Acad. Sci. U.S.A. 
100 , 2963 –2968 . 10.1073/pnas.0530162100 12601161 
MacKenzie S. M. Dewar D. Stewart W. Fraser R. Connell J. M. Davies E.   (2008 ). The transcription of steroidogenic genes in the human cerebellum and hippocampus: a comparative survey of normal and Alzheimer's tissue . J. Endocrinol. 
196 , 123 –130 . 10.1677/JOE-07-0427 18180323 
Maentausta O. Peltoketo H. Isomaa V. Jouppila P. Vihko R.   (1990 ). Immunological measurement of human 17β-hydroxysteroid dehydrogenase . J. Steroid. Biochem . 36 , 673 –680 .2170769 
Mäentausta O. Sormunen R. Isomaa V. Lehto V. P. Jouppila P. Vihko R.   (1991 ). Immunohistochemical localization of 17 beta-hydroxysteroid dehydrogenase in the human endometrium during the menstrual cycle . Lab. Invest. 
65 , 582 –587 .1721669 
Mahendroo M. S. Cala K. M. Hess D. L. Russell D. W.   (2001 ). Unexpected virilization in male mice lacking steroid 5 alpha-reductase enzymes . Endocrinology 
142 , 4652 –4662 . 10.1210/endo.142.11.8510 11606430 
Mahendroo M. S. Cala K. M. Russell D. W.   (1996 ). 5 alpha-reduced androgens play a key role in murine parturition . Mol. Endocrinol. 
10 , 380 –392 .8721983 
Maia H. Jr.Pimentel K. Casoy J. Correia T. Freitas L. A. Zausner B.  . (2007 ). Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use . Gynecol. Endocrinol. 
23 , 320 –324 . 10.1080/09513590701321565 17616855 
Maia H. Jr.Pimentel K. Silva T. M. Freitas L. A. Zausner B. Athayde C.  . (2006 ). Aromatase and cyclooxygenase-2 expression in endometrial polyps during the menstrual cycle . Gynecol. Endocrinol. 
22 , 219 –224 . 10.1080/09513590600585955 16723309 
Maltais R. Poirier D.   (2011 ). Steroid sulfatase inhibitors: a review covering the promising 2000-2010 decade . Steroids 
76 , 929 –948 . 10.1016/j.steroids.2011.03.010 21458474 
Manenda M. S. Hamel C. J. Masselot-Joubert L. Picard M. E. Shi R.   (2016 ). Androgen-metabolizing enzymes: A structural perspective . J. Steroid Biochem. Mol. Biol. 
161 , 54 –72 . 10.1016/j.jsbmb.2016.02.021 26924584 
Marchais-Oberwinkler S. Wetzel M. Ziegler E. Kruchten P. Werth R. Henn C.  . (2011 ). New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases . J. Med. Chem. 
54 , 534 –547 . 10.1021/jm1009082 21189020 
Masi L. Becherini L. Gennari L. Amedei A. Colli E. Falchetti A.  . (2001 ). Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk . J. Clin. Endocrinol. Metab. 
86 , 2263 –2269 . 10.1210/jc.86.5.2263 11344237 
Matsunaga T. Hojo A. Yamane Y. Endo S. El-Kabbani O. Hara A.   (2013 ). Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers . Chem. Biol. Interact. 
202 , 234 –242 . 10.1016/j.cbi.2012.09.024 23165153 
Matsuzaki S. Canis M. Pouly J. L. Dechelotte P. J. Mage G.   (2006 ). Analysis of aromatase and 17β-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection . Fertil. Steril. 
85 , 308 –313 . 10.1016/j.fertnstert.2005.08.017 16595205 
Mauvais-Jarvis F. Clegg D. J. Hevener A. L.   (2013 ). The role of estrogens in control of energy balance and glucose homeostasis . Endocr. Rev. 
34 , 309 –338 . 10.1210/er.2012-1055 23460719 
McCarthy M.   (2000 ). The “gender gap” in autoimmune disease . Lancet 
356 , 1088 
10.1016/S0140-6736(05)74535-9 11009154 
McEwen B. S. Milner T. A.   (2017 ). Understanding the broad influence of sex hormones and sex differences in the brain . J. Neurosci. Res. 
95 , 24 –39 . 10.1002/jnr.23809 27870427 
Meijer D. Gelderblom H. Karperien M. Cleton-Jansen A. M. Hogendoorn P. C. Bovee J. V.   (2011 ). Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo . Clin. Sarcoma Res. 
1 :5 . 10.1186/2045-3329-1-5 22613849 
Meloche C. A. Falany C. N.   (2001 ). Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b) . J. Steroid Biochem. Mol. Biol. 
77 , 261 –269 . 10.1016/S0960-0760(01)00064-4 11457664 
Miki Y. Nakata T. Suzuki T. Darnel A. D. Moriya T. Kaneko C.  . (2002 ). Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues . J. Clin. Endocrinol. Metab. 
87 , 5760 –5768 . 10.1210/jc.2002-020670 12466383 
Milewich L. Garcia R. L. Johnson A. R.   (1983 ). Steroid sulfatase activity in human lung tissue and in endothelial pulmonary cells in culture . J. Clin. Endocrinol. Metab. 
57 , 8 –14 . 10.1210/jcem-57-1-8 6222060 
Miller P. B. Parnell B. A. Bushnell G. Tallman N. Forstein D. A. Higdon H. L III. . (2012a ). Endometrial receptivity defects during IVF cycles with and without letrozole . Hum. Reprod. 
27 , 881 –888 . 10.1093/humrep/der452 22246449 
Miller V. L. Lin H. K. Murugan P. Fan M. Penning T. M. Brame L. S.   (2012b ). Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma . Int. J. Clin. Exp. Pathol. 
5 , 278 –289 .22670171 
Miller W. L. Auchus R. J.   (2011 ). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders . Endocr. Rev. 
32 , 81 –151 . 10.1210/er.2010-0013 21051590 
Mindnich R. Moller G. Adamski J.   (2004 ). The role of 17 beta-hydroxysteroid dehydrogenases . Mol. Cell. Endocrinol. 
218 , 7 –20 . 10.1016/j.mce.2003.12.006 15130507 
Miyaura C. Toda K. Inada M. Ohshiba T. Matsumoto C. Okada T.  . (2001 ). Sex- and age-related response to aromatase deficiency in bone . Biochem. Biophys. Res. Commun. 
280 , 1062 –1068 . 10.1006/bbrc.2001.4246 11162635 
Moeller G. Adamski J.   (2006 ). Multifunctionality of human 17β-hydroxysteroid dehydrogenases . Mol. Cell. Endocrinol. 
248 , 47 –55 . 10.1016/j.mce.2005.11.031 16413960 
Moeller G. Adamski J.   (2009 ). Integrated view on 17β-hydroxysteroid dehydrogenases . Mol. Cell. Endocrinol. 
301 , 7 –19 . 10.1016/j.mce.2008.10.040 19027824 
Möller G. Leenders F. van Grunsven E. G. Dolez V. Qualmann B. Kessels M. M.  . (1999 ). Characterization of the HSD17B4 gene: D-specific multifunctional protein 2/17β-hydroxysteroid dehydrogenase IV . J. Steroid Biochem. Mol. Biol. 
69 , 441 –446 . 10.1016/S0960-0760(99)00066-7 10419023 
Morgat A. Axelsen K. B. Lombardot T. Alcantara R. Aimo L. Zerara M.   (2015 ). Updates in Rhea–a manually curated resource of biochemical reactions . Nucleic Acids Res. 
43 , D459 –D464 . 10.1093/nar/gku961 25332395 
Mori T. Ito F. Matsushima H. Takaoka O. Koshiba A. Tanaka Y.  . (2015 ). Dienogest reduces HSD17β1 expression and activity in endometriosis . J. Endocrinol. 
225 , 69 –76 . 10.1530/JOE-15-0052 25767055 
Morice P. Leary A. Creutzberg C. Abu-Rustum N. Darai E.   (2015 ). Endometrial cancer . Lancet 
387 , 1094 –1108 . 10.1016/S0140-6736(15)00130-0 26354523 
Morishima A. Grumbach M. M. Simpson E. R. Fisher C. Qin K.   (1995 ). Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens . J. Clin. Endocrinol. Metab. 
80 , 3689 –3698 .8530621 
Mueller J. W. Gilligan L. C. Idkowiak J. Arlt W. Foster P. A.   (2015 ). The regulation of steroid action by sulfation and desulfation . Endocr. Rev. 
36 , 526 –563 . 10.1210/er.2015-1036 26213785 
Muir M. Romalo G. Wolf L. Elger W. Schweikert H. U.   (2004 ). Estrone sulfate is a major source of local estrogen formation in human bone . J. Clin. Endocrinol. Metab. 
89 , 4685 –4692 . 10.1210/jc.2004-0049 15356081 
Mukai H. Tsurugizawa T. Ogiue-Ikeda M. Murakami G. Hojo Y. Ishii H.  . (2006 ). Local neurosteroid production in the hippocampus: influence on synaptic plasticity of memory . Neuroendocrinology 
84 , 255 –263 . 10.1159/000097747 17142999 
Mullis P. E. Yoshimura N. Kuhlmann B. Lippuner K. Jaeger P. Harada H.   (1997 ). Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood . J. Clin. Endocrinol. Metab. 
82 , 1739 –1745 . 10.1210/jc.82.6.1739 9177373 
Munroe D. G. Chang P. L.   (1987 ). Tissue-specific expression of human arylsulfatase-C isozymes and steroid sulfatase . Am. J. Hum. Genet. 
40 , 102 –114 .3471087 
Murakami G. Tanabe N. Ishii H. T. Ogiue-Ikeda M. Tsurugizawa T. Mukai H.  . (2006 ). Role of cytochrome p450 in synaptocrinology: endogenous estrogen synthesis in the brain hippocampus . Drug Metab. Rev. 
38 , 353 –369 . 10.1080/03602530600724068 16877257 
Musatov S. Chen W. Pfaff D. W. Mobbs C. V. Yang X. J. Clegg D. J.  . (2007 ). Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome . Proc. Natl. Acad. Sci. U.S.A. 
104 , 2501 –2506 . 10.1073/pnas.0610787104 17284595 
Nadal A. Alonso-Magdalena P. Soriano S. Ripoll C. Fuentes E. Quesada I.  . (2011 ). Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells . Front Biosci (Landmark Ed) 
16 , 251 –260 . 10.2741/3686 21196169 
Naftolin F. Horvath T. L. Jakab R. L. Leranth C. Harada N. Balthazart J.   (1996 ). Aromatase immunoreactivity in axon terminals of the vertebrate brain. An immunocytochemical study on quail, rat, monkey and human tissues . Neuroendocrinology 
63 , 149 –155 . 10.1159/000126951 9053779 
Naftolin F. MacLusky N. J.   (1982 ). Aromatase in the central nervous system . Cancer Res 
42 , 3274s –3276s . 7083185 
Nakarai C. Osawa K. Akiyama M. Matsubara N. Ikeuchi H. Yamano T.  . (2015 ). Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer . Clin. Exp. Med. 
15 , 333 –341 . 10.1007/s10238-014-0298-1 24934327 
Nayeb-Hashemi H. Kaunitz J. D.   (2009 ). Gastroduodenal mucosal defense . Curr. Opin. Gastroenterol. 
25 , 537 –543 . 10.1097/MOG.0b013e328330da7b 19654540 
Nemoto Y. Toda K. Ono M. Fujikawa-Adachi K. Saibara T. Onishi S.  . (2000 ). Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice . J. Clin. Invest. 
105 , 1819 –1825 . 10.1172/JCI9575 10862797 
Niikawa H. Suzuki T. Miki Y. Suzuki S. Nagasaki S. Akahira J.  . (2008 ). Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma . Clin. Cancer Res. 
14 , 4417 –4426 . 10.1158/1078-0432.CCR-07-1950 18579664 
Nishimura M. Naito S.   (2006 ). Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes . Drug Metab. Pharmacokinet. 
21 , 357 –374 . 10.2133/dmpk.21.357 17072089 
Noble L. S. Simpson E. R. Johns A. Bulun S. E.   (1996 ). Aromatase expression in endometriosis . J. Clin. Endocrinol. Metab. 
81 , 174 –179 .8550748 
Noble L. S. Takayama K. Zeitoun K. M. Putman J. M. Johns D. A. Hinshelwood M. M.  . (1997 ). Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells . J. Clin. Endocrinol. Metab. 
82 , 600 –606 . 10.1210/jc.82.2.600 9024261 
Noël J. C. Anaf V. Borghese B. Vaiman D. Fayt I. Chapron C.   (2011 ). The steroidogenic factor-1 protein is not expressed in various forms of endometriosis but is strongly present in ovarian cortical or medullary mesenchymatous cells adjacent to endometriotic foci . Fertil. Steril. 
95 , 2655 –2657 . 10.1016/j.fertnstert.2011.01.131 21324456 
Nokelainen P. Peltoketo H. Mustonen M. Vihko P.   (2000 ). Expression of mouse 17β-hydroxysteroid dehydrogenase/17-ketosteroid reductase type 7 in the ovary, uterus, and placenta: localization from implantation to late pregnancy . Endocrinology 
141 , 772 –778 . 10.1210/endo.141.2.7309 10650959 
Oduwole O. O. Isomaa V. V. Nokelainen P. A. Stenback F. Vihko P. T.   (2002 ). Downregulation of estrogen-metabolizing 17 beta-hydroxysteroid dehydrogenase type 2 expression correlates inversely with Ki67 proliferation marker in colon-cancer development . Int. J. Cancer 
97 , 1 –6 . 10.1002/ijc.1567 11774236 
Oduwole O. O. Makinen J. M. Isomaa V. V. Karttunen T. J. Vihko P. T.   (2003a ). Sex steroid metabolism in human gastric mucosa: 17 beta-hydroxysteroid dehydrogenase type 2 in normal, inflamed and neoplastic gastric tissues . Anticancer Res. 
23 , 3889 –3897 .14666693 
Oduwole O. O. Makinen M. J. Isomaa V. V. Pulkka A. Jernvall P. Karttunen T. J.  . (2003b ). 17β-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer . J. Steroid Biochem. Mol. Biol. 
87 , 133 –140 . 10.1016/j.jsbmb.2003.08.008 14672733 
Ohno S. Nishikawa K. Honda Y. Nakajin S.   (2008 ). Expression in E. coli and tissue distribution of the human homologue of the mouse Ke 6 gene, 17β-hydroxysteroid dehydrogenase type 8 . Mol. Cell. Biochem. 
309 , 209 –215 . 10.1007/s11010-007-9637-9 17978863 
Olson S. H. Bandera E. V. Orlow I.   (2007 ). Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review . Am. J. Epidemiol. 
165 , 235 –245 . 10.1093/aje/kwk015 17110639 
Osinski M. Wirstlein P. Wender-Ozegowska E. Mikolajczyk M. Jagodzinski P. P. Szczepanska M.   (2018 ). HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in infertile women with endometriosis . Ginekol. Pol. 
89 , 125 –134 . 10.5603/GP.a2018.0022 29664547 
Oz O. K. Millsaps R. Welch R. Birch J. Zerwekh J. E.   (2001 ). Expression of aromatase in the human growth plate . J. Mol. Endocrinol. 
27 , 249 –253 . 10.1677/jme.0.0270249 11564607 
Oz O. K. Zerwekh J. E. Fisher C. Graves K. Nanu L. Millsaps R.  . (2000 ). Bone has a sexually dimorphic response to aromatase deficiency . J. Bone Miner. Res. 
15 , 507 –514 . 10.1359/jbmr.2000.15.3.507 10750565 
Palmer B. F. Clegg D. J.   (2015 ). The sexual dimorphism of obesity . Mol. Cell. Endocrinol. 
402 , 113 –119 . 10.1016/j.mce.2014.11.029 25578600 
Palmieri C. Stein R. C. Liu X. Hudson E. Nicholas H. Sasano H.  . (2017a ). IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients . Breast Cancer Res. Treat. 
165 , 343 –353 . 10.1007/s10549-017-4328-z 28612226 
Palmieri C. Szydlo R. Miller M. Barker L. Patel N. H. Sasano H.  . (2017b ). IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer . Breast Cancer Res. Treat. 
166 , 527 –539 . 10.1007/s10549-017-4427-x 28795252 
Park A. L. Lin H. K. Yang Q. Sing C. W. Fan M. Mapstone T. B.  . (2010 ). Differential expression of type 2, 3α/type 5, 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system . Int. J. Clin. Exp. Pathol. 
3 , 743 –754 .21151387 
Park Y. S. Gauna A. E. Cha S.   (2015 ). Mouse models of primary Sjogren's syndrome . Curr. Pharm. Des. 
21 , 2350 –2364 . 10.2174/1381612821666150316120024 25777752 
Pathirage N. Di Nezza L. A. Salmonsen L. A. Jobling T. Simpson E. R. Clyne C. D.   (2006 ). Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer . Fertil. Steril. 
86 , 469 –472 . 10.1016/j.fertnstert.2005.12.057 16730717 
Pautier P. Vergote I. Joly F. Melichar B. Kutarska E. Hall G.  . (2017 ). A Phase 2, randomized, open-label study of irosustat versus megestrol acetate in advanced endometrial cancer . Int. J. Gynecol. Cancer 
27 , 258 –266 . 10.1097/IGC.0000000000000862 27870712 
Pearson Murphy B. E. Steinberg S. I. Hu F. Y. Allison C. M.   (2001 ). Neuroactive ring A-reduced metabolites of progesterone in human plasma during pregnancy: elevated levels of 5 alpha-dihydroprogesterone in depressed patients during the latter half of pregnancy . J. Clin. Endocrinol. Metab. 
86 , 5981 –5987 . 10.1210/jcem.86.12.8122 11739473 
Pelletier G. Luu-The V. Tetu B. Labrie F.   (1999 ). Immunocytochemical localization of type 5, 17β-hydroxysteroid dehydrogenase in human reproductive tissues . J. Histochem. Cytochem. 
47 , 731 –738 . 10.1177/002215549904700602 10330449 
Penning T. M.   (2017 ). Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review . Expert Opin. Ther. Pat. 
27 , 1329 –1340 . 10.1080/13543776.2017.1379503 28895472 
Penning T. M. Burczynski M. E. Jez J. M. Hung C. F. Lin H. K. Ma H.  . (2000 ). Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones . Biochem. J. 
351 , 67 –77 . 10.1042/bj3510067 10998348 
Penning T. M. Jin Y. Steckelbroeck S. Lanisnik Rizner T. Lewis M.   (2004 ). Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins . Mol. Cell. Endocrinol. 
215 , 63 –72 . 10.1016/j.mce.2003.11.006 15026176 
Perez Carrion R. Alberola Candel V. Calabresi F. Michel R. T. Santos R. Delozier T.  . (1994 ). Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer . Ann. Oncol. 
5 (Suppl. 7 ), S19 –S24 .7873457 
Pezzi V. Mathis J. M. Rainey W. E. Carr B. R.   (2003 ). Profiling transcript levels for steroidogenic enzymes in fetal tissues . J. Steroid Biochem. Mol. Biol. 
87 , 181 –189 . 10.1016/j.jsbmb.2003.07.006 14672738 
Piccinato C. A. Neme R. M. Torres N. Sanches L. R. Cruz Derogis P. B. Brudniewski H. F.  . (2016a ). Increased expression of CYP1A1 and CYP1B1 in ovarian/peritoneal endometriotic lesions . Reproduction 
151 , 683 –692 . 10.1530/REP-15-0581 27012269 
Piccinato C. A. Neme R. M. Torres N. Sanches L. R. Derogis P. Brudniewski H. F.  . (2016b ). Effects of steroid hormone on estrogen sulfotransferase and on steroid sulfatase expression in endometriosis tissue and stromal cells . J. Steroid Biochem. Mol. Biol. 
158 , 117 –126 . 10.1016/j.jsbmb.2015.12.025 26723541 
Piekorz R. P. Gingras S. Hoffmeyer A. Ihle J. N. Weinstein Y.   (2005 ). Regulation of progesterone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20α-hydroxysteroid dehydrogenase . Mol. Endocrinol. 
19 , 431 –440 . 10.1210/me.2004-0302 15471942 
Platia M. P. Fencl M. D. Elkind-Hirsch K. E. Canick J. A. Tulchinsky D.   (1984 ). Estrone sulfatase activity in the human brain and estrone sulfate levels in the normal menstrual cycle . J. Steroid Biochem. 
21 , 237 –241 . 10.1016/0022-4731(84)90275-9 6492790 
Pohl O. Bestel E. Gotteland J. P.   (2014 ). Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age . Reprod. Sci. 
21 , 1256 –1265 . 10.1177/1933719114522526 24604234 
Pollow K. Lubbert H. Jeske R. Pollow B.   (1975a ). Studies on 17β-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma . Acta Endocrinol. 
79 , 146 –156 .236629 
Pollow K. Lubbert H. Pollow B.   (1975b ). Studies on 17 beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma. III. Partial purification and characterization of the microsomal enzyme . Acta Endocrinol (Copenh) 
80 , 355 –364 .241186 
Pollow K. Lubbert H. Pollow B.   (1976 ). On the mitochondrial 17β-hydroxysteroid dehydrogenase from human endometrium and endometrial carcinoma: characterization and intramitochondrial distribution . J. Steroid Biochem. 
7 , 45 –50 . 10.1016/0022-4731(76)90163-1 5632 
Polow K. Lubbert H. Boquoi E. Kreutzer G. Jeske R. Pollow B.   (1975 ). Studies on 17β-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma I. Subcellular distribution and variations of specific enzyme activity . Acta Endocrinol (Copenh) 
79 , 134 –145 .1173301 
Prehn C. Moller G. Adamski J.   (2009 ). Recent advances in 17β-hydroxysteroid dehydrogenases . J. Steroid Biochem. Mol. Biol. 
114 , 72 –77 . 10.1016/j.jsbmb.2008.12.024 19444936 
Prizant H. Hammes S. R.   (2016 ). Minireview: lymphangioleiomyomatosis (LAM): the “Other” steroid-sensitive cancer . Endocrinology 
157 , 3374 –3383 . 10.1210/en.2016-1395 27409646 
Prossnitz E. R. Barton M.   (2011 ). The G-protein-coupled estrogen receptor GPER in health and disease . Nat. Rev. Endocrinol. 
7 , 715 –726 . 10.1038/nrendo.2011.122 21844907 
Prost O. Adessi G. L.   (1983 ). Estrone and dehydroepiandrosterone sulfatase activities in normal and pathological human endometrium biopsies . J. Clin. Endocrinol. Metab. 
56 , 653 –661 . 10.1210/jcem-56-4-653 6220025 
Purohit A. Flanagan A. M. Reed M. J.   (1992 ). Estrogen synthesis by osteoblast cell lines . Endocrinology 
131 , 2027 –2029 . 10.1210/endo.131.4.1396346 1396346 
Purohit A. Foster P. A.   (2012 ). Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers . J. Endocrinol. 
212 , 99 –110 . 10.1530/JOE-11-0266 21859802 
Purohit A. Fusi L. Brosens J. Woo L. W. Potter B. V. Reed M. J.   (2008 ). Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy . Hum. Reprod. 
23 , 290 –297 . 10.1093/humrep/dem308 18056119 
Qaiser M. Z. Dolman D. E. M. Begley D. J. Abbott N. J. Cazacu-Davidescu M. Corol D. I.  . (2017 ). Uptake and metabolism of sulphated steroids by the blood-brain barrier in the adult male rat . J. Neurochem. 
142 , 672 –685 . 10.1111/jnc.14117 28665486 
Qian Y. M. Sun X. J. Tong M. H. Li X. P. Richa J. Song W. C.   (2001 ). Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation . Endocrinology 
142 , 5342 –5350 . 10.1210/endo.142.12.8540 11713234 
Qin K. Ehrmann D. A. Cox N. Refetoff S. Rosenfield R. L.   (2006 ). Identification of a functional polymorphism of the human type 5, 17β-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome . J. Clin. Endocrinol. Metab. 
91 , 270 –276 . 10.1210/jc.2005-2012 16263811 
Quinkler M. Sinha B. Tomlinson J. W. Bujalska I. J. Stewart P. M. Arlt W.   (2004 ). Androgen generation in adipose tissue in women with simple obesity–a site-specific role for 17β-hydroxysteroid dehydrogenase type 5 . J. Endocrinol. 
183 , 331 –342 . 10.1677/joe.1.05762 15531721 
Rajkowski K. M. Robel P. Baulieu E. E.   (1997 ). Hydroxysteroid sulfotransferase activity in the rat brain and liver as a function of age and sex . Steroids 
62 , 427 –436 . 10.1016/S0039-128X(97)00013-5 9178430 
Rantakari P. Lagerbohm H. Kaimainen M. Suomela J. P. Strauss L. Sainio K.  . (2010 ). Hydroxysteroid (17{beta}) dehydrogenase 12 is essential for mouse organogenesis and embryonic survival . Endocrinology 
151 , 1893 –1901 . 10.1210/en.2009-0929 20130115 
Rantakari P. Strauss L. Kiviranta R. Lagerbohm H. Paviala J. Holopainen I.  . (2008 ). Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-beta) dehydrogenase 2 gene . Mol. Endocrinol. 
22 , 665 –675 . 10.1210/me.2007-0257 18048640 
Rauschenberger K. Scholer K. Sass J. O. Sauer S. Djuric Z. Rumig C.  . (2010 ). A non-enzymatic function of 17β-hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival . EMBO Mol. Med. 
2 , 51 –62 . 10.1002/emmm.200900055 20077426 
Rawłuszko A. A. Horbacka K. Krokowicz P. Jagodzinski P. P.   (2011 ). Decreased expression of 17β-hydroxysteroid dehydrogenase type 1 is associated with DNA hypermethylation in colorectal cancer located in the proximal colon . BMC Cancer 
11 :522 . 10.1186/1471-2407-11-522 22176788 
Reddy D. S.   (2010 ). Neurosteroids: endogenous role in the human brain and therapeutic potentials . Prog. Brain Res. 
186 , 113 –137 . 10.1016/B978-0-444-53630-3.00008-7 21094889 
Reed M. J. Purohit A. Woo L. W. Newman S. P. Potter B. V.   (2005 ). Steroid sulfatase: molecular biology, regulation, and inhibition . Endocr. Rev. 
26 , 171 –202 . 10.1210/er.2004-0003 15561802 
Rege J. Karashima S. Lerario A. M. Smith J. M. Auchus R. J. Kasa-Vubu J. Z.  . (2016 ). Age-dependent increases in adrenal cytochrome b5 and serum 5-androstenediol-3-sulfate . J. Clin. Endocrinol. Metab. 
101 , 4585 –4593 . 10.1210/jc.2016-2864 27623070 
Rennert G. Rennert H. S. Pinchev M. Lavie O. Gruber S. B.   (2009 ). Use of hormone replacement therapy and the risk of colorectal cancer . J. Clin. Oncol. 
27 , 4542 –4547 . 10.1200/JCO.2009.22.0764 19704062 
Rhee H. S. Oh S. H. Ko B. J. Han D. M. Jeon B. H. Park H.  . (2003 ). Expression of 3β-hydroxysteroid dehydrogenase and P450 side chain cleavage enzyme in the human uterine endometrium . Exp. Mol. Med. 
35 , 160 –166 . 10.1038/emm.2003.22 12858014 
Riches Z. Stanley E. L. Bloomer J. C. Coughtrie M. W.   (2009 ). Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT “pie” . Drug Metab. Dispos. 
37 , 2255 –2261 . 10.1124/dmd.109.028399 19679676 
Riggs B. L. Khosla S. Melton L. J. III.  (2002 ). Sex steroids and the construction and conservation of the adult skeleton . Endocr. Rev. 
23 , 279 –302 . 10.1210/edrv.23.3.0465 12050121 
Rižner T. L.   (2013 ). Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer . Mol. Cell. Endocrinol. 
381 , 124 –139 . 10.1016/j.mce.2013.07.026 23911898 
Rižner T. L.   (2016 ). The important roles of steroid sulfatase and sulfotransferases in gynecological diseases . Front. Pharmacol. 
7 :30 . 10.3389/fphar.2016.00030 26924986 
Rižner T. L. Penning T. M.   (2014 ). Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism . Steroids 
79 , 49 –63 . 10.1016/j.steroids.2013.10.012 24189185 
Rizner T. L. Smuc T. Rupreht R. Sinkovec J. Penning T. M.   (2006 ). AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer . Mol. Cell. Endocrinol. 
248 , 126 –135 . 10.1016/j.mce.2005.10.009 16338060 
Rižner T. L. Thalhammer T. Ozvegy-Laczka C.   (2017 ). The importance of steroid uptake and intracrine action in endometrial and ovarian cancers . Front. Pharmacol. 
8 :346 . 10.3389/fphar.2017.00346 28674494 
Rodríguez-Sanz M. Garcia-Giralt N. Prieto-Alhambra D. Servitja S. Balcells S. Pecorelli R.  . (2015 ). CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss . J. Mol. Endocrinol. 
55 , 69 –79 . 10.1530/JME-15-0079 26108486 
Rose P. G. Brunetto V. L. VanLe L. Bell J. Walker J. L. Lee R. B.   (2000 ). A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study . Gynecol. Oncol. 
78 , 212 –216 . 10.1006/gyno.2000.5865 10926805 
Roshan M. H. Tambo A. Pace N. P.   (2016 ). The role of testosterone in colorectal carcinoma: pathomechanisms and open questions . EPMA J. 
7 , 22 . 10.1186/s13167-016-0071-5 27833666 
Rosner W. Hankinson S. E. Sluss P. M. Vesper H. W. Wierman M. E.   (2013 ). Challenges to the measurement of estradiol: an endocrine society position statement . J. Clin. Endocrinol. Metab. 
98 , 1376 –1387 . 10.1210/jc.2012-3780 23463657 
Rubin G. L. Harrold A. J. Mills J. A. Falany C. N. Coughtrie M. W.   (1999 ). Regulation of sulphotransferase expression in the endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy . Mol. Hum. Reprod. 
5 , 995 –1002 . 10.1093/molehr/5.11.995 10541560 
Sahu B. Sun W. Perusek L. Parmar V. Le Y. Z. Griswold M. D.  . (2015 ). Conditional ablation of retinol dehydrogenase 10 in the retinal pigmented epithelium causes delayed dark adaption in mice . J. Biol. Chem. 
290 , 27239 –27247 . 10.1074/jbc.M115.682096 26391396 
Saito H. Yanaihara T.   (1998 ). Steroid formation in osteoblast-like cells . J. Int. Med. Res. 
26 , 1 –12 . 10.1177/030006059802600101 9513072 
Saitoh Y. Sasano H. Naganuma H. Ohtani H. Sasano N. Ohuchi A.  . (1992 ). De novo expression of aromatase in gastric carcinoma. Light and electron microscopic immunohistochemical and immunoblot study . Pathol. Res. Pract. 
188 , 53 –60 . 10.1016/S0344-0338(11)81156-8 1594500 
Sakiani S. Olsen N. J. Kovacs W. J.   (2013 ). Gonadal steroids and humoral immunity . Nat. Rev. Endocrinol. 
9 , 56 –62 . 10.1038/nrendo.2012.206 23183675 
Sakurai N. Miki Y. Suzuki T. Watanabe K. Narita T. Ando K.  . (2006 ). Systemic distribution and tissue localizations of human 17β-hydroxysteroid dehydrogenase type 12 . J. Steroid Biochem. Mol. Biol. 
99 , 174 –181 . 10.1016/j.jsbmb.2006.01.010 16621523 
Salas S. Jezequel P. Campion L. Deville J. L. Chibon F. Bartoli C.  . (2009 ). Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2 . Int. J. Cancer 
125 , 851 –860 . 10.1002/ijc.24457 19449377 
Salman E. D. Faye-Petersen O. Falany C. N.   (2011 ). Hydroxysteroid sulfotransferase 2B1b expression and localization in normal human brain . Horm. Mol. Biol. Clin. Investig. 
8 , 445 –454 . 10.1515/HMBCI.2011.117 24683427 
Salman E. D. Kadlubar S. A. Falany C. N.   (2009 ). Expression and localization of cytosolic sulfotransferase (SULT) 1A1 and SULT1A3 in normal human brain . Drug Metab. Dispos. 
37 , 706 –709 . 10.1124/dmd.108.025767 19171676 
Saloniemi T. Jarvensivu P. Koskimies P. Jokela H. Lamminen T. Ghaem-Maghami S.  . (2010 ). Novel hydroxysteroid (17β) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice . Am. J. Pathol. 
176 , 1443 –1451 . 10.2353/ajpath.2010.090325 20093485 
Sánchez-Guijo A. Neunzig J. Gerber A. Oji V. Hartmann M. F. Schuppe H. C.  . (2016 ). Role of steroid sulfatase in steroid homeostasis and characterization of the sulfated steroid pathway: Evidence from steroid sulfatase deficiency . Mol. Cell. Endocrinol. 
437 , 142 –153 . 10.1016/j.mce.2016.08.019 27531568 
Sasano H. Takashashi K. Satoh F. Nagura H. Harada N.   (1998 ). Aromatase in the human central nervous system . Clin. Endocrinol. (Oxf). 
48 , 325 –329 . 10.1046/j.1365-2265.1998.00390.x 9578823 
Sasano H. Uzuki M. Sawai T. Nagura H. Matsunaga G. Kashimoto O.  . (1997 ). Aromatase in human bone tissue . J. Bone Miner. Res. 
12 , 1416 –1423 . 10.1359/jbmr.1997.12.9.1416 9286757 
Sathish V. Martin Y. N. Prakash Y. S.   (2015 ). Sex steroid signaling: implications for lung diseases . Pharmacol. Ther. 
150 , 94 –108 . 10.1016/j.pharmthera.2015.01.007 25595323 
Sato R. Suzuki T. Katayose Y. Miura K. Shiiba K. Miki Y.  . (2012 ). Aromatase in colon carcinoma . Anticancer Res. 
32 , 3069 –3075 .22843875 
Sato R. Suzuki T. Katayose Y. Miura K. Shiiba K. Tateno H.  . (2009 ). Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors . Cancer Res. 
69 , 914 –922 . 10.1158/0008-5472.CAN-08-0906 19141651 
Schweikert H. U. Wolf L. Romalo G.   (1995 ). Oestrogen formation from androstenedione in human bone . Clin. Endocrinol. (Oxf). 
43 , 37 –42 . 10.1111/j.1365-2265.1995.tb01890.x 7641410 
Scublinsky A. Marin C. Gurpide E.   (1976 ). Localization of estradiol 17β dehydrogenase in human endometrium . J. Steroid Biochem. 
7 , 745 –747 . 10.1016/0022-4731(76)90174-6 1011831 
Segawa T. Shozu M. Murakami K. Kasai T. Shinohara K. Nomura K.  . (2005 ). Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival . Clin. Cancer Res. 
11 , 2188 –2194 . 10.1158/1078-0432.CCR-04-1859 15788666 
Selcer K. W. Difrancesca H. M.   (2012 ). Characterization of steroid sulfatase in the MC3T3-E1 mouse pre-osteoblastic cell line . Steroids 
77 , 696 –702 . 10.1016/j.steroids.2012.02.024 22426324 
Setiawan V. W. Doherty J. A. Shu X. O. Akbari M. R. Chen C. De Vivo I.  . (2009 ). Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the epidemiology of endometrial cancer consortium . Cancer Epidemiol. Biomarkers Prev. 
18 , 242 –247 . 10.1158/1055-9965.EPI-08-0689 19124504 
Setiawan V. W. Hankinson S. E. Colditz G. A. Hunter D. J. De Vivo I.   (2004 ). HSD17B1 gene polymorphisms and risk of endometrial and breast cancer . Cancer Epidemiol. Biomarkers Prev. 
13 , 213 –219 . 10.1158/1055-9965.EPI-03-0241 14973105 
Shang E. Lai K. Packer A. I. Paik J. Blaner W. S. de Morais Vieira M.  . (2002 ). Targeted disruption of the mouse cis-retinol dehydrogenase gene: visual and nonvisual functions . J. Lipid Res. 
43 , 590 –597 .11907141 
Shehu A. Mao J. Gibori G. B. Halperin J. Le J. Devi Y. S.  . (2008 ). Prolactin receptor-associated protein/17β-hydroxysteroid dehydrogenase type 7 gene (Hsd17b7) plays a crucial role in embryonic development and fetal survival . Mol. Endocrinol. 
22 , 2268 –2277 . 10.1210/me.2008-0165 18669642 
Shen Z. Peng Z. Sun Y. Vaananen H. K. Poutanen M.   (2008 ). Overexpression of human hydroxysteroid (17β) dehydrogenase 2 induces disturbance in skeletal development in young male mice . J. Bone Miner. Res. 
23 , 1217 –1226 . 10.1359/jbmr.080322 18348690 
Shi L. Yang X. Dong X. Zhang B.   (2016 ). Polymorphism of HSD17B1 Ser312Gly with Cancer Risk: Evidence from 66,147 Subjects . Twin Res. Hum. Genet. 
19 , 136 –145 . 10.1017/thg.2016.6 26923943 
Shim G. J. Warner M. Kim H. J. Andersson S. Liu L. Ekman J.  . (2004 ). Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome . Proc. Natl. Acad. Sci. U.S.A. 
101 , 12628 –12633 . 10.1073/pnas.0405099101 15314222 
Shimizu K.   (1979 ). Metabolism of [17-2H]pregnenolone into 5-[17β-2H, 17α-18O]androstene-3β, 17α-diol and other products by incubation with the microsomal fraction of boar testis under 18O2 atmosphere . Biochim. Biophys. Acta 
575 , 37 –45 . 10.1016/0005-2760(79)90128-0 159724 
Shimodaira M. Nakayama T. Sato I. Sato N. Izawa N. Mizutani Y.  . (2012 ). Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive disorders of pregnancy . Endocrine 
42 , 700 –707 . 10.1007/s12020-012-9699-7 22638611 
Shimodaira M. Nakayama T. Sato N. Aoi N. Sato M. Izumi Y.  . (2010 ). Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, aldosterone level, and left ventricular structure . Eur. J. Endocrinol. 
163 , 671 –680 . 10.1530/EJE-10-0428 20660004 
Siegfried J. M. Stabile L. P.   (2014 ). Estrongenic steroid hormones in lung cancer . Semin. Oncol. 
41 , 5 –16 . 10.1053/j.seminoncol.2013.12.009 24565577 
Simard J. Ricketts M. L. Gingras S. Soucy P. Feltus F. A. Melner M. H.   (2005 ). Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family . Endocr. Rev. 
26 , 525 –582 . 10.1210/er.2002-0050 15632317 
Simard M. Plante J. Boucher M. Provost P. R. Tremblay Y.   (2010 ). Type 2 and 5, 17β-hydroxysteroid dehydrogenases and androgen receptor in human fetal lungs . Mol. Cell. Endocrinol. 
319 , 79 –87 . 10.1016/j.mce.2009.12.007 20025932 
Simoens S. Dunselman G. Dirksen C. Hummelshoj L. Bokor A. Brandes I.  . (2012 ). The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres . Hum. Reprod. 
27 , 1292 –1299 . 10.1093/humrep/des073 22422778 
Simoens S. Hummelshoj L. Dunselman G. Brandes I. Dirksen C. D'Hooghe T.   (2011 ). Endometriosis cost assessment (the EndoCost study): a cost-of-illness study protocol . Gynecol. Obstet. Invest. 
71 , 170 –176 . 10.1159/000316055 21160141 
Singh M. M. Trivedi R. N. Chauhan S. C. Srivastava V. M. Makker A. Chowdhury S. R.  . (1996 ). Uterine estradiol and progesterone receptor concentration, activities of certain antioxidant enzymes and dehydrogenases and histoarchitecture in relation to time of secretion of nidatory estrogen and high endometrial sensitivity in rat . J. Steroid Biochem. Mol. Biol. 
59 , 215 –224 . 10.1016/S0960-0760(96)00102-1 9010337 
Singhal N. Vatandoust S. Brown M. P.   (2015 ). Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity . Cancer Chemother. Pharmacol. 
75 , 325 –331 . 10.1007/s00280-014-2644-0 25502181 
Sinreih M. Anko M. Zukunft S. Adamski J. Rizner T. L.   (2014 ). Important roles of the AKR1C2 and SRD5A1 enzymes in progesterone metabolism in endometrial cancer model cell lines . Chem. Biol. Interact . 234 , 297 –308 . 10.1016/j.cbi.2014.11.012 25463305 
Sinreih M. Hevir N. Rizner T. L.   (2013 ). Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer . Chem. Biol. Interact. 
202 , 210 –217 . 10.1016/j.cbi.2012.11.012 23200943 
Sinreih M. Knific T. Anko M. Hevir N. Vouk K. Jerin A.  . (2017a ). The significance of the sulfatase pathway for local estrogen formation in endometrial cancer . Front. Pharmacol. 
8 :368 . 10.3389/fphar.2017.00368 28690541 
Sinreih M. Stupar S. Cemazar L. Verdenik I. Frkovic Grazio S. Smrkolj S.  . (2017b ). STAR and AKR1B10 are down-regulated in high-grade endometrial cancer . J. Steroid Biochem. Mol. Biol. . 10.1016/j.jsbmb.2017.02.015 28232277 
Sivik T.   (2012 ). Elucidating the Role of 17β Hydroxysteroid Dehydrogenase Type 14 in Normal Physiology and in Breast Cancer . Department of Clinical and Experimental Medicine : Linköping University (Linköping) .
Skjefstad K. Grindstad T. Khanehkenari M. R. Richardsen E. Donnem T. Kilvaer T.  . (2016 ). Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer . Steroids 
113 , 5 –13 . 10.1016/j.steroids.2016.05.008 27234503 
Slominski A. Zbytek B. Nikolakis G. Manna P. R. Skobowiat C. Zmijewski M.  . (2013 ). Steroidogenesis in the skin: implications for local immune functions . J. Steroid Biochem. Mol. Biol. 
137 , 107 –123 . 10.1016/j.jsbmb.2013.02.006 23435015 
Slomovitz B. M. Jiang Y. Yates M. S. Soliman P. T. Johnston T. Nowakowski M.  . (2015 ). Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma . J. Clin. Oncol. 
33 , 930 –936 . 10.1200/JCO.2014.58.3401 25624430 
Smith A. Contreras C. Ko K. H. Chow J. Dong X. Tuo B.  . (2008 ). Gender-specific protection of estrogen against gastric acid-induced duodenal injury: stimulation of duodenal mucosal bicarbonate secretion . Endocrinology 
149 , 4554 –4566 . 10.1210/en.2007-1597 18499763 
Smith E. P. Boyd J. Frank G. R. Takahashi H. Cohen R. M. Specker B.  . (1994 ). Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man . N. Engl. J. Med. 
331 , 1056 –1061 . 10.1056/NEJM199410203311604 8090165 
Smuc T. Hevir N. Ribic-Pucelj M. Husen B. Thole H. Rizner T. L.   (2009 ). Disturbed estrogen and progesterone action in ovarian endometriosis . Mol. Cell. Endocrinol. 
301 , 59 –64 . 10.1016/j.mce.2008.07.020 18762229 
Smuc T. Pucelj M. R. Sinkovec J. Husen B. Thole H. Lanisnik Rizner T.   (2007 ). Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis . Gynecol. Endocrinol. 
23 , 105 –111 . 10.1080/09513590601152219 17454161 
Smuc T. Rizner T. L.   (2009 ). Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer . Mol. Cell. Endocrinol. 
301 , 74 –82 . 10.1016/j.mce.2008.09.019 18930784 
Smuc T. Rupreht R. Sinkovec J. Adamski J. Rizner T. L.   (2006 ). Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer . Mol. Cell. Endocrinol. 
248 , 114 –117 . 10.1016/j.mce.2005.10.013 16337331 
Soma K. K. Rendon N. M. Boonstra R. Albers H. E. Demas G. E.   (2015 ). DHEA effects on brain and behavior: insights from comparative studies of aggression . J. Steroid Biochem. Mol. Biol. 
145 , 261 –272 . 10.1016/j.jsbmb.2014.05.011 24928552 
Soubhye J. Alard I. C. van Antwerpen P. Dufrasne F.   (2015 ). Type 2, 17-beta hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis . Future Med. Chem. 
7 , 1431 –1456 . 10.4155/fmc.15.74 26230882 
Steckelbroeck S. Jin Y. Gopishetty S. Oyesanmi B. Penning T. M.   (2004a ). Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action . J. Biol. Chem. 
279 , 10784 –10795 . 10.1074/jbc.M313308200 14672942 
Steckelbroeck S. Lutjohann D. Bauman D. R. Ludwig M. Friedl A. Hans V. H.  . (2010 ). Non-stereo-selective cytosolic human brain tissue 3-ketosteroid reductase is refractory to inhibition by AKR1C inhibitors . Biochim. Biophys. Act. 
1801 , 1221 –1231 . 10.1016/j.bbalip.2010.07.005 20673851 
Steckelbroeck S. Nassen A. Ugele B. Ludwig M. Watzka M. Reissinger A.  . (2004b ). Steroid sulfatase (STS) expression in the human temporal lobe: enzyme activity, mRNA expression and immunohistochemistry study . J. Neurochem. 
89 , 403 –417 . 10.1046/j.1471-4159.2004.02336.x 15056284 
Steckelbroeck S. Stoffel-Wagner B. Reichelt R. Schramm J. Bidlingmaier F. Siekmann L.  . (1999 ). Characterization of 17β-hydroxysteroid dehydrogenase activity in brain tissue: testosterone formation in the human temporal lobe . J. Neuroendocrinol. 
11 , 457 –464 . 10.1046/j.1365-2826.1999.00363.x 10336727 
Steckelbroeck S. Watzka M. Reichelt R. Hans V. H. Stoffel-Wagner B. Heidrich D. D.  . (2001 ). Characterization of the 5α-reductase-3α-hydroxysteroid dehydrogenase complex in the human brain . J. Clin. Endocrinol. Metab. 
86 , 1324 –1331 . 10.1210/jcem.86.3.7325 11238528 
Steckelbroeck S. Watzka M. Reissinger A. Wegener-Toper P. Bidlingmaier F. Bliesener N.  . (2003 ). Characterisation of estrogenic 17β-hydroxysteroid dehydrogenase (17β-HSD) activity in the human brain . J. Steroid Biochem. Mol. Biol. 
86 , 79 –92 . 10.1016/S0960-0760(03)00251-6 12943747 
Stelzer G. Rosen N. Plaschkes I. Zimmerman S. Twik M. Fishilevich S.  . (2016 ). The GeneCards suite: from gene data mining to disease genome sequence analyses . Curr Protoc Bioinformatics 
54 , 1.30, 31 –31 , 30, 33. 10.1002/cpbi.5 27322403 
Stoffel-Wagner B.   (2001 ). Neurosteroid metabolism in the human brain . Eur. J. Endocrinol. 
145 , 669 –679 . 10.1530/eje.0.1450669 11720889 
Stoffel-Wagner B. Beyenburg S. Watzka M. Blumcke I. Bauer J. Schramm J.  . (2000 ). Expression of 5α-reductase and 3α-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy . Epilepsia 
41 , 140 –147 . 10.1111/j.1528-1157.2000.tb00133.x 10691110 
Stoffel-Wagner B. Watzka M. Schramm J. Bidlingmaier F. Klingmuller D.   (1999a ). Expression of CYP19 (aromatase) mRNA in different areas of the human brain . J. Steroid Biochem. Mol. Biol. 
70 , 237 –241 . 10.1016/S0960-0760(99)00114-4 10622413 
Stoffel-Wagner B. Watzka M. Steckelbroeck S. Ludwig M. Clusmann H. Bidlingmaier F.  . (2003 ). Allopregnanolone serum levels and expression of 5 alpha-reductase and 3 alpha-hydroxysteroid dehydrogenase isoforms in hippocampal and temporal cortex of patients with epilepsy . Epilepsy Res. 
54 , 11 –19 . 10.1016/S0920-1211(03)00036-6 12742591 
Stoffel-Wagner B. Watzka M. Steckelbroeck S. Schramm J. Bidlingmaier J. F. Klingmuller D.   (1999b ). Expression of 17β-hydroxysteroid dehydrogenase types 1, 2, 3 and 4 in the human temporal lobe . J. Endocrinol. 
160 , 119 –126 . 10.1677/joe.0.1600119 9854183 
Stoffel-Wagner B. Watzka M. Steckelbroeck S. Schwaab R. Schramm J. Bidlingmaier F.  . (1998a ). Expression of CYP19 (aromatase) mRNA in the human temporal lobe . Biochem. Biophys. Res. Commun. 
244 , 768 –771 . 10.1006/bbrc.1998.8337 9535740 
Stoffel-Wagner B. Watzka M. Steckelbroeck S. Wickert L. Schramm J. Romalo G.  . (1998b ). Expression of 5α-reductase in the human temporal lobe of children and adults . J. Clin. Endocrinol. Metab. 
83 , 3636 –3642 .9768677 
Strott C. A.   (2002 ). Sulfonation and molecular action . Endocr. Rev. 
23 , 703 –732 . 10.1210/er.2001-0040 12372849 
Sudeshna T. Anand K. Medhamurthy R.   (2013 ). Analysis of 20α-hydroxysteroid dehydrogenase expression in the corpus luteum of the buffalo cow: effect of prostaglandin F2-α treatment on circulating 20α-hydroxyprogesterone levels . Reprod. Biol. Endocrinol.  11 :111 
10.1186/1477-7827-11-111 
Sun X. F. Ahmadi A. Arbman G. Wallin A. Asklid D. Zhang H.   (2005 ). Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients' survival . World J. Gastroenterol. 
11 , 6875 –6879 . 10.3748/wjg.v11.i43.6875 16425401 
Svoboda M. Hamilton G. Thalhammer T.   (2010 ). Steroid hormone metabolizing enzymes in benign and malignant human bone tumors . Expert Opin. Drug Metab. Toxicol. 
6 , 427 –437 . 10.1517/17425251003592129 20102288 
Svoboda M. Thalhammer T. Aust S. Arrich F. Assadian O. Toma C. D.   (2007 ). Estrogen sulfotransferase (SULT1E1) expression in benign and malignant human bone tumors . J. Surg. Oncol. 
95 , 572 –581 . 10.1002/jso.20748 17230544 
Syed F. Khosla S.   (2005 ). Mechanisms of sex steroid effects on bone . Biochem. Biophys. Res. Commun. 
328 , 688 –696 . 10.1016/j.bbrc.2004.11.097 15694402 
Taga S. Yoshida N. Sekiba K.   (1990 ). Distribution and cyclic change of aromatase cytochrome P-450 activity in human uteri . J. Steroid Biochem. Mol. Biol. 
37 , 741 –745 . 10.1016/0960-0760(90)90359-S 2278858 
Takeyama J. Suzuki T. Hirasawa G. Muramatsu Y. Nagura H. Iinuma K.  . (2000 ). 17β-hydroxysteroid dehydrogenase type 1 and 2 expression in the human fetus . J. Clin. Endocrinol. Metab. 
85 , 410 –416 . 10.1210/jcem.85.1.6323 10634418 
Tanaka K. Kubushiro K. Iwamori Y. Okairi Y. Kiguchi K. Ishiwata I.  . (2003 ). Estrogen sulfotransferase and sulfatase: Roles in the regulation of estrogen activity in human uterine endometrial carcinomas . Cancer Sci. 
94 , 871 –876 . 10.1111/j.1349-7006.2003.tb01369.x 14556660 
Tanaka K. Shimizu K. Kakegawa S. Ohtaki Y. Nagashima T. Kaira K.  . (2016 ). Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma . Am. J. Transl. Res. 
8 , 81 –97 .27069542 
Tanaka S. Miki Y. Hashimoto C. Takagi K. Doe Z. Li B.  . (2015 ). The role of 5α-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma . Mol. Cell. Endocrinol. 
401 , 56 –64 . 10.1016/j.mce.2014.11.022 25475427 
Tang T. Li L. Tang J. Li Y. Lin W. Y. Martin F.  . (2010 ). A mouse knockout library for secreted and transmembrane proteins . Nat. Biotechnol. 
28 , 749 –755 . 10.1038/nbt.1644 20562862 
Tangen I. L. Onyango T. B. Kopperud R. Berg A. Halle M. K. Oyan A. M.  . (2016 ). Androgen receptor as potential therapeutic target in metastatic endometrial cancer . Oncotarget 
7 , 49289 –49298 . 10.18632/oncotarget.10334 27384477 
Tangen I. L. Werner H. M. Berg A. Halle M. K. Kusonmano K. Trovik J.  . (2014 ). Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions . Eur J Cancer 
50 , 3003 –3010 . 10.1016/j.ejca.2014.09.003 25281525 
Taniuchi S. Fujishima F. Miki Y. Abe K. Nakamura Y. Sato S.  . (2014 ). Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung . Mol. Cell. Endocrinol. 
392 , 136 –143 . 10.1016/j.mce.2014.05.016 24861259 
Tashiro A. Sasano H. Nishikawa T. Yabuki N. Muramatsu Y. Coughtrie M. W.  . (2000 ). Expression and activity of dehydroepiandrosterone sulfotransferase in human gastric mucosa . J. Steroid Biochem. Mol. Biol. 
72 , 149 –154 . 10.1016/S0960-0760(00)00020-0 10775806 
Taveira-DaSilva A. M. Moss J.   (2014 ). Management of lymphangioleiomyomatosis . F1000Prime Rep. 
6 , 116 . 10.12703/P6-116 25580270 
Terry K. McGrath M. Lee I. M. Buring J. De Vivo I.   (2010 ). Genetic variation in CYP11A1 and StAR in relation to endometrial cancer risk . Gynecol. Oncol. 
117 , 255 –259 . 10.1016/j.ygyno.2010.02.002 20199803 
Teubner W. Meinl W. Florian S. Kretzschmar M. Glatt H.   (2007 ). Identification and localization of soluble sulfotransferases in the human gastrointestinal tract . Biochem. J. 
404 , 207 –215 . 10.1042/BJ20061431 17335415 
Thiboutot D. Martin P. Volikos L. Gilliland K.   (1998 ). Oxidative activity of the type 2 isozyme of 17β-hydroxysteroid dehydrogenase (17β-HSD) predominates in human sebaceous glands . J. Invest. Dermatol. 
111 , 390 –395 . 10.1046/j.1523-1747.1998.00322.x 9740229 
Thompson D. J. O'Mara T. A. Glubb D. M. Painter J. N. Cheng T. Folkerd E.  . (2016 ). CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer . Endocr. Relat. Cancer 
23 , 77 –91 . 10.1530/ERC-15-0386 26574572 
Tong M. H. Jiang H. Liu P. Lawson J. A. Brass L. F. Song W. C.   (2005 ). Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice . Nat. Med. 
11 , 153 –159 . 10.1038/nm1184 15685171 
Törn S. Nokelainen P. Kurkela R. Pulkka A. Menjivar M. Ghosh S.  . (2003 ). Production, purification, and functional analysis of recombinant human and mouse 17β-hydroxysteroid dehydrogenase type 7 . Biochem. Biophys. Res. Commun. 
305 , 37 –45 . 10.1016/S0006-291X(03)00694-6 12732193 
Townsend E. A. Miller V. M. Prakash Y. S.   (2012 ). Sex differences and sex steroids in lung health and disease . Endocr. Rev. 
33 , 1 –47 . 10.1210/er.2010-0031 22240244 
Townsend E. A. Thompson M. A. Pabelick C. M. Prakash Y. S.   (2010 ). Rapid effects of estrogen on intracellular Ca2+ regulation in human airway smooth muscle . Am. J. Physiol. Lung Cell. Mol. Physiol. 
298 
L521 –530 . 10.1152/ajplung.00287.2009 20097735 
Tsai S. J. Wu M. H. Lin C. C. Sun H. S. Chen H. M.   (2001 ). Regulation of steroidogenic acute regulatory protein expression and progesterone production in endometriotic stromal cells . J. Clin. Endocrinol. Metab. 
86 , 5765 –5773 . 10.1210/jcem.86.12.8082 11739437 
Tseng L. Gurpide E.   (1974 ). Estradiol and 20α-dihydroprogesterone dehydrogenase activities in human endometrium during the menstrual cycle . Endocrinology 
94 , 419 –423 . 10.1210/endo-94-2-419 4359125 
Tseng L. Gusberg S. B. Gurpide E.   (1977 ). Estradiol receptor and 17 beta-dehydrogenase in normal and abnormal human endometrium . Ann. N. Y. Acad. Sci. 
286 , 190 –198 . 10.1111/j.1749-6632.1977.tb29416.x 281172 
Tseng L. Mazella J.   (2002 ). Endometrial cell specific gene activation during implantation and early pregnancy . Front. Biosci. 
7 , d1566 –d1574 . 10.2741/A861 12045017 
Tseng L. Mazella J. Mann W. J. Chumas J.   (1982 ). Estrogen synthesis in normal and malignant human endometrium . J. Clin. Endocrinol. Metab. 
55 , 1029 –1031 . 10.1210/jcem-55-5-1029 7119084 
Tsuchiya M. Nakao H. Katoh T. Sasaki H. Hiroshima M. Tanaka T.  . (2005 ). Association between endometriosis and genetic polymorphisms of the estradiol-synthesizing enzyme genes HSD17B1 and CYP19 . Hum. Reprod. 
20 , 974 –978 . 10.1093/humrep/deh726 15640252 
Tuo B. Wen G. Wei J. Liu X. Wang X. Zhang Y.  . (2011 ). Estrogen regulation of duodenal bicarbonate secretion and sex-specific protection of human duodenum . Gastroenterology 
141 , 854 –863 . 10.1053/j.gastro.2011.05.044 21699784 
Utsunomiya H. Ito K. Suzuki T. Kitamura T. Kaneko C. Nakata T.  . (2004 ). Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma . Clin. Cancer Res. 
10 , 5850 –5856 . 10.1158/1078-0432.CCR-04-0040 15355916 
Utsunomiya H. Suzuki T. Ito K. Moriya T. Konno R. Sato S.  . (2003 ). The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17β-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma . Clin. Endocrinol. (Oxf). 
58 , 696 –703 . 10.1046/j.1365-2265.2003.01766.x 12780745 
Utsunomiya H. Suzuki T. Kaneko C. Takeyama J. Nakamura J. Kimura K.  . (2001 ). The analyses of 17β-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma . J. Clin. Endocrinol. Metab. 
86 , 3436 –3443 . 10.1210/jcem.86.7.7661 11443221 
van der Eerden B. C. Lowik C. W. Wit J. M. Karperien M.   (2004 ). Expression of estrogen receptors and enzymes involved in sex steroid metabolism in the rat tibia during sexual maturation . J. Endocrinol. 
180 , 457 –467 . 10.1677/joe.0.1800457 15012600 
Vanderschueren D. Gaytant J. Boonen S. Venken K.   (2008 ). Androgens and bone . Curr. Opin. Endocrinol. Diabetes Obes. 
15 , 250 –254 . 10.1097/MED.0b013e3282fe6ca9 18438173 
Vani S. McDonald S. E. Williams A. R. Mason J. I. Thong K. J. Critchley H. O.   (2007 ). Mid-luteal endometrial intracrinology following controlled ovarian hyperstimulation involving use of a gonadotrophin releasing hormone antagonist . Hum. Reprod. 
22 , 2981 –2991 . 10.1093/humrep/dem269 17848403 
Varlamov O. Bethea C. L. Roberts C. T. Jr.  (2014 ). Sex-specific differences in lipid and glucose metabolism . Front. Endocrinol. (Lausanne). 
5 :241 . 10.3389/fendo.2014.00241 25646091 
Vasquez Y. M. DeMayo F. J.   (2013 ). Role of nuclear receptors in blastocyst implantation . Semin. Cell Dev. Biol. 
24 , 724 –735 . 10.1016/j.semcdb.2013.08.004 23994285 
Velasco I. Rueda J. Acien P.   (2006 ). Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis . Mol. Hum. Reprod. 
12 , 377 –381 . 10.1093/molehr/gal041 16641167 
Vercellini P. Vigano P. Somigliana E. Fedele L.   (2014 ). Endometriosis: pathogenesis and treatment . Nat. Rev. Endocrinol. 
10 , 261 –275 . 10.1038/nrendo.2013.255 24366116 
Verma M. K. Miki Y. Abe K. Suzuki T. Niikawa H. Suzuki S.  . (2013 ). Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor . J. Transl. Med. 
11 , 167 . 10.1186/1479-5876-11-167 23837683 
Verma M. K. Miki Y. Sasano H.   (2011 ). Aromatase in human lung carcinoma . Steroids 
76 , 759 –764 . 10.1016/j.steroids.2011.02.020 21392519 
Vidal O. Lindberg M. K. Hollberg K. Baylink D. J. Andersson G. Lubahn D. B.  . (2000 ). Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice . Proc. Natl. Acad. Sci. U.S.A. 
97 , 5474 –5479 . 10.1073/pnas.97.10.5474 10805804 
Vouk K. Smuc T. Guggenberger C. Ribic-Pucelj M. Sinkovec J. Husen B.  . (2011 ). Novel estrogen-related genes and potential biomarkers of ovarian endometriosis identified by differential expression analysis . J. Steroid Biochem. Mol. Biol. 
125 , 231 –242 . 10.1016/j.jsbmb.2011.03.010 21397694 
Walker V. R. Korach K. S.   (2004 ). Estrogen receptor knockout mice as a model for endocrine research . ILAR J. 
45 , 455 –461 . 10.1093/ilar.45.4.455 15454684 
Wang F. Vihma V. Soronen J. Turpeinen U. Hamalainen E. Savolainen-Peltonen H.  . (2013 ). 17β-Estradiol and estradiol fatty acyl esters and estrogen-converting enzyme expression in adipose tissue in obese men and women . J. Clin. Endocrinol. Metab. 
98 , 4923 –4931 . 10.1210/jc.2013-2605 24081738 
Wang H. Dey S. K.   (2006 ). Roadmap to embryo implantation: clues from mouse models . Nat. Rev. Genet. 
7 , 185 –199 . 10.1038/nrg1808 16485018 
Wang X. Q. Aka J. A. Li T. Xu D. Doillon C. J. Lin S. X.   (2017 ). Inhibition of 17β-hydroxysteroid dehydrogenase type 7 modulates breast cancer protein profile and enhances apoptosis by down-regulating GRP78 . J. Steroid Biochem. Mol. Biol. 
172 , 188 –197 . 10.1016/j.jsbmb.2017.06.009 28645527 
Warren J. C. French A. P.   (1965 ). DISTRIBUTION OF STEROID SULFATASE IN HUMAN TISSUES . J. Clin. Endocrinol. Metab. 
25 , 278 –282 . 10.1210/jcem-25-2-278 14264248 
Watanabe K. Sasano H. Harada N. Ozaki M. Niikura H. Sato S.  . (1995 ). Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies . Am. J. Pathol. 
146 , 491 –500 .7856758 
Watzka M. Bidlingmaier F. Schramm J. Klingmuller D. Stoffel-Wagner B.   (1999 ). Sex- and age-specific differences in human brain CYP11A1 mRNA expression . J. Neuroendocrinol. 
11 , 901 –905 . 10.1046/j.1365-2826.1999.00407.x 10583724 
Wishart D. S. Feunang Y. D. Guo A. C. Lo E. J. Marcu A. Grant J. R.  . (2018 ). DrugBank 5.0: a major update to the DrugBank database for 2018 . Nucleic Acids Res. 
46 , D1074 –D1082 . 10.1093/nar/gkx1037 29126136 
Wishart D. S. Jewison T. Guo A. C. Wilson M. Knox C. Liu Y.  . (2013 ). HMDB 3.0–the human metabolome database in 2013 . Nucleic Acids Res. 
41 , D801 –D807 . 10.1093/nar/gks1065 23161693 
Wöhrle D. Barbi G. Schulz W. Steinbach P.   (1990 ). Heterozygous expression of X-linked chondrodysplasia punctata. Complex chromosome aberration including deletion of MIC2 and STS . Hum. Genet. 
86 , 215 –218 . 10.1007/BF00197708 2265834 
Woo L. W. Purohit A. Potter B. V.   (2011 ). Development of steroid sulfatase inhibitors . Mol. Cell. Endocrinol. 
340 , 175 –185 . 10.1016/j.mce.2010.12.035 21238537 
Wu H. C. Tuo B. G. Wu W. M. Gao Y. Xu Q. Q. Zhao K.   (2008 ). Prevalence of peptic ulcer in dyspeptic patients and the influence of age, sex, and Helicobacter pylori infection . Dig. Dis. Sci. 
53 , 2650 –2656 . 10.1007/s10620-007-0177-7 18270835 
Xiao J. Zheng Y. Zhou Y. Zhang P. Wang J. Shen F.  . (2014 ). Sulfotransferase SULT1A1 Arg213His polymorphism with cancer risk: a meta-analysis of 53 case-control studies . PLoS ONE 
9 :e106774 . 10.1371/journal.pone.0106774 25225888 
Yague J. G. Azcoitia I. DeFelipe J. Garcia-Segura L. M. Munoz A.   (2010 ). Aromatase expression in the normal and epileptic human hippocampus . Brain Res. 
1315 , 41 –52 . 10.1016/j.brainres.2009.09.111 19815003 
Yague J. G. Munoz A. de Monasterio-Schrader P. Defelipe J. Garcia-Segura L. M. Azcoitia I.   (2006 ). Aromatase expression in the human temporal cortex . Neuroscience 
138 , 389 –401 . 10.1016/j.neuroscience.2005.11.054 16426763 
Yamaki J. Yamamoto T. Okada H.   (1985 ). Aromatization of androstenedione by normal and neoplastic endometrium of the uterus . J. Steroid Biochem. 
22 , 63 –66 . 10.1016/0022-4731(85)90142-6 3974228 
Yamamoto T. Fukuoka M. Fujimoto Y. Kitawaki J. Nakakoshi M. Yoshihama M.   (1990a ). Inhibitory effect of a new androstenedione derivative, 14α-hydroxy-4-androstene-3,6,17-trione (14α-OHAT) on aromatase activity of human uterine tumors . J. Steroid Biochem. 
36 , 517 –21 . 10.1016/0022-4731(90)90167-Q 2214767 
Yamamoto T. Kitawaki J. Urabe M. Honjo H. Tamura T. Noguchi T.  . (1993a ). Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells . J. Steroid Biochem. Mol. Biol. 
44 , 463 –468 . 10.1016/0960-0760(93)90251-Q 8476761 
Yamamoto T. Noguchi T. Tamura T. Kitawaki J. Okada H.   (1993b ). Evidence for estrogen synthesis in adenomyotic tissues . Am. J. Obstet. Gynecol . 169 , 734 –738 . 10.1016/0002-9378(93)90654-2 8372890 
Yamamoto T. Urabe M. Naitoh K. Kitawaki J. Honjo H. Okada H.   (1990b ). Estrone sulfatase activity in human uterine leiomyoma . Gynecol. Oncol. 
37 , 315 –318 . 10.1016/0090-8258(90)90358-R 2351313 
Yanaihara Yanaihara, T. Toma Y. Shimizu Y. Saito H. Okai T.  . (2001 ). Localization and expression of steroid sulfatase in human fallopian tubes . Steroids 
66 , 87 –91 . 10.1016/S0039-128X(00)00204-X 11146087 
Yang W. Wu G. Broeckel U. Smith C. A. Turner V. Haidar C. E.  . (2016 ). Comparison of genome sequencing and clinical genotyping for pharmacogenes . Clin. Pharmacol. Ther. 
100 , 380 –388 . 10.1002/cpt.411 27311679 
Yang X. Y. Wu W. J. Yang C. Yang T. He J. D. Yang Z.  . (2013 ). Association of HSD17B3 and HSD3B1 polymorphisms with acne vulgaris in Southwestern Han Chinese . Dermatology 
227 , 202 –208 . 10.1159/000353581 24157973 
Ye X. Y. Chen S. Y. Wu S. Yoon D. S. Wang H. Hong Z.  . (2017 ). Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an orally active novel selective 11β-Hydroxysteroid dehydrogenase type 1 inhibitor . J. Med. Chem. 
60 , 4932 –4948 . 10.1021/acs.jmedchem.7b00211 28537398 
Yu L. Romero D. G. Gomez-Sanchez C. E. Gomez-Sanchez E. P.   (2002 ). Steroidogenic enzyme gene expression in the human brain . Mol. Cell. Endocrinol. 
190 , 9 –17 . 10.1016/S0303-7207(02)00041-2 11997174 
Yuchi Y. Cai Y. Legein B. De Groef S. Leuckx G. Coppens V.  . (2015 ). Estrogen receptor α regulates β-cell formation during pancreas development and following injury . Diabetes 
64 , 3218 –3228 . 10.2337/db14-1798 26015547 
Zacher A. Kaulich K. Stepanow S. Wolter M. Kohrer K. Felsberg J.  . (2016 ). Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel . Brain Pathol . 27 , 146 –159 . 10.1111/bpa.12367 26919320 
Zakharov V. Lin H. K. Azzarello J. McMeekin S. Moore K. N. Penning T. M.  . (2010 ). Suppressed expression of type 2, 3α/type 5, 17β-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma . Int. J. Clin. Exp. Pathol. 
3 , 608 –617 .20661409 
Zarrabeitia M. T. Hernandez J. L. Valero C. Zarrabeitia A. Amado J. A. Gonzalez-Macias J.  . (2007 ). Adiposity, estradiol, and genetic variants of steroid-metabolizing enzymes as determinants of bone mineral density . Eur. J. Endocrinol. 
156 , 117 –122 . 10.1530/eje.1.02318 17218734 
Zeitoun K. Takayama K. Sasano H. Suzuki T. Moghrabi N. Andersson S.  . (1998 ). Deficient 17β-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17β-estradiol . J. Clin. Endocrinol. Metab. 
83 , 4474 –4480 .9851796 
Zeng C. Matsuda K. Jia W. H. Chang J. Kweon S. S. Xiang Y. B.  . (2016 ). Identification of susceptibility loci and genes for colorectal cancer risk . Gastroenterology 
150 , 1633 –1645 . 10.1053/j.gastro.2016.02.076 26965516 
Zhang J. Yin Y. Niu X. M. Liu Y. Garfield D. Chen S. F.  . (2013 ). CYP19A1 gene polymorphisms and risk of lung cancer . J. Int. Med. Res. 
41 , 735 –742 . 10.1177/0300060513477291 23669293 
Zhao H. Zhou L. Shangguan A. J. Bulun S. E.   (2016 ). Aromatase expression and regulation in breast and endometrial cancer . J. Mol. Endocrinol. 
57 
R19 –33 . 10.1530/JME-15-0310 27067638 
Zhongyi S. Rantakari P. Lamminen T. Toppari J. Poutanen M.   (2007 ). Transgenic male mice expressing human hydroxysteroid dehydrogenase 2 indicate a role for the enzyme independent of its action on sex steroids . Endocrinology 
148 , 3827 –3836 . 10.1210/en.2007-0365 17510238 
Zwart W. Theodorou V. Kok M. Canisius S. Linn S. Carroll J. S.   (2011 ). Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer . EMBO J. 
30 , 4764 –4776 . 10.1038/emboj.2011.368 22002538

